Compositions and methods for providing hematopoietic function without hla matching

ABSTRACT

The present invention relates to methods and compositions for providing hematopoietic function in immunodeficient human patients, by selecting an expanded human umbilical cord blood stem/progenitor cell sample without taking into account the HLA-type of the expanded human cord blood stem/progenitor sample or the HLA-type of the patient; and administering the selected expanded human cord blood stem/progenitor cell sample to the patient. Methods for obtaining the expanded human cord blood stem/progenitor cell samples, banks of frozen expanded human cord blood stem/progenitor cell samples, and methods for producing such banks are also provided herein.

This application claims benefit of U.S. Provisional Application No.61/322,544 filed Apr. 9, 2010, which is incorporated by reference hereinin its entirety.

This invention was made with government support under Grant No.HHS010020080064C awarded by the U.S. Department of Health and HumanServices (HHS/OS/ASPR/BARDA) and under Grant No. 1RC2HL101844 awarded bythe National Heart, Lung and Blood Institute of the National Institutesof Health, U.S. Department of Health and Human Services. The U.S.government has certain rights in the invention.

1. FIELD OF THE INVENTION

The present invention relates to methods and compositions for providing,hematopoietic function to human patients in need thereof, by selectingan expanded human umbilical cord blood stem/progenitor cell samplewithout taking into account the HLA-type of the expanded human cordblood stem cell/progenitor sample or the HLA-type of the patient; andadministering the selected expanded human cord blood stem/progenitorcell sample to the patient. Methods for obtaining the expanded humancord blood stem/progenitor cell samples, banks of frozen expanded humanumbilical cord blood stem/progenitor cell samples, and methods forproducing such banks are also provided herein.

2. BACKGROUND OF THE INVENTION

Prolonged pancytopenia is common following intensive chemotherapyregimens, myeloablative and reduced intensity regimens for hematopoieticcell transplantation (HCT), and exposure to acute ionizing radiation. Ofparticular concern is prolonged neutropenia, which results in asignificant risk of infection despite improved antimicrobial therapy andincreases morbidity and mortality. Thus, novel therapies that canabrogate prolonged pancytopenia/neutropenia following high dosechemotherapy and/or radiation, and potentially facilitate more rapidhematopoietic recovery, are needed.

Expansion techniques for cord blood stem cells have been described. See,e.g., U.S. Pat. No. 7,399,633 B2 to Bernstein et al., and Delaney etal., 2010, Nature Med. 16(2): 232-236. Delaney et al. reported rapidengraftment after infusion of previously cryopreserved cord blood stemcells which had been selected on the basis of HLA matching, and whichhad been expanded ex vivo.

International Patent Publication No. WO 2006/047569 A2 discloses methodsfor expanding myeloid progenitor cells that do not typicallydifferentiate into cells of the lymphoid lineage, and which can beMHC-mismatched with respect to the recipient of the cells.

International Patent Publication No. WO 2007/095594 A2 discloses methodsfor facilitating engraftment of hematopoietic stem cells byadministering myeloid progenitor cells in conjunction with thehematopoietic stem cell graft, for example, where the hematopoietic stemcell graft is suboptimal because it has more than one MHC mismatch withrespect to the cells of the recipient patient.

U.S. Pat. No. 5,004,681 to Boyse et al. discloses the use of human cordblood stem cells for hematopoietic reconstitution.

2.1 Human Leukocyte Antigen

The human leukocyte antigen system (HLA) is the name of the majorhistocompatibility complex (MHC) in humans. The superlocus contains alarge number of genes related to immune system function in humans. Thisgroup of genes resides on chromosome 6, and encodes cell-surfaceantigen-presenting proteins and many other genes. The HLA genes are thehuman versions of the MHC genes that are found in most vertebrates (andthus are the most studied of the MHC genes). The proteins encoded by theHLA genes are also known as antigens, as a result of their historicdiscovery as factors in organ transplantations. The major HLA antigensare essential elements for immune function. Different classes havedifferent functions.

HLA class I antigens (HLA-A, HLA-B and HLA-C) are transmembrane proteinsthat are expressed on the surface of almost all the cells of the body(except for red blood cells and the cells of the central nervous system)and present peptides on the cell surface, which peptides are producedfrom digested proteins that are broken down in the proteasomes.

HLA class II antigens (HLA-DP, HLA-DM, HLA-DOA, HLA-DOB, HLA-DQ, andHLA-DR) present antigens from outside of the cell to T-lymphocytes.These particular antigens stimulate T-helper cells to multiply, andthese T-helper cells then stimulate antibody-producing B-cells toproduce antibodies to that specific antigen. Self-antigens aresuppressed by suppressor T-cells.

HLA class III antigens encode components of the complement system.

HLA antigens have other roles. They are important in disease defense.They may be the cause of organ transplant rejections. They may protectagainst or fail to protect against (if down regulated by an infection)cancers. They may mediate autoimmune disease, e.g., type I diabetes,coeliac disease). Also, in reproduction, HLA may be related to theindividual smell of people and may be involved in mate selection.

Diversity of HLA in human population is one aspect of disease defense,and, as a result, the chance of two unrelated individuals havingidentical HLA molecules on all loci is very low. Thus, in the prior art,there was a need for HLA typing to determine suitable allele matching toavoid rejection of the donor tissue by the recipient or, in the case ofhematopoietic stem cell transplants, to avoid the possibility of thedonated hematopoietic cells from attacking the recipient. Most tissuetyping is done using serological methods with antibodies specific foridentified HLA antigens. DNA-based methods for detecting polymorphismsin the HLA antigen-encoding gene are also used for typing HLA alleles.Currently in the clinical setting for cord blood transplants, HLA typingof the donor tissue and the recipient concerns determining six HLAantigens or alleles, usually two each at the loci HLA-A, HLA-B andHLA-DR, or one each at the loci HLA-A, HLA-B and HLA-C and one each atthe loci HAL-DRB1, HLA-DQB1 and HLA-DPB1 (see e.g., Kawase et al., 2007,Blood 110:2235-2241). HLA typing can be done (1) by determining the HLAallele, which is done on the DNA sequence level by determining theallele-specific sequences, and/or (2) by determining the HLA antigenserologically, by way of antibodies specific for the HLA-antigen.

2.2 Hematopoietic Stem Cells

The hematopoietic stem cell is pluripotent and ultimately gives rise toall types of terminally differentiated blood cells. The hematopoieticstem cell can self-renew, or it can differentiate into more committedprogenitor cells, which progenitor cells are irreversibly determined tobe ancestors of only a few types of blood cell. For instance, thehematopoietic stem cell can differentiate into (i) myeloid progenitorcells, which myeloid progenitor cells ultimately give rise to monocytesand macrophages, neutrophils, basophils, eosinophils, erythrocytes,megakaryocytes/platelets, dendritic cells, or (ii) lymphoid progenitorcells, which lymphoid progenitor cells ultimately give rise to T-cells,B-cells, and lymphocyte-like cells called natural killer cells(NK-cells). Once the stem cell differentiates into a myeloid progenitorcell, its progeny cannot give rise to cells of the lymphoid lineage,and, similarly, lymphoid progenitor cells cannot give rise to cells ofthe myeloid lineage. For a general discussion of hematopoiesis andhematopoietic stem cell differentiation, see Chapter 17, DifferentiatedCells and the Maintenance of Tissues, Alberts et al., 1989, MolecularBiology of the Cell, 2nd Ed., Garland Publishing, New York, N.Y.;Chapter 2 of Regenerative Medicine, Department of Health and HumanServices, August 2006(http://stemcells.nih.gov/info/scireport/2006report.htm), and Chapter 5of Hematopoietic Stem Cells, 2009, Stem Cell Information, Department ofHealth and Human Services(http://stemcells.nih.gov/info/scireport/chapter5.asp).

In vitro and in vivo assays have been developed to characterizehematopoietic stem cells, for example, the spleen colony forming (CFU-S)assay and reconstitution assays in immune-deficient mice. Further,presence or absence of cell surface protein markers defined bymonoclonal antibody recognition have been used to recognize and isolatehematopoietic stem cells. Such markers include, but are not limited to,Lin, CD34, CD38, CD43, CD45RO, CD45RA, CD59, CD90, CD109, CD117, CD133,CD166, and HLA DR, and combinations thereof. See Chapter 2 ofRegenerative Medicine, Department of Health and Human Services, August2006 (http://stemcells.nih.gov/info/scireport/2006report.htm) and thereferences cited therein.

2.3 Notch Pathway

Members of the Notch family encode large transmembrane proteins thatplay central roles in cell-cell interactions and cell-fate decisionsduring early development in a number of invertebrate systems (Simpson,1995, Nature 375:736-7; Artavanis-Tsakonis et al., 1995, Science.268:225-232; Simpson, 1998, Semin. Cell Dev. Biol. 9:581-2; Go et al.,1998, Development. 125:2031-2040; Artavanis-Tsakonas and Simpson, 1991,Trends Genet. 7:403-408). The Notch receptor is part of a highlyconserved pathway that enables a variety of cell types to choose betweenalternative differentiation pathways based on those taken by immediatelyneighboring cells. This receptor appears to act through an undefinedcommon step that controls the progression of uncommitted cells towardthe differentiated state by inhibiting their competence to adopt one oftwo alternative fates, thereby allowing the cell either to delaydifferentiation, or in the presence of the appropriate developmentalsignal, to commit to differentiate along the non-inhibited pathway.

Genetic and molecular studies have led to the identification of a groupof genes which define distinct elements of the Notch signaling pathway.While the identification of these various elements has come exclusivelyfrom Drosophila using genetic tools as the initial guide, subsequentanalyses have lead to the identification of homologous proteins invertebrate species including humans. The molecular relationships betweenthe known Notch pathway elements as well as their subcellularlocalization are depicted in Artavanis-Tsakonas et al., 1995, Science268:225-232; Artavanis-Tsakonas et al., 1999, Science 284:770-776; andin Kopan et al., 2009, Cell 137:216-233. Delta and Serrate (or Jagged,the mammalian homolog of Serrate) are extracellular ligands of Notch.The portion of Delta and Serrate (“Serrate” shall be used herein torefer to both Drosophila Serrate and its mammalian homolog, Jagged)responsible for binding to Notch is called the DSL domain, which domainis located in the extracellular domain of the protein. Epidermal growthfactor-like repeats (ELRs) 11 and 12 in the extracellular domain ofNotch are responsible for binding to Delta, Serrate and Jagged. SeeArtavanis-Tsakonas et al., 1995, Science 268:225-232 and Kopan et al.,2009, Cell 137:216-233.

2.4 Notch Pathway in Hematopoiesis

Evidence of Notch-1 mRNA expression in human CD34⁺ precursors has led tospeculation for a role for Notch signaling in hematopoiesis (Milner etal., 1994, Blood 3:2057-62). This is further supported by thedemonstration that Notch-1 and -2 proteins are present in hematopoieticprecursors, and, in higher amounts, in T cells, B cells, and monocytes,and by the demonstration of Jagged-1 protein in hematopoietic stroma(Ohishi et al., 2000, Blood 95:2847-2854; Varnum-Finney et al., 1998,Blood 91:4084-91; Li et al., 1998, Immunity 8:43-55).

The clearest evidence for a physiologic role of Notch signaling has comefrom studies of T cell development which showed that activated Notch-1inhibited B cell maturation but permitted T cell maturation (Pui et al.,1999, Immunity 11:299-308). In contrast, inactivation of Notch-1 orinhibition of Notch-mediated signaling by knocking out HES-1 inhibited Tcell development but permitted B cell maturation (Radtke et al., 1999,Immunity 10: 47-58; Tomita et al., 1999, Genes Dev. 13:1203-10). Theseopposing effects of Notch-1 on B and T cell development raise thepossibility that Notch-1 regulates fate decisions by a common lymphoidprogenitor cell.

Other studies in transgenic mice have shown that activated Notch-1affects the proportion of cells assuming a CD4 vs. CD8 phenotype as wellas an αβ vs. γδ cell-fate (Robey et al., 1996, Cell 87:483-92; Washburnet al., 1997, Cell 88:833-43). Although this may reflect an effect onfate decisions by a common precursor, more recent studies have suggestedthat these effects may result from an anti-apoptotic effect of Notch-1that enables the survival of differentiating T cells that wouldotherwise die (Deftos et al., 1998, Immunity 9:777-86; Jehn et al.,1999, J. Immunol. 162:635-8).

Studies have also shown that the differentiation of isolatedhematopoietic precursor cells can be inhibited by ligand-induced Notchsignaling. Co-culture of murine marrow precursor cells (Lin⁻Sca-1⁺c-kit⁺) with 3T3 cells expressing human Jagged-1 led to a 2 to 3fold increase in the formation of primitive precursor cell populations(Varnum-Finney et al., 1998, Blood 91:4084-4991; Jones et al., 1998,Blood 92:1505-11). Incubation of sorted precursors with beads coatedwith the purified extracellular domain of human Jagged-1 also led toenhanced generation of precursor cells (Varnum-Finney et al., 1998,Blood 91:4084-91).

In a study of human CD34⁺ cells, expression of the intracellular domainof Notch-1 or exposure to cells that overexpressed Jagged-2 also led toenhanced generation of precursor cells and prolonged maintenance of CD34expression (Carlesso et al., 1999, Blood 93:838-48). In another study,the effects of Jagged-1-expressing cells on CD34⁺ cells were influencedby the cytokines present in the cultures; in the absence of added growthfactors, the interaction with cell-bound Jagged-1 led to maintenance ofCD34⁺ cells in a non-proliferating, undifferentiated state, whereas theaddition of c-kit ligand led to a 2-fold increase in erythroidcolony-forming cells (Walker et al., 1999, Stem Cells 17:162-71).

Varnum-Finney et al., 1993, Blood 101:1784-1789 demonstrated thatactivation of endogenous Notch receptors in mouse marrow precursor cellsby an immobilized Notch ligand revealed profound effects on the growthand differentiation of the precurosor cells, and that a multilogincrease in the number of precursor cells with short-term lymphoid andmyeloid repopulating ability was observed. Delaney et al., 2005, Blood106:2693-2699 and Ohishi et al., 2002, J. Clin. Invest. 110:1165-1174demonstrated that incubation of human cord blood progenitors in thepresence of an immobilized Notch ligand generated an approximate100-fold increase in the number of CD34⁺ cells with enhancedrepopulating ability as determined in an immunodeficient mouse model.See also U.S. Pat. No. 7,399,633 B2.

Delaney et al., 2010, Nature Med. 16(2): 232-236 demonstrated that apopulation of CD34⁺ cells obtained from a frozen cord blood sample,which population had been cultured in the presence of a Notch ligand(resulting in a greater than 100 fold increase in the number of CD34⁺cells), repopulated immunodeficient mice with markedly enhanced kineticsand magnitude, and provided more rapid myeloid engraftment in humans ina clinical phase 1 myeloablative cord blood transplant trial.

Citation or identification of any reference in Section 2 or any othersection of this application shall not be construed as an admission thatsuch reference is available as prior art to the present invention.

3. SUMMARY OF THE INVENTION

There exists a need in the art for an “off-the-shelf” product for rapidhematopoietic reconstitution without the need for HLA matching, thatcould be stockpiled long term after manufacture. The present inventionfulfills such a need. The present invention provides methods forproviding hematopoietic function to a human patient in need thereof,comprising administering an expanded human cord blood stem cell sampleto the patient, wherein said administering is done without matching theHLA-type of the expanded human cord blood stem cell sample to theHLA-type of the patient. The present invention also provides methods forproviding hematopoietic function to a human patient in need thereof,comprising: (a) selecting an expanded human cord blood stem cell samplefor administration to the patient, wherein said selecting does not takeinto account the HLA-type of the sample or the HLA-type of the patient;and (b) administering the selected sample to the patient. In a specificembodiment, at least one HLA antigen or allele is different between theexpanded human cord blood stem cell sample and the patient, among thoseantigens or alleles HLA-typed, respectively. In another specificembodiments, the expanded cord blood stem cell sample and the patientare different at two, three, four, five, six or more HLA antigens oralleles, among those antigens or alleles, HLA-typed, respectively. Inyet another embodiment, the expanded human cord blood stem cell sampleadministered to the patient contains at least 75 million viable CD34⁺cells, preferably at least 250 million viable CD34⁺ cells.

In one embodiment, the expanded human cord blood stem cell sample of thepresent invention has been subjected to an expansion technique that hasbeen shown to result in an at least 50-fold increase in hematopoieticstem cells or hematopoietic stem and progenitor cells in an aliquot of ahuman cord blood stem cell sample subjected to the expansion technique,relative to an aliquot of the human cord blood stem cell sample prior tobeing subjected to the expansion technique. The hematopoietic stem cellsor the hematopoietic stem and progenitor cells can be positive for oneor more of the following cell surface markers expressed in increasedlevels on hematopoietic stem cells or hematopoietic stem and progenitorcells, relative to other types of hematopoietic cells: CD34, CD43,CD45RO, CD45RA, CD59, CD90, CD109, CD117, CD133, CD166, and HLA DRand/or negative for Lin and/or CD38 cell surface markers. Preferably,the hematopoietic stem cells or hematopoietic stem and progenitor cellsare positive for one or more of CD34, CD133 or CD90 cell surfacemarkers. Preferably, the expanded human cord blood stem cell sample ofthe present invention has been subjected to an expansion technique thathas been shown (i) to result in an at least 50-fold increase in CD34⁺cells in an aliquot of a human cord blood stem cell sample subjected tothe expansion technique, relative to an aliquot of the human cord bloodstem cell sample prior to being subjected to the expansion technique; or(ii) to increase the number of SCID repopulating cells in a human cordblood stem cell sample subject to the expansion technique, relative tothe human cord blood cell stem cell sample prior to being subject to theexpansion technique.

In particular embodiments, the expanded human cord blood stem cellsample is frozen and thawed prior to administering to the patient.

In a specific embodiment, the expanded human cord blood stem cell samplethat is administered is a pool of two or more expanded human cord bloodstem cell samples, each sample obtained from a different human at birth.Optionally, the HLA-types of at least two samples in the pool areHLA-mismatched, i.e., wherein at least one HLA antigen or allele typedin the samples is different. Optionally, the expanded human cord bloodstem cell sample is a pool of two or more human cord blood stem cellsamples pooled prior to, or after, expansion, which pool is thenexpanded according to the invention. In one embodiment, the samples inthe pool are all derived from umbilical cord blood and/or placentalblood of individuals of the same race, e.g., African-American,Caucasian, Asian, Hispanic, Native-American, Australian Aboriginal,Inuit, Pacific Islander, or are all derived from umbilical cord bloodand/or placental blood of individuals of the same ethnicity, e.g.,Irish, Italian, Indian, Japanese, Chinese, Russian, etc. Preferably,pooling of the samples is done without regard to the HLA type of thesamples.

In yet another embodiment, the method of providing hematopoieticfunction comprises, prior to said administering, a step of expanding exvivo isolated human cord blood stem cells, or stem and progenitor cells,obtained from the umbilical cord blood and/or placental blood of one ormore humans at birth. Preferably, the expanding step comprisescontacting the human cord blood stem cells, or stem and progenitorcells, with an agonist of Notch function. The agonist can be a Deltaprotein or a Serrate protein, or a fragment of a Delta protein orSerrate protein, which fragment is able to bind a Notch protein.

In a particular embodiment of the present invention, a method forproviding hematopoietic function to a human patient in need thereof isprovided, which method comprises (a) enriching for hematopoietic stemcells, or hematopoietic stem and progenitor cells, from isolated humancord blood stem cells or stem and progenitor cells obtained from theumbilical cord blood and/or placental blood of one or more humans atbirth to produced enriched hematopoietic stem cells or hematopoieticstem and progenitor cells; (b) expanding ex vivo the enrichedhematopoietic stem cells or hematopoietic stem and progenitor cells toproduce an expanded stem cell sample; and (c) administering the expandedstem cell sample to a human patient in need thereof, wherein saidadministering is done without matching the HLA type of the expanded cellsample to the HLA-type of the patient. In a preferred embodiment, theexpanded cells are CD34⁺ cells. In another preferred embodiment, theexpanded cells are CD133⁺ cells. In another preferred embodiment, theexpanded cells are CD90⁺ cells. In yet another embodiment, the expandedcells are positive for one or more of the following cell surface markersexpressed in increased levels on hematopoietic stem cells orhematopoietic stem and progenitor cells, relative to other types ofhematopoietic cells: CD34, CD43, CD45RO, CD45RA, CD59, CD90, CD109,CD117, CD133, CD166, and HLA DR and/or negative for Lin and/or CD38 cellsurface markers. Preferably, the expanded cells are positive for one ormore of CD34, CD133 or CD90 cell surface markers. This method canfurther comprise the steps of freezing and thawing the expanded cellsample after step (b) and before step (c). In certain embodiments, thepatient suffers from pancytopenia or neutropenia, wherein thepancytopenia or neutropenia is caused by an intensive chemotherapyregimen, a myeloablative regimen for hematopoietic cell transplantation,or exposure to acute ionizing radiation.

In another embodiment, the present invention provides a method ofproducing a bank of frozen expanded human cord blood stem cellscomprising the following steps in the order stated: (a) expanding, exvivo, isolated human cord blood stem cells, or stem and progenitorcells, obtained from the umbilical cord blood and/or placental blood ofone or more humans at birth of said individual to produce an expandedhuman cord blood stem cell sample; (b) freezing the expanded human cordblood stem cell sample to produce a frozen expanded human cord bloodstem cell sample; (c) storing the frozen expanded human cord blood stemcell sample; and (d) repeating steps (a)-(c) at least 50 times toproduce a bank of at least 50 stored, frozen, expanded human cord bloodstem cell samples. In specific embodiments, steps (a)-(c) are repeatedat least 5, 10, 20, 25, 50, 75, 100, 200, 250, 500, 750, 1000, 1500,2,000, 3,000, 5,000, 7,500, 10,000, 25,000, 50,000 or 100,000 times toproduce the corresponding number of stored, frozen, expanded human cordblood stem cell samples. In one embodiment, the method further comprisesprior to step (b) pooling one or more expanded human cord blood stemcell samples. In one embodiment, the method further comprises a step ofassigning each frozen expanded human cord blood stem cell sample anidentifier that distinguishes the frozen expanded human cord blood stemcell sample from other frozen expanded stem cell samples. In anotherembodiment, the method further comprises a step of storing theidentifier in one or more computer databases, wherein said storedidentifier is associated with information on the physical location wherethe frozen expanded human cord blood stem cell sample is stored in saidbank. The present invention is also directed to a blood bank comprisingat least 50 units of frozen expanded human cord blood stem cell samples.In specific embodiments, the blood bank comprises at least 5, 10, 20,25, 50, 75, 100, 200, 250, 500, 750, 1000, 1500, 2,000, 3,000, 5,000,7,500, 10,000, 25,000, 50,000 or 100,000 units of frozen expanded humancord blood stem cells.

In another embodiment of the invention, a computer-implemented methodfor selecting a frozen expanded human cord blood stem cell sample foruse in providing hematopoietic function to a human patient in needthereof is provided, which method comprises (a) selecting an identifierfrom a plurality of at least 50 identifiers stored in a computerdatabase, each identifier identifying a frozen stored expanded humancord blood stem cell sample derived from the umbilical cord blood and/orplacental blood of one or more humans birth, wherein the selecting doesnot take into account the respective HLA types of the stored frozenexpanded human cord blood stem cell samples corresponding to therespective identifiers, wherein the selecting is for administration ofthe expanded human cord blood stem cell sample identified by saididentifier to a human patient in need thereof; and (b) outputting ordisplaying the selected identifier. In specific embodiments, theidentifier is outputted or displayed to a user, an internal or externalcomponent of a computer, a remote computer, or to storage on a computerreadable medium. In another specific embodiment, the outputting ordisplaying further outputs or displays information on the physicallocation of the expanded human cord blood stem cell sample identified bythe identifier. In yet another embodiment, the computer-implementedmethod further comprises implementing robotic retrieval of theidentified, frozen, expanded human cord blood stem cell sample.

In another embodiment of the invention, a computer program product isprovided for use in conjunction with a computer system, which computerprogram product comprises a computer readable storage medium and acomputer program mechanism embedded therein, the computer programmechanism comprising (a) executable instructions for selecting anidentifier from a plurality of at least 50 identifiers stored in acomputer database, each identifier identifying a frozen, stored,expanded human cord blood stem cell sample derived from the umbilicalcord blood and/or placental blood of one or more humans at birth,wherein the selecting does not take into account the respective HLAtypes of the frozen, stored, expanded human cord blood stem cell samplescorresponding to the respective identifiers, wherein the selecting isfor administration of the expanded human cord blood stem cell sampleidentified by said identifier to a human patient in need thereof; and(b) executable instructions for outputting or displaying the selectedidentifier. In particular embodiments, the identifier is outputted ordisplayed to a user, an internal or external component of a computer, aremote computer, or to storage on a computer readable medium.

In yet another embodiment, the present invention provides an apparatuscomprising a processor; a memory, coupled to the processor, the memorystoring a module, the module comprising (a) executable instructions forselecting an identifier from a plurality of at least 50 identifiersstored in a computer database, each identifier identifying a frozenstored expanded human cord blood stem cell sample derived from theumbilical cord blood and/or placental blood of one or more humans atbirth, wherein the selecting does not take into account the respectiveHLA types of the stored frozen expanded human cord blood stem cellsamples corresponding to the respective identifiers, wherein theselecting is for administration of the expanded human cord blood stemcell sample identified by said identifier to a human patient in needthereof; and (b) executable instructions for outputting or displayingthe selected identifier. In particular embodiments, the identifier isoutputted or displayed to a user, an internal or external component of acomputer, a remote computer, or to storage on a computer readablemedium.

4. DEFINITIONS

Although any methods and materials similar or equivalent to thosedescribed herein can be used in the practice or testing of the presentinvention, the preferred methods and materials are described. Forpurposes of the present invention, the following terms are definedbelow.

As used herein, the term “CB Stem Cells,” referred to hereininterchangeably as “a CB Stem Cell Sample,” refers to a populationenriched in hematopoietic stem cells, or enriched in hematopoietic stemand progenitor cells, derived from human umbilical cord blood and/orhuman placental blood collected at birth. The hematopoietic stem cells,or hematopoietic stem and progenitor cells, can be positive for aspecific marker expressed in increased levels on hematopoietic stemcells or hematopoietic stem and progenitor cells, relative to othertypes of hematopoietic cells. For example, such markers can be, but arenot limited to CD34, CD43, CD45RO, CD45RA, CD59, CD90, CD109, CD117,CD133, CD166, HLA DR, or a combination thereof. Also, the hematopoieticstem cells, or hematopoietic stem and progenitor cells, can be negativefor an expressed marker, relative to other types of hematopoietic cells.For example, such markers can be, but are not limited to Lin, CD38, or acombination thereof. Preferably, the hematopoietic stem cells, orhematopoietic stem and progenitor cells, are CD34⁺ cells.

As used herein, “Expanded CB Stem Cells,” referred to hereininterchangeably as “an Expanded CB Stem Cell Sample,” refers to CB StemCells that have been subjected to a technique for expanding the cordblood hematopoietic stem cells, or hematopoietic stem and progenitorcells, which technique has been shown to result in (i) an increase inthe number of hematopoietic stem cells, or hematopoietic stem andprogenitor cells, in an aliquot of the sample thus expanded, or (ii) anincreased number of SCID repopulating cells determined bylimiting-dilution analysis as shown by enhanced engraftment in NOD/SCIDmice infused with an aliquot of the sample thus expanded; relative tothat seen with an aliquot of the sample that is not subjected to theexpansion technique. In a specific embodiment, the enhanced engraftmentin NOD/SCID mice can be detected by detecting an increased percentage ofhuman CD45⁺ cells in the bone marrow of mice infused with an aliquot ofthe expanded sample relative to mice infused with an aliquot of thesample prior to expansion, at, e.g., 10 days, 3 weeks or 9 weekspost-infusion (see Delaney et al., 2010, Nature Med. 16(2): 232-236). Ina specific embodiment, the expansion technique results in an at least50-, 75-, 100-, 150-, 200-, 250-, 300-, 350-, 400-, 450-, or 500-foldincrease in the number of hematopoietic stem cells or hematopoietic stemand progenitor cells, in an aliquot of the sample expanded, andpreferably is a 100-200 fold increase.

5. BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates an exemplary embodiment of a computer system usefulfor implementing the methods of the present invention.

FIGS. 2 a-2 b are graphs showing SCID repopulating frequency with cordblood cells cultured with Delta1^(ext-IgG) generates a significantincrease in the SRC frequency and improved overall engraftment.Sublethally irradiated NOD/SCID mice were transplanted with non-culturedCD34⁺ cord blood cells or the progeny of CD34⁺ cells cultured for 17days on Delta1^(ext-IgG) or control human IgG1 in 5 independentexperiments. Human engraftment (CD45%) was measured at 3 (marrowaspiration from knee joint) and 9 (sacrificed and marrow harvested frombilateral femurs and tibiae) weeks. (FIG. 2 a) Limiting dilutiontransplants were carried out as described above to calculate the SRCfrequency, shown as the SRC frequency per 10⁶ starting cells. Resultsare the mean±SEM. *P values shown represent Delta1^(ext-IgG) culturedcells compared to control cultured or non-cultured cells. (FIG. 2 b)Human engraftment as measured by total CD45%, lymphoid subsetCD19⁺/CD45⁺ cells (black) and myeloid subset of CD33⁺/CD45⁺ doublepositive cells.

FIG. 3 is a graph showing that rapid early engraftment is dependent uponculture with Delta1^(ext-IgG). CD34⁺ cord blood progenitors werecultured with Delta1^(ext-IgG) and compared to non-cultured cells forNOD/SCID repopulating ability. Human engraftment (CD45%) in the marrowwas assessed 10 days and 3 weeks after infusion of the cells. Resultsshown are the mean CD45%±sem and is representative of one of twoexperiments where early engraftment was assessed.

FIGS. 4 a-4 c show that cryopreservation of ex vivo expanded cord bloodprogenitors does not impair in vivo repopulating ability. Overall humanengraftment as measured by human CD45 in the marrow of recipient mice isshown on the y axis. The solid lines represent the mean level of humanengraftment. (FIG. 4 a) Cells infused immediately post culture comparedwith harvested cells that were cryopreserved prior to infusion. Resultsshown are at 4 weeks post infusion. (FIG. 4 b) Ex vivo expanded andcryopreserved progenitor cells were thawed and infused. The figurerepresents the combined results of two experiments. (FIG. 4 c) Theexpanded progeny derived from expansion of CD34⁺ progenitors obtainedfrom a single cord blood unit were divided into equal groups andcryopreserved per standard practice. Three methods of thawing prior toinfusion were then compared for in vivo repopulating ability: thaw andwash, thaw and dilute (albumin/dextran dilution), thaw and directinfusion.

FIG. 5 shows a comparison of engraftment of Delta1^(ext-IgG) culturedcells in congenic and allogeneic hematopoietic stem cells transplants(HCTs). LSK cells were cultured on Delta1^(ext-IgG) for 4 weeks asdescribed in Dallas et al., 2007 Blood 109:3579-3587. In the congenicHCT, lethally irradiated (1000 cGY) C57 (H-2d) mice received 10⁵ C57whole BM+10⁶ Delta1^(ext-IgG)-cultured cells. In the allogeneic HCT,lethally irradiated (1000 cGy) BALB.c (H-2d) mice received 10⁵ BALB.cwhole BM+10⁶ Delta1^(ext-IgG)-cultured cells. Blood was analyzed by FACSanalysis at 2, 3, 5, and 7 weeks after HCT. N=5−7.

FIG. 6 shows engraftment of Delta1^(ext-IgG)-cultured cells inHLA-mismatched recipients. LSK cells were cultured for 4 weeks asdescribed in Ohisi et al., 2002, J. Clin. Invest. 110:1165-1174 andDallas et al., 2007 Blood 109:3579-3587. Lethally irradiated BALB.c(H-2d, CD45.2) recipients received 10⁶ Ly5.1 (H-2b, CD45.1)Delta1^(ext-IgG)-cultured LSK cells along with 10³ BALB.c (H-2d, CD45.2)LSK cells or 10³ Ly5.1 (H-2b, CD45.1) LSK cells+10³ BALB.c (H-2d,CD45.2). Mice were sacrificed at day 3 and 7; bone marrow engraftmentwas determined by FAC analysis (n=5).

FIG. 7 is a schematic drawing of the experimental protocol for expansionof stem and progenitor cells and infusion of the expanded cells intoirradiated mice, in order to compare engraftment of the expanded stemand progenitor cells with non-expanded stem and progenitor cells.

FIGS. 8 a-8 b graphically show the engraftment of mismatched expandedstem and progenitor cells as detected in bone marrow and in peripheralblood of lethally irradiated mice.

FIGS. 9 a-9 b show the overall survival of mice exposed to 7.5 Gy or 8Gy of radiation after infusion with expanded stem and progenitor cellsthat were previously cryopreserved, as compared to a control salinegroup.

FIG. 10 depicts the overall survival of mice irradiated at 8.5 Gy afterinfusion of expanded stem and progenitor cells (cultured with a Deltaderivative) as compared to infusion of non-expanded cord blood stem andprogenitor cells (IgG cultured).

FIGS. 11 a-11 b show that donor engraftment of expanded murine stem andprogenitor cells (DXI) is enhanced with an increasing dose of radiation.

FIG. 12 shows clinical grade culture of cord blood progenitors withDelta^(ext-IgG) results in significant in vitro expansion of CD34⁺ cellsand more rapid neutrophil recovery in a myeloablative double CBTsetting. CD34⁺ cord blood progenitor cells were enriched and placed intoculture with Delta1^(ext-IgG). The individual and median times (solidline) to absolute neutrophil counts (ANC) of ≧500/μl for patientsreceiving double unit cord blood transplants with two non-manipulatedunits (“conventional”) versus with one ex vivo expanded unit and onenon-manipulated unit (“expanded”) is presented.

FIG. 13 is a flowchart demonstrating an exemplary procedure forenriching a population of CD34⁺ cells, and expanding the enrichedpopulation.

FIG. 14 is a flow chart setting forth a plan for induction therapy forpatients with AML.

FIG. 15 is a chart setting forth the characteristics of the patientstreated, and infused cell count and neutrophil recovery time.

FIG. 16 is a chart depicting expanded cord blood stem and progenitorcell engraftment expressed as a percentage of donor cells at day 7post-infusion of the expanded cord blood stem and progenitor cellsample.

FIG. 17 is a flow chart setting forth a protocol for treating ahematologic malignancy, such as AML, by administering a cord bloodtransplant and an expanded cord blood stem and progenitor cell sample.

FIG. 18 shows the time required post-transplant to achieve an absoluteneutrophil count (ANC) of greater than or equal to 100 per μl.

FIG. 19 shows the time required post-transplant to achieve an absoluteneutrophil count (ANC) of greater than or equal to 500 per μl.

FIG. 20 is a chart depicting the results of a peripheral blood cell DNAchimerism analysis at day 7 post-infusion (QNS, quantity notsufficient).

6. DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a method for providing hematopoieticfunction to a human patient in need thereof by administering an expandedhuman cord blood stem cell sample to the patient, wherein saidadministering is done without matching the HLA-type of the expandedhuman cord blood stem cell sample to the HLA type of the patient. By“without matching the HLA-type,” what is meant is that no steps aretaken to have any of the HLA antigens or alleles match between thepatient and the sample. In one embodiment, the expanded human cord bloodstem cells can differentiate into cells of the myeloid lineage. Inanother embodiment, the expanded human cord blood stem cell candifferentiate into cells of the lymphoid lineage. The selection of theExpanded CB Stem Cells to be administered to the patient is done withouttaking into account whether the patient to whom the Expanded CB StemCells will be administered matches or mismatches the Expanded CB StemCells at any of the HLA antigens or alleles.

The ideal therapeutic product for treatment of chemotherapy or radiationinduced pancytopenia is one that, when infused, would give rise to rapidhematopoietic reconstitution, especially of granulocytes, and alsofacilitate autologous recovery of hematopoiesis. Moreover, in order tobe delivered in an expedited fashion, it is essential that thetherapeutic product be developed as on “off-the-shelf” product thatcould be stockpiled long term after generation (manufacture).Hypothetically, while marrow or mobilized peripheral blood stem cellscould provide a transient population of blood cells that could beinfused to help mitigate pancytopenia that results from high dosechemotherapy/radiation, these would require HLA-matching for use, andprocurement of these cells would not be easy or amenable to stockpiling.Similarly, the collection and use of granulocytes for transfusion astreatment for infection occurring in the setting of prolongedneutropenia is not promising. Current evidence indicates relativelylittle or no effect of granulocyte transfusions, possibly due to alimited lifespan (hours) of the cells infused and absence of in vivogeneration of additional cells (not a renewable source of cells).

Prior to the present invention, it was not appreciated that Expanded CBStem Cells could provide hematopoietic benefit to a human patientirrespective of HLA matching, since it was believed that the host immuneresponse against the graft would destroy the potential therapeuticbenefit. The present invention takes advantage of the prompthematopoietic benefit provided by the Expanded CB Stem Cells to providea benefit to a human patient even if the Expanded CB Stem Cells and thepatient are HLA mismatched. While not being bound by any mechanism, itis believed that the Expanded CB Stem Cells can provide therapeuticbenefit in a mismatch setting because the rapidity of engraftmentprovided by these cells allows for a beneficial effect on hematopoieticfunction before GVHD can develop and obviate such effect. Also, theincreased hematopoietic cell numbers (including stem and progenitorcells) provided by the expansion methods described herein are believedto overcome, at least temporarily, host resistance to foreign cells.Additionally, other cell types generated in the expanded population,such as dendritic cell or natural killer (NK) cell precursors, isbelieved to prevent rejection of the infused cells by the host. Thus,provision of hematopoietic function can be achieved even in a mismatchedsetting, and administration to a patient can be therapeutic regardlessof whether the patient and the expanded cord blood stem cell sample areHLA-matched.

Frequent infections are a common complication of induction chemotherapyand salvage regimens used in the treatment of hematopoieticmalignancies, and in fact are a leading cause of treatment failure. Thechemotherapeutic agents also can be profoundly immunosuppressive and/orhighly myelosuppressive, which can lead to periods of prolongedneutropenia. Infusion of the Expanded CB Stem Cells of the invention canprovide a therapeutic benefit in overcoming these challenges byabrogating neutropenia, preventing infectious complications, andfacilitating host hematopoietic recovery post-chemotherapy.

Moreover, since according to the present invention, matching of HLA-typeis not necessary for therapeutic use of the Expanded CB Stem Cells, itis now practical to store frozen Expanded CB Stem Cells, since thepresent invention teaches that useful amounts can practically be stored.In the prior art, since it was expected that HLA matching to therecipient would generally be necessary to find a useful sample ofExpanded CB Stem Cells for therapeutic use, an unattainably large numberof different Expanded CB Stem Cell samples had to be stored to make itfeasible generally to find a match for a patient, the large numbersmaking it impractical to store expanded samples, due to the even largeramount of storage space needed to store expanded units. In contrast, andin accordance with the present invention, no HLA matching is required,and thus, the generation of a “bank” of CB Stem Cells which have beenexpanded and then cryopreserved, useful for the general human populationto use in stem cell transplantation, is feasible, since any Expanded CBStem Cell sample in the bank could feasibly be used with any recipientin a therapeutic method of the invention.

6.1 Collecting Cord Blood

Human umbilical cord blood and/or human placental blood are sources ofthe CB Stem Cells according to the present invention. Such blood can beobtained by any method known in the art. The use of cord or placentalblood as a source of Stem Cells provides numerous advantages, includingthat the cord and placental blood can be obtained easily and withouttrauma to the donor. See, e.g., U.S. Pat. No. 5,004,681 for a discussionof collecting cord and placental blood at the birth of a human. In oneembodiment, cord blood collection is performed by the method disclosedin U.S. Pat. No. 7,147,626 B2 to Goodman et al. Collections should bemade under sterile conditions. Immediately upon collection, cord orplacental blood should be mixed with an anticoagulent. Such ananticoagulent can be any known in the art, including but not limited toCPD (citrate-phosphate-dextrose), ACD (acid citrate-dextrose), Alsever'ssolution (Alsever et al., 1941, N.Y. St. J. Med. 41:126), De Gowin'sSolution (De Gowin, et al., 1940, J. Am. Med. Ass. 114:850),Edglugate-Mg (Smith, et al., 1959, J. Thorac. Cardiovasc. Surg. 38:573),Rous-Turner Solution (Rous and Turner, 1916, J. Exp. Med. 23:219), otherglucose mixtures, heparin, ethyl biscoumacetate, etc. See, generally,Hurn, 1968, Storage of Blood, Academic Press, New York, pp. 26-160). Inone embodiment, ACD can be used.

The cord blood can preferably be obtained by direct drainage from thecord and/or by needle aspiration from the delivered placenta at the rootand at distended veins. See, generally, U.S. Pat. No. 5,004,681.Preferably, the collected human cord blood and/or placental blood isfree of contamination.

In certain embodiments, the following tests on the collected bloodsample can be performed either routinely, or where clinically indicated:

(i) Bacterial culture: To ensure the absence of microbial contamination,established assays can be performed, such as routine hospital culturesfor bacteria under aerobic and anaerobic conditions.

(ii) Diagnostic screening for pathogenic microorganisms: To ensure theabsence of specific pathogenic microorganisms, various diagnostic testscan be employed. Diagnostic screening for any of the numerous pathogenstransmissible through blood can be done by standard procedures. As oneexample, the collected blood sample (or a maternal•blood sample) can besubjected to diagnostic screening for the presence of HumanImmunodeficiency Virus-1 or 2 (HIV-1 or HIV-2). Any of numerous assaysystems can be used, based on the detection of virions, viral-encodedproteins, HIV-specific nucleic acids, antibodies to HIV proteins, etc.The collected blood can also be tested for other infectious diseases,including but not limited to human T-Cell lymphotropic virus I and II(HTLV-I and HTLV-II), Hepatitis B, Hepatitis C, Cytomegalovirus,Syphilis, West Nile Virus.

Preferably, prior to collection of the cord blood, maternal healthhistory is determined in order to identify risks that the cord bloodcells might pose in transmitting genetic or infectious diseases, such ascancer, leukemia, immune disorders, neurological disorders, hepatitis orAIDS. The collected cord blood samples can undergo testing for one ormore of cell viability, HLA typing, ABO/Rh typing, CD34⁺ cell count, andtotal nucleated cell count.

6.2 Enrichment of Cord Blood Stem Cells

Once the umbilical cord blood and/or placental blood is collected from asingle human at birth, the blood is processed to produce an enrichedhematopoietic stem cell population, or enriched hematopoietic stem andprogenitor cell population, forming a population of CB Stem Cells. Thehematopoietic stem cells, or hematopoietic stem and progenitor cells,can be positive for a specific marker expressed in increased levels onthe hematopoietic stem cells or hematopoietic stem and progenitor cells,relative to other types of hematopoietic cells. For example, suchmarkers can be, but are not limited to, CD34, CD43, CD45RO, CD45RA,CD59, CD90, CD109, CD117, CD133, CD166, HLA DR, or a combinationthereof. The hematopoietic stem cells, or hematopoietic stem andprogenitor cells, also can be negative for a specific marker, relativeto other types of hematopoietic cells. For example, such markers can be,but are not limited to, Lin, CD38, or a combination thereof. Preferably,the hematopoietic stem cells, or hematopoietic stem and progenitorcells, are CD34⁺ cells. Preferably, the CB Stem Cell population isenriched in CD34⁺ stem cells or CD34⁺ stem and progenitor cells (and,thus, T cell depleted). Enrichment thus refers to a process wherein thepercentage of hematopoietic stem cells, or hematopoietic stem andprogenitor cells in the sample is increased (relative to the percentagein the sample before the enrichment procedure). Purification is oneexample of enrichment. In certain embodiments, the increase in thenumber of CD34⁺ cells (or other suitable antigen-positive cells) as apercentage of cells in the enriched sample, relative to the sample priorto the enrichment procedure, is at least 25-, 50-, 75-, 100-, 150-,200-, 250-, 300-, 350-fold, and preferably is 100-200 fold. In apreferred embodiment, the CD34⁺ cells are enriched using a monoclonalantibody to CD34, which antibody is conjugated to a magnetic bead, and amagnetic cell separation device to separate out the CD34⁺ cells.

In a preferred embodiment, prior to processing for enrichment, thecollected cord and/or placental blood is fresh and has not beenpreviously cryopreserved.

Any technique known in the art for cell separation/selection can be usedto carry out the enrichment for hematopoietic stem cells, orhematopoietic stem and progenitor cells. For example, methods which relyon differential expression of cell surface markers can be used. Forexample, cells expressing the cell surface marker CD34 can be positivelyselected using a monoclonal antibody to CD34, such that cells expressingCD34 are retained, and cells not expressing CD34 are not retained.Moreover, the separation techniques employed should maximize theviability of the cell to be selected. The particular technique employedwill depend upon efficiency of separation, cytotoxicity of themethodology, ease and speed of performance, and necessity forsophisticated equipment and/or technical skill.

Procedures for separation may include magnetic separation, usingantibody-coated magnetic beads, affinity chromatography, cytotoxicagents joined to a monoclonal antibody or used in conjunction with amonoclonal antibody, e.g., complement and cytotoxins, and “panning” withantibody attached to a solid matrix, e.g., plate, or other convenienttechnique. Techniques providing accurate separation/selection includefluorescence activated cell sorters, which can have varying degrees ofsophistication, e.g., a plurality of color channels, low angle andobtuse light scattering detecting channels, impedance channels, etc.

The antibodies may be conjugated with markers, such as magnetic beads,which allow for direct separation, biotin, which can be removed withavidin or streptavidin bound to a support, fluorochromes, which can beused with a fluorescence activated cell sorter, or the like, to allowfor ease of separation of the particular cell type. Any technique may beemployed which is not unduly detrimental to the viability of theremaining cells.

In a preferred embodiment of the present invention, a fresh cord bloodunit is processed to select for, i.e., enrich for, CD34⁺ cells usinganti-CD34 antibodies directly or indirectly conjugated to magneticparticles in connection with a magnetic cell separator, for example, theCliniMACS® Cell Separation System (Miltenyi Biotec, Bergisch Gladbach,Germany), which employs nano-sized super-paramagnetic particles composedof iron oxide and dextran coupled to specific monoclonal antibodies. TheCliniMACS® Cell Separator is a closed sterile system, outfitted with asingle-use disposable tubing set. The disposable set can be used for anddiscarded after processing a single unit of collected cord and/orplacental blood to enrich for CD34⁺ cells. Similarly, CD133⁺ cells canbe enriched using anti-CD133 antibodies. In a specific embodiment, CD34⁺CD90⁺ cells are enriched for. Similarly, cells expressing CD43, CD45RO,CD45RA, CD59, CD90, CD109, CD117, CD166, HLA DR, or a combination of theforegoing, can be enriched for using antibodies against the antigen.

In one embodiment, one or more umbilical cord blood and/or placentalblood samples can be pooled prior to enriching for the hematopoieticstem cells, or hematopoietic stem and progenitor cells. In anotherembodiment, individual CB Stem Cell samples can be pooled afterenriching for the hematopoietic stem cells, or hematopoietic stem andprogenitor cells. In specific embodiments, the number of umbilical cordblood and/or placental blood samples, or CB Stem Cell samples, that arepooled is 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, or 40, or atleast any of the foregoing numbers, preferably 20, or no more than 20 or25, umbilical cord blood and/or placental blood samples, or CB Stem Cellsamples, respectively. Preferably, the umbilical cord blood and/orplacental blood samples or CB Stem Cell samples are pooled withoutregard to the HLA type of the hematopoietic stem or hematopoietic stemand progenitor cells. In certain embodiments, the samples in the poolare derived from the umbilical cord blood and/or placental blood ofindividuals of the same race, e.g., African-American, Caucasian, Asian,Hispanic, Native-American, Australian Aboriginal, Inuit, PacificIslander, or derived from umbilical cord blood and/or placental blood ofindividuals of the same ethnicity, e.g., Irish, Italian, Indian,Japanese, Chinese, Russian, etc.

Optionally, prior to enrichment for hematopoietic stem cells orhematopoietic stem and progenitor cells, the red blood cells and whiteblood cells of the cord blood can be separated. Once the separation ofthe red blood cells and the white blood cells has taken place, the redblood cell fraction can be discarded, and the white blood cell fractioncan be processed in the magnetic cell separator as above. Separation ofthe white and red blood cell fractions can be performed by any methodknown in the art, including centrifugation techniques. Other separationmethods that can be used include the use of commercially availableproducts FICOLL™ or FICOLL-PAQUE™ or PERCOLL™ (GE Healthcare,Piscataway, N.J.). FICOLL-PAQUE™ is normally placed at the bottom of aconical tube, and the whole blood is layered above. After beingcentrifuged, the following layers will be visible in the conical tube,from top to bottom: plasma and other constituents, a layer ofmono-nuclear cells called buffy coat containing the peripheral bloodmononuclear cells (white blood cells), FICOLL-PAQUE™, and erythrocytesand granulocytes, which should be present in pellet form. Thisseparation technique allows easy harvest of the peripheral bloodmononuclear cells.

Optionally, prior to CD34⁺ cell selection, an aliquot of the fresh cordblood unit can be checked for total nucleated cell count and/or CD34⁺content. In a specific embodiment, after the CD34⁺ cell selection, bothCD34⁺ (“CB Stem Cells”) and CD34-cell fractions are recovered.Optionally, DNA can be extracted from a sample of the CD34-cell fractionfor initial HLA typing and future chimerism studies, even though HLAmatching to the patient is not done according to the methods of thepresent invention. The CD34⁺ enriched stem cell fraction (“CB StemCells”) can be subsequently processed prior to expansion, for example,the Stem Cells can be suspended in an appropriate cell culture mediumfor transport or storage. In a preferred embodiment, the cell culturemedium consists of STEMSPANT™ Serum Free Expansion Medium (StemCellTechnologies, Vancouver, British Columbia) supplemented with 10 ng/mlrecombinant human Interleukin-3 (rhIL-3), 50 ng/ml recombinant humanInterleukin-6 (rhIL-6), 50 ng/ml recombinant human Thrombopoietin(rhTPO), 50 ng/ml recombinant human Flt-3 Ligand (rhFlt-3L), 50 ng/mland recombinant human stem cell factor (rhSCF).

In a specific embodiment, the umbilical cord blood and/or placentalblood sample are red cell depleted, and the number of CD34⁺ cells in thered cell depleted fraction is calculated. Preferably, the umbilical cordblood and/or placental blood samples containing more than 3.5 millionCD34⁺ cells are enriched by the enrichment methods described above.

6.3 Methods of Cord Blood Stem Cell Expansion

After the CB Stem Cells have been isolated from human cord blood and/orhuman placental blood collected from one or more humans at birthaccording to the enrichment methods described above or other methodsknown in the art, the CB Stem Cells are expanded in order to increasethe number of hematopoietic stem cells or hematopoietic stem andprogenitor cells, e.g., CD34⁺ cells. Any method known in the art forexpanding the number of CB Stem Cells that gives rise to Expanded CBStem Cell can be used. Preferably, the CB Stem Cells are cultured undercell growth conditions (e.g., promoting mitosis) such that the CB StemCells grow and divide (proliferate) to obtain a population of ExpandedCB Stem Cells. In one embodiment, individual populations of CB StemCells each derived from the umbilical cord blood and/or placental bloodof a single human at birth can be pooled, without regard to the HLA typeof the CB Stem Cells, prior to or after the expansion technique. Inanother embodiment, the sample that is expanded is not a pool ofsamples. Preferably, the technique used for expansion is one that hasbeen shown to (i) result in an increase in the number of hematopoieticstem cells, or hematopoietic stem and progenitor cells, e.g., CD34⁺cells, in the expanded sample relative to the unexpanded CB Stem Cellsample, or (ii) results in an increased number of SCID repopulatingcells in the expanded sample determined by limiting-dilution analysis asshown by enhanced engraftment in NOD/SCID mice infused with the expandedsample, relative to that seen with the unexpanded sample, where theunexpanded sample and expanded sample are from different aliquots of thesame sample, wherein the expanded sample but not the unexpanded sampleis subjected to the expansion technique. In certain embodiments, thetechnique results in a 50-, 75-, 100-, 150-, 200-, 250-, 300-, 350-,400-, 450-, or 500-fold increase, preferably a 100-200 fold increase inthe number of hematopoietic stem cells or hematopoietic stem andprogenitor cells in the expanded sample, relative to the unexpanded CBStem Cell sample. The hematopoietic stem cells or hematopoietic stem andprogenitor cells can be positive for one or more of CD34, CD43, CD45RO,CD45RA, CD59, CD90, CD109, CD117, CD133, CD166, and HLA DR and/ornegative for Lin and/or CD38. In a specific embodiment, the enhancedengraftment can be detected by detecting an increased percentage ofhuman CD45⁺ cells in the bone marrow of mice infused with an aliquot ofthe expanded sample relative to mice infused with an aliquot of theunexpanded sample at, e.g., 10 days, 3 weeks or 9 weeks post-infusion(see Delaney et al., 2010, Nature Med. 16(2): 232-236).

Such expansion techniques include, but are not limited to thosedescribed in U.S. Pat. No. 7,399,633 B2; Delaney et al., 2010, NatureMed. 16(2): 232-236; Zhang et al., 2008, Blood 111:3415-3423; andHimburg et al., 2010, Nature Medicine doi:10.1038/nm.2119 (advancedonline publication), as well as those described below.

In one embodiment of the invention, the CB Stem Cells are cultured withgrowth factors, and are exposed to cell growth conditions (e.g.,promoting mitosis) such that the Stem Cells proliferate to obtain anExpanded CB Stem Cell population according to the present invention. Ina preferred embodiment of the invention, the CB Stem Cells are culturedwith an amount of an agonist of Notch function effective to inhibitdifferentiation, and are exposed to cell growth conditions (e.g.,promoting mitosis) such that the CB Stem Cells proliferate to obtain anExpanded CB Stem Cell population according to the present invention. Ina more preferred embodiment, the CB Stem Cells are cultured with anamount of an agonist of Notch function effective to inhibitdifferentiation and in the presence of growth factors, and are exposedto cell growth conditions (e.g., promoting mitosis) such that the CBStem Cells proliferate to obtain an Expanded CB Stem Cell populationaccording to the present invention. The Expanded CB Stem Cell populationso obtained can be frozen and stored for later use, for example, toprovide hematopoietic function to an immunodeficient human patient.Optionally, the Notch pathway agonist is inactivated or removed from theExpanded CB Stem Cell population prior to transplantation into thepatient (e.g., by separation, dilution).

In specific embodiments, the CB Stem Cells are cultured for 2, 3, 4, 5,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,or 25 days or more; or, preferably, the CB Stem Cells are cultured forat least 10 days.

An exemplary culture condition for expanding the CB Stem Cells includeis set forth in Section 7.1 infra, and comprises culturing the StemCells for 17-21 days in the presence of fibronectin fragments and theextracellular domain of a Delta protein fused to the Fc domain of humanIgG (Delta1^(ext-IgG)) in serum free medium supplemented with thefollowing human growth factors: stem cell factor, Flt-3 receptor ligand,thrombopoietin, interleukin-6 and interleukin-3. Preferably, theforegoing growth factors are present at the following concentrations:50-300 ng/ml stem cell factor, 50-300 ng/ml Flt-3 receptor ligand,50-100 ng/ml thrombopoietin, 50-100 ng/ml interleukin-6 and 10 ng/mlinterleukin-3. In more specific embodiments, 300 ng/ml stem cell factor,300 ng/ml of Flt-3 receptor ligand, 100 ng/ml thrombopoietin, 100 ng/mlinterleukin-6 and 10 ng/ml interleukin-3, or 50 ng/ml stem cell factor,50 ng/ml of Flt-3 receptor ligand, 50 ng/ml thrombopoietin, 50 ng/mlinterleukin-6 and 10 ng/ml interleukin-3 are used. Preferably, theDelta1^(ext-IgG) is immobilized on the surface of the cell culturedishes. In a specific embodiment, the cell culture dishes are coatedovernight at 4° C. (or for a minimum of 2 hours at 37° C.) with 2.5μg/ml Delta1^(ext-IgG) and 5 μg/ml RetroNectin® (a recombinant humanfibronectin fragment) in phosphate buffered saline, before adding the CBStem Cells.

Other exemplary culture condition for expanding the CB Stem Cells of theinvention comprises are set forth in Zhang et al., 2008, Blood111:3415-3423. In a specific embodiment, the CB Stem Cells can becultured in serum free medium supplemented with heparin, stem cellfactor, thrombopoietin, insulin-like growth factor-2 (IGF-2), fibroblastgrowth factor-1 (FGF-1), and Angpt13 or Angpt15. In a specificembodiment, the medium is supplemented with 10 μg/ml heparin, 10 ng/mlstem cell factor, 20 ng/ml thrombopoietin, 20 ng/ml IGF-2, and 10 ng/mlFGF-1, and 100 ng/ml Angpt13 or Angpt15 and the cells are cultured for19-23 days. In another specific embodiment, the CB Stem Cells can beexpanded by culturing the CB Stem Cells in serum free mediumsupplemented with 10 μg/ml heparin, 10 ng/ml stem cell factor, 20 ng/mlthrombopoietin, 10 ng/ml FGF-1, and 100 ng/ml Angpt15 for 11-19 days. Inanother specific embodiment, the CB Stem Cells can be expanded byculturing the CB Stem Cells in serum free medium supplemented with 50ng/ml stem cell factor, 10 ng/ml thrombopoietin, 50 ng/ml Flt-3 receptorligand, and 100 ng/ml insulin-like growth factor binding protein-2(IGFBP2) or 500 ng/ml Angpt15 for 10 days. In yet another embodiment,the CB Stem Cells can be expanded by culturing the CB Stem Cells inserum free medium supplemented with 10 μg/ml heparin, 10 ng/ml stem cellfactor, 20 ng/ml thrombopoietin, 10 ng/ml FGF-1, 500 ng/ml Angpt15, and500 ng/ml IGFBP2 for 11 days. See Zhang et al., 2008, Blood111:3415-3423.

Another exemplary culture condition for expanding the CB Stem Cells ofthe invention is set forth in Himburg et al., 2010, Nature Medicinedoi:10.1038/nm.2119 (advanced online publication). In a specificembodiment, the CB Stem Cells can be cultured in liquid suspensionculture supplemented with thrombopoietin, stem cell factor, Flt-3receptor ligand, and pleiotrophin. In a specific embodiment, the liquidsuspension culture is supplemented with 20 ng/ml thrombopoietin, 125ng/ml stem cell factor, 50 ng/ml Flt-3 receptor ligand, and 10, 100,500, or 1000 ng/ml pleiotrophin and the CB Stem Cells are cultured for 7days.

In a preferred embodiment of the invention, after expansion of the CBStem Cells, the total number of cells and viable CD34⁺ cells aredetermined to measure the potency of the sample to provide hematopoieticfunction. Numerous clinical studies have shown that the total nucleatedcell dose and the CD34⁺ cell dose in stem cell grafts are highlycorrelated with neutrophil and platelet engraftment as well as theincidence of graft failure and early transplant-related complications(primarily lethal infections) following stem cell transplantation. Forexample, at day 5-8 post culture initiation during expansion, a samplecan be taken for determination of the total viable nucleated cell count.In addition, the total number of CD34⁺ cells can be determined bymulti-parameter flow cytometry, and, thus, the percentage of CD34⁺ cellsin the sample. Preferably, cultures that have not resulted in at least a10-fold increase in the absolute number of CD34⁺ cells at this time arediscontinued. Similarly, prior to cryopreservation or after thawing, analiquot of the Expanded CB Stem Cell sample can be taken fordetermination of total nucleated cells and percentage of viable CD34⁺cells in order to calculate the total viable CD34⁺ cell number in theExpanded CB Stem Cell sample. In a preferred embodiment, those ExpandedCB Stem Cell samples containing less than 75 million CD34⁺ viable cellscan be discarded.

In a specific embodiment, total viable CD34⁺ (or other antigen-positive)cell numbers can be considered the potency assay for release of thefinal product for therapeutic use. Viability can be determined by anymethod known in the art, for example, by trypan blue exclusion or 7-AADexclusion. Preferably, the total nucleated cell count (TNC) and otherdata are used to calculate the potency of the product. The percentage ofviable CD34⁺ cells can be assessed by flow cytometry and use of a stainthat is excluded by viable cells. The percentage of viable CD34⁺cells=the number of CD34⁺ cells that exclude 7-AAD (or other appropriatestain) in an aliquot of the sample divided by the TNC (both viable andnon-viable) of the aliquot. Viable CD34⁺ cells in the sample can becalculated as follows: Viable CD34⁺ cells=TNC of sample x % viable CD34⁺cells in the sample. The proportional increase during enrichment orexpansion in viable CD34⁺ cells can be calculated as follows: TotalViable CD34⁺ cells Post-culture/Total Viable CD34⁺ cells Pre-culture. Aswill be apparent, antigens other than or in addition to CD34 can beused.

6.3.1 Notch Agonists

In a preferred embodiment of the present invention, the CB Stem Cellsare expanded by culturing the cells in the presence of an agonist ofNotch function and one of more growth factors or cytokines for a givenperiod of time. Culturing the CB Stem Cells can take place under anysuitable culture medium/conditions known in the art (see, e.g., FreshneyCulture of Animal Cells, Wiley-Liss, Inc., New York, N.Y. (1994)). Thetime in culture is for a time sufficient to produce an Expanded CB StemCell population, as defined herein. For example, the CB Stem Cells canbe cultured in a serum-free medium in the presence of an agonist ofNotch function and one or more growth factors or cytokines for 2, 3, 4,5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23,24, or 25 days; or, preferably, for at least 10 days. Optionally, at anypoint during the culturing period, the culture medium can be replacedwith fresh medium or fresh medium can be added.

A Notch agonist is an agent that promotes, i.e., causes or increases,activation of Notch pathway function. As used herein, “Notch pathwayfunction” shall mean a function mediated by the Notch signaling (signaltransduction) pathway, including but not limited to nucleartranslocation of the intracellular domain of Notch, nucleartranslocation of RBP-Jκ or its Drosophila homolog Suppressor ofHairless; activation of bHLH genes of the Enhancer of Split complex,e.g., Mastermind; activation of the HES-1 gene or the KBF2 (also calledCBF 1) gene; inhibition of Drosophila neuroblast segregation; andbinding of Notch to Delta, Jagged/Serrate, Fringe, Deltex orRBP-Jκ/Suppressor of Hairless, or homologs or analogs thereof. Seegenerally the review article by Kopan et al., 2009, Cell 137:216-233 fora discussion of the Notch signal transduction pathway and its effectsupon activation; see also Jarriault et al., 1998, Mol. Cell. Biol.18:7423-7431.

Notch activation is carried out by exposing a cell to a Notch agonist.The agonist of Notch can be but is not limited to a soluble molecule, amolecule that is recombinantly expressed on a cell-surface, a moleculeon a cell monolayer to which the precursor cells are exposed, or amolecule immobilized on a solid phase. Exemplary Notch agonists are theextracellular binding ligands Delta and Serrate which bind to theextracellular domain of Notch and activate Notch signal transduction, ora fragment of Delta or Serrate that binds to the extracellular domain ofNotch and activates Notch signal transduction. Nucleic acid and aminoacid sequences of Delta and Serrate have been isolated from severalspecies, including human, are known in the art, and are disclosed inInternational Patent Publication Nos. WO 93/12141, WO 96/27610, WO97/01571, Gray et al., 1999, Am. J. Path. 154:785-794. In a preferredmode of the embodiment, the Notch agonist is an immobilized fragment ofa Delta or Serrate protein consisting of the extracellular domain of theprotein fused to a myc epitope tag (Delta^(ext-myc) orSerrate^(ext-myc), respectively) or an immobilized fragment of a Deltaor Serrate protein consisting of the extracellular domain of the proteinfused to the Fc portion of IgG (Delta^(ext-IgG) or Serrate^(ext-IgG),respectively). Notch agonists of the present invention include but arenot limited to Notch proteins and analogs and derivatives (includingfragments) thereof; proteins that are other elements of the Notchpathway and analogs and derivatives (including fragments) thereof;antibodies thereto and fragments or other derivatives of such antibodiescontaining the binding region thereof; nucleic acids encoding theproteins and derivatives or analogs; as well as proteins and derivativesand analogs thereof which bind to or otherwise interact with Notchproteins or other proteins in the Notch pathway such that Notch pathwayactivity is promoted. Such agonists include but are not limited to Notchproteins and derivatives thereof comprising the intracellular domain,Notch nucleic acids encoding the foregoing, and proteins comprising theNotch-interacting domain of Notch ligands (e.g., the extracellulardomain of Delta or Serrate). Other agonists include but are not limitedto RBPR/Suppressor of Hairless or Deltex. Fringe can be used to enhanceNotch activity, for example in conjunction with Delta protein. Theseproteins, fragments and derivatives thereof can be recombinantlyexpressed and isolated or can be chemically synthesized.

In another specific embodiment, the Notch agonist is a cell whichrecombinantly expresses a protein or fragment or derivative thereof,which agonizes Notch. The cell expresses the Notch agonist in such amanner that it is made available to the CB Stem Cells in which Notchsignal transduction is to be activated, e.g., it is secreted, expressedon the cell surface, etc.

In yet another specific embodiment, the agonist of Notch is apeptidomimetic or peptide analog or organic molecule that binds to amember of the Notch signaling pathway. Such an agonist can be identifiedby binding assays selected from those known in the art, for example thecell aggregation assays described in Rebay et al., 1991, Cell 67:687-699and in International Patent Publication No. WO 92/19734.

In a preferred embodiment the agonist is a protein consisting of atleast a fragment of a protein encoded by a Notch-interacting gene whichmediates binding to a Notch protein or a fragment of Notch, whichfragment of Notch contains the region of Notch responsible for bindingto the agonist protein, e.g., epidermal growth factor-like repeats 11and 12 of Notch. Notch interacting genes, as used herein, shall mean thegenes Notch, Delta, Serrate, RBPJκ, Suppressor of Hairless and Deltex,as well as other members of the Delta/Serrate family or Deltex familywhich may be identified by virtue of sequence homology or geneticinteraction and more generally, members of the “Notch cascade” or the“Notch group” of genes, which are identified by molecular interactions(e.g., binding in vitro, or genetic interactions (as depictedphenotypically, e.g., in Drosophila). Exemplary fragments ofNotch-binding proteins containing the region responsible for binding toNotch are described in U.S. Pat. Nos. 5,648,464; 5,849,869; and5,856,441.

The Notch agonists utilized by the methods of the invention can beobtained commercially, produced by recombinant expression, or chemicallysynthesized.

In a specific embodiment, exposure of the cells to a Notch agonist isnot done by incubation with other cells recombinantly expressing a Notchligand on the cell surface (although in other embodiments, this methodcan be used), but rather is by exposure to a cell-free Notch ligand,e.g., incubation with a cell-free ligand of Notch, which ligand isimmobilized on the surface of a solid phase, e.g., immobilized on thesurface of a tissue culture dish.

In specific embodiments, Notch activity is promoted by the binding ofNotch ligands (e.g., Delta, Serrate) to the extracellular portion of theNotch receptor. Notch signaling appears to be triggered by the physicalinteraction between the extracellular domains of Notch and its ligandsthat are either membrane-bound on adjacent cells or immobilized on asolid surface. Full length ligands are agonists of Notch, as theirexpression on one cell triggers the activation of the pathway in theneighboring cell which expresses the Notch receptor. Soluble truncatedDelta or Serrate molecules, comprising the extracellular domains of theproteins or Notch-binding portions thereof, that have been immobilizedon a solid surface, such as a tissue culture plate, are particularlypreferred Notch pathway agonists. Such soluble proteins can beimmobilized on a solid surface by an antibody or interacting protein,for example an antibody directed to an epitope tag with which Delta orSerrate is expressed as a fusion protein (e.g., a myc epitope tag, whichis recognized by the antibody 9E10) or a protein which interacts with anepitope tag with which Delta or Serrate is expressed as a fusion protein(e.g., an immunoglobulin epitope tag, which is bound by Protein A).

In another specific embodiment, and as described in U.S. Pat. No.5,780,300 to Artavanis-Tsakonas et al., Notch agonists include reagentsthat promote or activate cellular processes that mediate the maturationor processing steps required for the activation of Notch or a member ofthe Notch signaling pathway, such as the furin-like convertase requiredfor Notch processing, Kuzbanian, the metalloprotease-disintegrin (ADAM)thought to be required for the activation of the Notch pathway upstreamor parallel to Notch (Schlondorff and Blobel, 1999, J. Cell Sci.112:3603-3617), or, more generally, cellular trafficking and processingproteins such as the rab family of GTPases required for movement betweencellular compartments (for a review on Rab GTPases, see Olkkonen andStenmark, 1997, Int. Rev. Cytol. 176:1-85). The agonist can be anymolecule that increases the activity of one of the above processes, suchas a nucleic acid encoding a furin, Kuzbanian or rab protein, or afragment or derivative or dominant active mutant thereof, or apeptidomimetic or peptide analog or organic molecule that binds to andactivates the function of the above proteins.

U.S. Pat. No. 5,780,300 further discloses classes of Notch agonistmolecules (and methods of their identification) which can be used toactivate the Notch pathway in the practice of the present invention, forexample molecules that trigger the dissociation of the Notch ankyrinrepeats with RBP-Jκ, thereby promoting the translocation of RBP-Jκ fromthe cytoplasm to the nucleus.

6.3.2 Growth Factors/Cytokines

In a preferred embodiment of the present invention, the CB Stem Cellsare expanded by culturing the cells in the presence of an agonist ofNotch function, discussed supra, and one of more growth factors orcytokines for a given period of time. Alternatively, the CB Stem Cellsare expanded by culturing the cells in the presence of one of moregrowth factors or cytokines for a given period of time. Whereinexpansion of the CB Stem Cells without differentiation is to beachieved, the CB Stem Cells of the invention are cultured in thepresence of growth factors that support growth but not differentiation.The growth factor can be any type of molecule, such as a protein or achemical compound, that promotes cellular proliferation and/or survival.

Exposing the CB Stem Cells to one or more growth factors can be doneprior to, concurrently with, or following exposure of the cells to aNotch agonist.

In specific exemplary embodiments, the growth factors present in theexpansion medium include one or more of the following growth factors:stem cell factor (SCF), also known as the c-kit ligand or mast cellgrowth factor, Flt-3 ligand (Flt-3L), interleukin-6 (IL-6),interleukin-3 (IL-3), interleukin-11 (IL-11) and thrombopoietin (TPO),granulocyte-macrophage colony stimulating factor (GM-CSF), granulocytecolony stimulating factor (G-CSF), angiopoietin-like proteins (Angptls)(Angptl2, Angptl3, Angptl5, Angptl7, and Mfap4), insulin growth factor-2(IFG-2), fibroblast growth factor-1 (FGF-1). The amount of SCF, Flt-3L,IL-6, or TPO can be in the range of 10-1000 ng/ml, more preferably about50-500 ng/ml, most preferably about 100-300 ng/ml. In certain specificembodiments, the amount of SCF, Flt-3L, IL-6, or TPO is 100, 125, 150,175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425 or 450 ng/ml. Theamount of 11-3, IL-11, G-CSF, or GM-CSF can be in the range of 2-100ng/ml, more preferably about 5-50 ng/ml, more preferably about 7.5-25ng/ml, most preferably about 10-15 ng/ml. In certain specificembodiments, the amount of 11-3, IL-11, G-CSF, or GM-CSF is 5, 6, 7, 8,9, 10, 12.5, or 15 ng/ml.

In a preferred embodiment for expanding CB Stem Cells, the cells arecultured in a tissue culture dish onto which an extracellular matrixprotein is bound. In a preferred mode of the embodiment, theextracellular matrix protein is fibronectin (FN), or a fragment thereof.Such a fragment can be but is not limited to CH-296 (Dao et al., 1998,Blood 92(12):4612-21) or RetroNectin® (a recombinant human fibronectinfragment) (Clontech Laboratories, Inc., Madison, Wis.).

In a specific embodiment for expanding CB Stem Cells of the presentinvention, the cells are cultured on a plastic tissue culture dishcontaining immobilized Delta ligand, e.g., the extracellular domain ofDelta, and fibronectin in the presence of 100 ng/ml of each of SCF andTPO, and 10 ng/ml GM-CSF. In another specific embodiment for expandingCB Stem Cells, the cells are cultured on a plastic tissue culture dishcontaining immobilized Delta ligand and fibronectin in the presence of100 ng/ml of each of SCF, Flt-3L, TPO and IL-6 and 10 ng/ml of IL-3. Inanother specific embodiment for expanding Stem Cells of the presentinvention, the cells are cultured on a plastic tissue culture dishcontaining immobilized Delta ligand and fibronectin in the presence of100 ng/ml of each of SCF and Flt-3L and 10 mg/ml of each of G-CSF andGM-CSF. In another specific embodiment for expanding CB Stem Cells, thecells are cultured on a plastic tissue culture dish containingimmobilized Delta ligand and fibronectin in the presence of 100 ng/ml ofeach of SCF, Flt-3L and TPO and 10 mg/ml of GM-CSF. In yet anotherspecific embodiment for expanding CB Stem Cells, the cells are culturedon a plastic tissue culture dish containing immobilized Delta ligand andfibronectin in the presence of 300 ng/ml of each of SCF and Flt-3L, 100ng/ml of each of TPO and IL-6, and 10 mg/ml of IL-3. In anotherembodiment for expanding CB Stem Cells, the cells are cultured on aplastic tissue culture dish containing immobilized Delta ligand andfibronectin in the presence of 100 ng/ml of each of SCF, Flt-3L, and TPOand 10 mg/ml of each of G-CSF and GM-CSF. In alternative embodiments tothe foregoing culture conditions, fibronectin is excluded from thetissue culture dishes or is replaced by another extracellular matrixprotein. See also U.S. Pat. No. 7,399,633 B2 to Bernstein et al. foradditional exemplary culture conditions for CB Stem Cell expansion.

The growth factors utilized by the methods of the invention can beobtained commercially, produced by recombinant expression, or chemicallysynthesized. For example, Flt-3L (human), IGF-1 (human), IL-6 (human andmouse), IL-11 (human), SCF (human), TPO (human and murine) can bepurchased from Sigma (St. Louis, Mo.). IL-6 (human and murine), IL-7(human and murine), and SCF (human) can be purchased from LifeTechnologies, Inc. (Rockville, Md.).

In other embodiments, the growth factors are produced by recombinantexpression or by chemical peptide synthesis (e.g. by a peptidesynthesizer). Growth factor nucleic acid and peptide sequences aregenerally available from GenBank.

Preferably, but not necessarily, the growth factor(s) used to expand theCB Stem Cells in the presence of a Notch agonist by the methods of theinvention is derived from the same species as the CB Stem Cells.

The amount or concentration of growth factors suitable for expanding theCB Stem Cells of the present invention will depend on the activity ofthe growth factor preparation, and the species correspondence betweenthe growth factors and the CB Stem Cells, etc. Generally, when thegrowth factor(s) and the CB Stem Cells are of the same species, thetotal amount of growth factor in the culture medium ranges from 1 ng/mlto 5 μg/ml, more preferably from 5 ng/ml to 1 μg/ml, and most preferablyfrom about 10 ng/ml to 200 ng/ml. In one embodiment, the CB Stem Cellsare expanded by exposing the CB Stem Cells to a Notch agonist and 100ng/ml of SCF. In another embodiment, the CB Stem Cells are expanded byexposing the CB Stem Cells to a Notch agonist and 100 ng/ml of each ofFlt-3L, IL-6 and SCF and 10 ng/ml of IL-11.

6.4 Cryopreservation and Thawing

6.4.1 Cryopreservation

Once the Expanded CB Stem Cell population is obtained after expanding CBStem Cells from cord blood, the Expanded CB Stem Cell population can becryopreserved. In one embodiment, an Expanded CB Stem Cell populationcan be divided and frozen in one or more bags (or units). In anotherembodiment, two or more Expanded CB Stem Cell populations can be pooled,divided into separate aliquots, and each aliquot is frozen. In apreferred embodiment, a maximum of approximately 4 billion nucleatedcells is frozen in a single bag. In a preferred embodiment, the ExpandedCB Stem Cells are fresh, i.e., they have not been previously frozenprior to expansion or cryopreservation. The terms “frozen/freezing” and“cryopreserved/cryopreserving” are used interchangeably in the presentapplication. Cryopreservation can be by any method in known in the artthat freezes cells in viable form. The freezing of cells is ordinarilydestructive. On cooling, water within the cell freezes. Injury thenoccurs by osmotic effects on the cell membrane, cell dehydration, soluteconcentration, and ice crystal formation. As ice forms outside the cell,available water is removed from solution and withdrawn from the cell,causing osmotic dehydration and raised solute concentration whicheventually destroy the cell. For a discussion, see Mazur, P., 1977,Cryobiology 14:251-272.

These injurious effects can be circumvented by (a) use of acryoprotective agent, (b) control of the freezing rate, and (c) storageat a temperature sufficiently low to minimize degradative reactions.

Cryoprotective agents which can be used include but are not limited todimethyl sulfoxide (DMSO) (Lovelock and Bishop, 1959, Nature183:1394-1395; Ashwood-Smith, 1961, Nature 190:1204-1205), glycerol,polyvinylpyrrolidine (Rinfret, 1960, Ann. N.Y. Acad. Sci. 85:576),polyethylene glycol (Sloviter and Ravdin, 1962, Nature 196:548),albumin, dextran, sucrose, ethylene glycol, i-erythritol, D-ribitol,D-mannitol (Rowe et al., 1962, Fed. Proc. 21:157), D-sorbitol,i-inositol, D-lactose, choline chloride (Bender et al., 1960, J. Appl.Physiol. 15:520), amino acids (Phan The Tran and Bender, 1960, Exp. CellRes. 20:651), methanol, acetamide, glycerol monoacetate (Lovelock, 1954,Biochem. J. 56:265), and inorganic salts (Phan The Tran and Bender,1960, Proc. Soc. Exp. Biol. Med. 104:388; Phan The Tran and Bender,1961, in Radiobiology, Proceedings of the Third Australian Conference onRadiobiology, Ilbery ed., Butterworth, London, p. 59). In a preferredembodiment, DMSO is used, a liquid which is nontoxic to cells in lowconcentration. Being a small molecule, DMSO freely permeates the celland protects intracellular organelles by combining with water to modifyits freezability and prevent damage from ice formation. Addition ofplasma (e.g., to a concentration of 20-25%) can augment the protectiveeffect of DMSO. After addition of DMSO, cells should be kept at 0° C.until freezing, since DMSO concentrations of about 1% are toxic attemperatures above 4° C.

A controlled slow cooling rate can be critical. Different cryoprotectiveagents (Rapatz et al., 1968, Cryobiology 5(1):18-25) and different celltypes have different optimal cooling rates (see e.g., Rowe and Rinfret,1962, Blood 20:636; Rowe, 1966, Cryobiology 3(1):12-18; Lewis, et al.,1967, Transfusion 7(1):17-32; and Mazur, 1970, Science 168:939-949 foreffects of cooling velocity on survival of marrow-stem cells and ontheir transplantation potential). The heat of fusion phase where waterturns to ice should be minimal. The cooling procedure can be carried outby use of, e.g., a programmable freezing device or a methanol bathprocedure.

Programmable freezing apparatuses allow determination of optimal coolingrates and facilitate standard reproducible cooling. Programmablecontrolled-rate freezers such as Cryomed or Planar permit tuning of thefreezing regimen to the desired cooling rate curve. For example, formarrow cells in 10% DMSO and 20% plasma, the optimal rate is 1° to 3°C./minute from 0° C. to −80° C. In a preferred embodiment, this coolingrate can be used for the neonatal cells of the invention. The containerholding the cells must be stable at cryogenic temperatures and allow forrapid heat transfer for effective control of both freezing and thawing.Sealed plastic vials (e.g., Nunc, Wheaton cryules) or glass ampules canbe used for multiple small amounts (1-2 ml), while larger volumes(100-200 ml) can be frozen in polyolefin bags (e.g., Dehned) heldbetween metal plates for better heat transfer during cooling. Bags ofbone marrow cells have been successfully frozen by placing them in −80°C. freezers which, fortuitously, gives a cooling rate of approximately3° C./minute).

In an alternative embodiment, the methanol bath method of cooling can beused. The methanol bath method is well-suited to routinecryopreservation of multiple small items on a large scale. The methoddoes not require manual control of the freezing rate nor a recorder tomonitor the rate. In a preferred embodiment, DMSO-treated cells arepre-cooled on ice and transferred to a tray containing chilled methanolwhich is placed, in turn, in a mechanical refrigerator (e.g., Harris orRevco) at −80° C. Thermocouple measurements of the methanol bath and thesamples indicate the desired cooling rate of 1° to 3° C./minute. Afterat least two hours, the specimens have reached a temperature of −80° C.and can be placed directly into liquid nitrogen (−196° C.) for permanentstorage.

After thorough freezing, the Expanded CB Stem Cells can be rapidlytransferred to a long-term cryogenic storage vessel. In a preferredembodiment, samples can be cryogenically stored in liquid nitrogen(−196° C.) or its vapor (−165° C.). Such storage is greatly facilitatedby the availability of highly efficient liquid nitrogen refrigerators,which resemble large Thermos containers with an extremely low vacuum andinternal super insulation, such that heat leakage and nitrogen lossesare kept to an absolute minimum.

Suitable racking systems are commercially available and can be used forcataloguing, storage, and retrieval of individual specimens.

Considerations and procedures for the manipulation, cryopreservation,and long-term storage of the hematopoietic stem cells, particularly frombone marrow or peripheral blood, are largely applicable to the ExpandedCB Stem Cells of the invention. Such a discussion can be found, forexample, in the following references, incorporated by reference herein:Gorin, 1986, Clinics In Haematology 15(1):19-48; Bone-MarrowConservation, Culture and Transplantation, Proceedings of a Panel,Moscow, Jul. 22-26, 1968, International Atomic Energy Agency, Vienna,pp. 107-186.

Other methods of cryopreservation of viable cells, or modificationsthereof, are available and envisioned for use (e.g., cold metal-mirrortechniques; Livesey and Linner, 1987, Nature 327:255; Linner et al.,1986, J. Histochem. Cytochem. 34(9):1123-1135; see also U.S. Pat. No.4,199,022 by Senkan et al., U.S. Pat. No. 3,753,357 by Schwartz, U.S.Pat. No. 4,559,298 by Fahy).

6.4.2 Thawing

Frozen cells are preferably thawed quickly (e.g., in a water bathmaintained at 37°-41° C.) and chilled immediately upon thawing. In aspecific embodiment, the vial containing the frozen cells can beimmersed up to its neck in a warm water bath; gentle rotation willensure mixing of the cell suspension as it thaws and increase heattransfer from the warm water to the internal ice mass. As soon as theice has completely melted, the vial can be immediately placed in ice.

In an embodiment of the invention, the Expanded CB Stem Cell sample asthawed, or a portion thereof, can be infused for providing hematopoieticfunction in a human patient in need thereof. Several procedures,relating to processing of the thawed cells are available, and can beemployed if deemed desirable.

It may be desirable to treat the cells in order to prevent cellularclumping upon thawing. To prevent clumping, various procedures can beused, including but not limited to, the addition before and/or afterfreezing of DNase (Spitzer et al., 1980, Cancer 45:3075-3085), lowmolecular weight dextran and citrate, hydroxyethyl starch (Stiff et al.,1983, Cryobiology 20:17-24), etc.

The cryoprotective agent, if toxic in humans, should be removed prior totherapeutic use of the thawed Expanded CB Stem Cells. In an embodimentemploying DMSO as the cryopreservative, it is preferable to omit thisstep in order to avoid cell loss, since DMSO has no serious toxicity.However, where removal of the cryoprotective agent is desired, theremoval is preferably accomplished upon thawing.

One way in which to remove the cryoprotective agent is by dilution to aninsignificant concentration. This can be accomplished by addition ofmedium, followed by, if necessary, one or more cycles of centrifugationto pellet cells, removal of the supernatant, and resuspension of thecells. For example, intracellular DMSO in the thawed cells can bereduced to a level (less than 1%) that will not adversely affect therecovered cells. This is preferably done slowly to minimize potentiallydamaging osmotic gradients that occur during DMSO removal.

After removal of the cryoprotective agent, cell count (e.g., by use of ahemocytometer) and viability testing (e.g., by trypan blue exclusion;Kuchler, 1977, Biochemical Methods in Cell Culture and Virology, Dowden,Hutchinson & Ross, Stroudsburg, Pa., pp. 18-19; 1964, Methods in MedicalResearch, Eisen et al., eds., Vol. 10, Year Book Medical Publishers,Inc., Chicago, pp. 39-47) can be done to confirm cell survival. Thepercentage of viable antigen (e.g., CD34) positive cells in a sample canbe determined by calculating the number of antigen positive cells thatexclude 7-AAD (or other suitable dye excluded by viable cells) in analiquot of the sample, divided by the total number of nucleated cells(TNC) (both viable and non-viable) in the aliquot of the sample. Thenumber of viable antigen positive cells in the sample can be thendetermined by multiplying the percentage of viable antigen positivecells by TNC of the sample.

Prior to cryopreservation and/or after thawing, the total number ofnucleated cells, or in a specific embodiment, the total number of CD34⁺or CD133⁺ cells can be determined. For example, total nucleated cellcount can be performed by using a hemocytometer and exclusion of trypanblue dye. Specimens that are of high cellularity can be diluted to aconcentration range appropriate for manual counting. Final cell countsfor products are corrected for any dilution factors. Total nucleatedcell count=viable nucleated cells per mL×volume of product in mL. Thenumber of CD34⁺ or CD133⁺ positive cells in the sample can bedetermined, e.g., by the use of flow cytometry using anti-CD34 oranti-CD133 monoclonal antibodies conjugated to a fluorochrome.

Optionally, the Expanded CB Stem Cell sample can undergo HLA typingeither prior to cryopreservation and/or after cryopreservation andthawing. HLA typing can be performed using serological methods withantibodies specific for identified HLA antigens, or using DNA-basedmethods for detecting polymophisms in the HLA antigen-encoding genes fortyping HLA alleles. In a specific embodiment, HLA typing can beperformed at intermediate resolution using a sequence specificoligonucleotide probe method for HLA-A and HLA-B or at high resolutionusing a sequence based typing method (allele typing) for HLA-DRB1.

In certain embodiments, the identity and purity of the startingumbilical cord blood and/or placental blood, the CB Stem Cells, and theExpanded CB Stem Cells prior to cryopreservation, or the Expanded CBStem Cells after thawing can be subjected to multi-parameter flowcytometric immunophenotyping, which provides the percentage of viableantigen positive cells present in a sample. Each sample can be testedfor one or more of the following cell phenotypes using a panel ofmonoclonal antibodies directly conjugated to fluorochromes:

-   -   1. CD34⁺ HPC    -   2. T cells (CD3⁺, including both CD4⁺ and CD8⁺ subsets)    -   3. B cells (CD 19⁺ or CD20⁺)    -   4. NK cells (CD56⁺)    -   5. Monocytes (CD14⁺)    -   6. Myelomonocytes (CD 15⁺)    -   7. Megakaryocytes (CD41⁺)    -   8. Dendritic Cells (lineage negative/HLA-DRbright and        CD123bright, or lineage negative/HLA-DRbright and CD11cbright).

6.5 Genetically Engineered Stem Cells

In a preferred embodiment, the Expanded CB Stem Cells administered tothe patient are non-recombinant. However, in a different embodiment, theCB Stem Cells prior to expansion or the Expanded CB Stem Cells can begenetically engineered to produce gene products beneficial upontransplantation of the genetically engineered cells to a subject. Suchgene products include but are not limited to anti-inflammatory factors,e.g., anti-TNF, anti-IL-1, anti-IL-2, etc. The CB Stem Cells can begenetically engineered for use in gene therapy to adjust the level ofgene activity in a subject to assist or improve the results oftransplantation or to treat a disease caused by, for example, adeficiency in the recombinant gene. The CB Stem Cells are maderecombinant by the introduction of a recombinant nucleic acid into theCB Stem Cells or into the Expanded CB Stem Cells.

In its broadest sense, gene therapy refers to therapy performed by theadministration of a nucleic acid to a subject. The nucleic acid, eitherdirectly or indirectly via its encoded protein, mediates a therapeuticeffect in the subject. The present invention provides methods of genetherapy wherein a nucleic acid encoding a protein of therapeutic value(preferably to humans) is introduced into the CB Stem Cells, before orafter expansion, such that the nucleic acid is expressible by the StemCells and/or their progeny, followed by administration of therecombinant Expanded CB Stem Cells to a subject.

The recombinant CB Stem Cells of the present invention can be used inany of the methods for gene therapy available in the art. Thus, thenucleic acid introduced into the cells may encode any desired protein,e.g., a protein missing or dysfunctional in a disease or disorder. Thedescriptions below are meant to be illustrative of such methods. It willbe readily understood by those of skill in the art that the methodsillustrated represent only a sample of all available methods of genetherapy.

For general reviews of the methods of gene therapy, see Gardlik et al.,2005, Med. Sci. Monit. 11:RA110-121; Lundstrom, 1999, J. Recept. SignalTransduct. Res. 19:673-686; Robbins and Ghivizzani, 1998, Pharmacol.Ther. 80:35-47; Pelegrin et al., 1998, Hum. Gene Ther. 9:2165-2175;Harvey and Caskey, 1998, Curr. Opin. Chem. Biol. 2:512-518; Guntaka andSwamynathan, 1998, Indian J. Exp. Biol. 36:539-535; Desnick andSchuchman, 1998, Acta Paediatr. Jpn. 40:191-203; Vos, 1998, Curr. Opin.Genet. Dev. 8:351-359; Tarahovsky and Ivanitsky, 1998, Biochemistry(Mosc) 63:607-618; Morishita et al., 1998, Circ. Res. 2:1023-1028; Vileet al., 1998, Mol. Med. Today 4:84-92; Branch and Klotman, 1998, Exp.Nephrol. 6:78-83; Ascenzioni et al., 1997, Cancer Lett. 118:135-142;Chan and Glazer, 1997, J. Mol. Med. 75:267-282. Methods commonly knownin the art of recombinant DNA technology which can be used are describedin Ausubel et al. (eds.), 1993, Current Protocols in Molecular Biology,John Wiley & Sons, NY; and Kriegler, 1990, Gene Transfer and Expression,A Laboratory Manual, Stockton Press, NY.

In an embodiment in which recombinant CB Stem Cells are used in genetherapy, a gene whose expression is desired in a subject is introducedinto the CB Stem Cells such that it is expressible by the cells and/ortheir progeny, and the recombinant cells are then administered in vivofor therapeutic effect.

Recombinant Expanded CB Stem Cells can be used in any appropriate methodof gene therapy, as would be recognized by those in the art uponconsidering this disclosure. The resulting action of recombinant cellpopulations administered to a subject can, for example, lead to theactivation or inhibition of a pre-selected gene in the subject, thusleading to improvement of the diseased condition afflicting the subject.

In this embodiment, the desired gene is introduced into the CB Stem Cellor its progeny prior to administration in vivo of the resultingrecombinant cell. Such introduction can be carried out by any methodknown in the art, including but not limited to transfection,electroporation, microinjection, lipofection, calcium phosphate mediatedtransfection, infection with a viral or bacteriophage vector containingthe gene sequences, cell fusion, chromosome-mediated gene transfer,microcell-mediated gene transfer, spheroplast fusion, etc. Numeroustechniques are known in the art for the introduction of foreign genesinto cells (see e.g., Loeffler and Behr, 1993, Meth. Enzymol.217:599-618; Cohen et al., 1993, Meth. Enzymol. 217:618-644; Cline,1985, Pharmac. Ther. 29:69-92) and may be used in accordance with thepresent invention, provided that the necessary developmental andphysiological functions of the recipient cells are not disrupted. Thetechnique should provide for the stable transfer of the gene to thecell, so that the gene is expressible by the cell and preferablyheritable and expressible by its cell progeny. Usually, the method oftransfer includes the transfer of a selectable marker to the cells. Thecells are then placed under selection to isolate those cells that havetaken up and are expressing the transferred gene. Those cells are thendelivered to a subject.

More detail about retroviral vectors can be found in Boesen et al.,1994, Biotherapy 6:291-302, Clowes et al., 1994, J. Clin. Invest.93:644-651; Kiem et al., 1994, Blood 83:1467-1473; Salmons and Gunzberg,1993, Human Gene Therapy 4:129-141; and Grossman and Wilson, 1993, Curr.Opin. in Genetics and Devel. 3:110-114.

Adenoviruses are also of use in gene therapy. See Kozarsky and Wilson,1993, Current Opinion in Genetics and Development 3:499-503, Rosenfeldet al., 1991, Science 252:431-434; Rosenfeld et al., 1992, Cell68:143-155; and Mastrangeli et al., 1993, J. Clin. Invest. 91:225-234.

It has been proposed that adeno-associated virus (AAV) be used in genetherapy (Walsh et al., 1993, Proc. Soc. Exp. Biol. Med. 204:289-300). Ithas also been proposed that alphaviruses be used in gene therapy(Lundstrom, 1999, J. Recept. Signal Transduct. Res. 19:673-686).

Other methods of gene delivery in gene therapy include the use ofmammalian artificial chromosomes (Vos, 1998, Curr. Op. Genet. Dev.8:351-359); liposomes (Tarahovsky and Ivanitsky, 1998, Biochemistry(Mosc) 63:607-618); ribozymes (Branch and Klotman, 1998, Exp. Nephrol.6:78-83); and triplex DNA (Chan and Glazer, 1997, J. Mol. Med.75:267-282).

A desired gene can be introduced intracellularly and incorporated withinCB Stem Cell DNA for expression, by homologous recombination (Koller andSmithies, 1989, Proc. Natl. Acad. Sci. USA 86:8932-8935; Zijlstra etal., 1989, Nature 342:435-438).

In a specific embodiment, the desired gene recombinantly expressed inthe CB Stem Cells or their progeny after expansion to be introduced forpurposes of gene therapy comprises an inducible promoter operably linkedto the coding region, such that expression of the recombinant gene iscontrollable by controlling the presence or absence of the appropriateinducer of transcription.

6.6 Selection of Expanded Cord Blood Cells

In accordance with the present invention, an Expanded CB Stem Cellsample is selected for administration to a human patient in need thereofin order to provide hematopoietic function to the patient, whichselection is without regard to matching the HLA type of the sample tothe HLA type of the patient, i.e., the selection does not take intoaccount the HLA type of the sample or the HLA type of the patient. Thus,the Expanded CB Stem Cell sample may have the same HLA type as thepatient or the HLA type of the Expanded CB Stem Cell sample may differfrom the HLA type of the patient at 1, 2, 3, 4, 5, 6 or more of thetyped HLA antigens and/or alleles. In another embodiment, the HLA typeof the Expanded CB Stem Cell sample may differ from the HLA type of thepatient at all of the HLA antigens and/or alleles typed.

In one embodiment of the invention, a method for providing hematopoieticfunction to a human patient in need thereof is provided, which methodcomprises (a) selecting an expanded human cord blood stem cell samplefor administration to the patient, wherein said selecting does not takeinto account the HLA-type of the sample or the HLA-type of the patient;and (b) administering the selected sample to the patient. In a preferredembodiment, the selecting is from a plurality of different samples(e.g., at least 100, 200, 250, 500, 750, 1000, 1500, 2,000, 3,000,5,000, 7,500, 10,000, 25,000, 50,000 or 100,000 different expanded cordblood stem cell samples), preferably stored frozen in a bank. In aspecific embodiment, at least the foregoing numbers of samples in theplurality are not pooled samples. In a specific embodiment, theplurality of samples does not contain pooled samples. In a differentspecific embodiment, the plurality of different samples comprises atleast 5, 10, 20, 25, 50, 75, 100, 500, or 1000 pooled samples.

Optional parameters for consideration in the selection of an Expanded CBStem Cell sample for use in a method of treatment according to thepresent invention include, but are not limited to one or more of totalnucleated cell count, total CD34⁺ (or other suitable antigen) cellcount, age of sample, age of patient, race or ethnic background ofdonor, weight of the patient, type of disease to be treated and itslevel of severity in a particular patient, presence of CD3⁺ cells in theExpanded CB Stem Cell sample, panel reactive antibody result of thepatient, etc. For example, in a specific embodiment, an Expanded CB StemCell sample can be rejected, and thus not selected for use in a methodof treatment if there are more than 500,000 CD3⁺ cells per kilogram(patient weight) in the sample.

In a specific embodiment, the selecting can be computer-implemented,whereby the selection software can take into account any one or more ofthe foregoing information characterizing the sample, e.g., by filteringout (rejecting) samples that do not meet certain criteria, e.g., that donot contain threshold amounts of CD34⁺ cells (e.g., at least 75 millionCD34⁺ cells, preferably, at least 100 million, 150 million, 200 million,250 million, 300 million, 350 million, most preferably at least 250million), and/or that contain more than a threshold amount of CD3⁺ cells(e.g., more than 500,000 CD3⁺ per kilogram patient weight). In aspecific embodiment, samples left after filtering are selected, forexample, by choosing the sample stored for the longest period, or atrandom, or based on any characteristic useful to the skilledpractitioner.

The selection of the sample can be carried out by a suitably programmedcomputer by selecting an appropriate identifier for the frozen, ExpandedCB Stem Cell sample, from among a plurality of identifiers stored in acomputer database, each identifying a different frozen, Expanded CB StemCell sample. Each identifier is preferably associated with theinformation for its corresponding sample as described above (one or moreof total nucleated cell count, total CD34⁺ cell count, etc.), so thatthe software can take into account the information as described above inthe selection process.

6.7 Therapeutic Methods

The Expanded CB Stem Cell populations, whether recombinantly expressinga desired gene or not, can be administered into a human patient in needthereof for hematopoietic function for the treatment of disease orinjury or for gene therapy by any method known in the art which isappropriate for the Expanded CB Stem Cells and the transplant site.Preferably, the Expanded CB Stem Cells are transplanted (infused)intravenously. In one embodiment, the Expanded CB Stem Cellsdifferentiate into cells of the myeloid lineage in the patient. Inanother embodiment, the Expanded CB Stem Cells differentiate into cellsof the lymphoid lineage in the patient. Administration of the ExpandedCB Stem Cells is without regard to whether the patient matches ormismatches the Expanded CB Stem Cells at HLA antigens and/or alleles.HLA-mismatched cells do not match at one or two or more of the human HLAantigens and/or alleles that are typed. In one embodiment, at least oneHLA antigen or allele is found to be different between the expandedhuman cord blood stem cell sample and the recipient patient among thoseHLA antigens or alleles typed. The present invention provides a methodfor providing hematopoietic function to a human patient in need thereofby administering an expanded human cord blood stem cell sample to thepatient, wherein said administering is done without matching theHLA-type of the expanded human cord blood stem cell sample to thepatient.

In specific embodiments, the Expanded CB Stem Cells are not administeredto the patient within 12 hours of administration of a myeloid progenitorcell population as defined in International Patent Publication Nos. WO2006/047569 A2 and/or WO 2007/095594 A2. In other specific embodiments,the Expanded CB Stem Cells are not administered to the patient within 18or 24 or 36 or 48 or 72 or 96 hours or within 7, 10, 14, 21, 30 days ofadministration of such a myeloid progenitor cell population to thepatient.

In a specific embodiment, the Expanded CB Stem Cell sample that isadministered to the patient is not a pooled sample, i.e., it is derivedfrom the umbilical cord blood and/or placental blood of one individual.

In a specific embodiment, the methods of the invention described herein,involving administration of Expanded CB Stem Cell samples, furthercomprise administering one or more umbilical cord blood/placental bloodsamples (hereinafter called “Grafts” or “cord blood transplants”). SuchGrafts are umbilical cord blood and/or placental blood samples fromhumans that are whole blood samples, except that red blood cells havebeen removed from the whole blood samples, but which samples have notbeen further fractionated and have not been expanded. In a specificembodiment, the Grafts have been cryopreserved and are thawed prior toadministration. In a specific embodiment, at least 4 of the HLA antigensor alleles of the Grafts are typed. In a preferred embodiment, 6 HLAantigens or alleles (e.g., each of the 2 HLA-A, HLA-B and HLA-DRalleles) are typed. In a preferred embodiment, the one or more Graftsadministered to the patient match the patient at at least 4 out of 6 HLAantigens or alleles. In contrast to embodiments where the Graft isselected to match or partially match the patient at typed HLA antigensor alleles, the Expanded CB Stem Cell sample is administered withoutmatching the HLA-type of the Expanded CB Stem Cell sample to theHLA-type of the patient. In a specific embodiment, the Graft is alsoadministered without matching the HLA-type of the Graft with theHLA-type of the patient. The Grafts can be administered concurrentlywith, sequentially with respect to, before, or after the Expanded CBStem Cell sample is administered to the patient. In a specificembodiment, the Expanded CB Stem Cell sample that is administered to thepatient is administered within 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 days ofadministering the one or more Grafts. In a specific embodiment, theExpanded CB Stem Cell sample is administered before administering theone or more Grafts. In another specific embodiment, the Expanded CB StemCell sample is administered after administering the one or more Grafts.In a specific embodiment, the Expanded CB Stem Cell sample isadministered 1 to 24 hours, 2 to 12 hours, 3 to 8 hours, or 3 to 5 hoursbefore or after administering the one or more Grafts. In other specificembodiments, the Expanded CB Stem Cell sample is administered about 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18, or 24 hours before or afteradministering the one or more Grafts. In a preferred embodiment, theExpanded CB Stem Cell sample is administered about 4 hours afteradministering the one or more Grafts. In a specific embodiment, a singleGraft is administered that is derived from the cord and/or placentalblood of a single human individual. In a specific embodiment, two Graftsare administered, each derived from the cord and/or placental blood of adifferent human individual. In another specific embodiment, a singleGraft is administered that is a combination of cord and/or placentalblood derived from two or more different human individuals. In theforegoing embodiments, the Expanded CB Stem Cell sample is intended toprovide temporary hematopoietic benefit to the patient, while the Graftis intended to provide long-term engraftment.

Other suitable methods of administration of the Expanded CB Stem Cellsare encompassed by the present invention. The Expanded CB Stem Cellpopulations can be administered by any convenient route, for example byinfusion or bolus injection, and may be administered together with otherbiologically active agents. Administration can be systemic or local.

The titer of Expanded CB Stem Cells administered which, will beeffective in the treatment of a particular disorder or condition willdepend on the nature of the disorder or condition, and can be determinedby standard clinical techniques. In addition, in vitro and in vivoassays may optionally be employed to help identify optimal dosageranges. The precise dose to be employed in the formulation will alsodepend on the route of administration, and the seriousness of thedisease or disorder, and should be decided according to the judgment ofthe practitioner and each subject's circumstances. In specificembodiments, suitable dosages of Expanded CB Stem Cells foradministration are generally about at least 5×10⁶,10⁷, 5×10⁷, 75×10⁶,10⁷, 5×10⁷, 10⁸, 5×10⁸, 1×10⁹, 5×10⁹, 1×10¹⁰, 5×10¹⁰, 1×10¹¹, 5×10¹¹ or10¹² CD34⁺ cells per kilogram patient weight, and most preferably about10⁷ to about 10¹² CD34⁺ cells per kilogram patient weight, and can beadministered to a patient once, twice, three or, more times withintervals as often as needed. In a specific embodiment, a singleExpanded Stem Cell sample provides one or more doses for a singlepatient. In one specific embodiment, a single Expanded Stem Cell sampleprovides four doses for a single patient.

The patient is a human patient, preferably an immunodeficient humanpatient.

In a specific embodiment, the Expanded CB Stem Cell populationadministered to a human patient in need thereof can be a pool of atleast two individual Expanded CB Stem Cell samples, each sample derivedfrom the umbilical cord blood and/or placental blood of a single human.For example, an aliquot of a frozen, thawed, expanded sample that is apool of samples (i.e., a pooled sample) can be administered. In oneembodiment, the individual Expanded CB Stem Cell samples in the pool canhave different HLA types. For example, where the mixture contains threeindividual samples, each sample can differ from the others by at leastone or more of the typed HLA antigens or alleles, e.g., by at least oneof the commonly typed HLA antigens or alleles. In one embodiment, theindividual samples in the pool are all derived from umbilical cord bloodand/or placental blood of individuals of the same race, e.g.,African-American, Caucasian, Asian, Hispanic, Native-American,Australian Aboriginal, Inuit, Pacific Islander, or are all derived fromumbilical cord blood and/or placental blood of individuals of the sameethnicity, e.g., Irish, Italian, Indian, Japanese, Chinese, Russian,etc. In an alternative embodiment, the administered sample is not a poolof samples.

6.8 Pharmaceutical Compositions

The invention provides methods of treatment by administration to apatient of a pharmaceutical (therapeutic) composition comprising atherapeutically effective amount of recombinant or non-recombinantExpanded CB Stem Cells produced by the methods of the present inventionas described herein above, wherein administration is done withoutmatching the HLA-type of the Expanded CB Stem Cells to the patient.Preferably, a myeloid progenitor cell population is not administered tothe patient within 12 hours of the administering of the expanded humancord blood stem cell sample, wherein a majority of the cells in themyeloid progenitor cell population do not produce lymphoid cells in cellculture. In other embodiments, a myeloid progenitor cell population isnot administered to the patient within 18, 20, 24, 36, 48, 72 hours orwithin 1 week of the administering of the expanded human cord blood stemcell sample, wherein a majority of the cells in the myeloid progenitorcell population do not produce lymphoid cells in cell culture. In aspecific embodiment, a majority of the cells in the myeloid cellpopulation express the cell surface marker CD33 and/or do not expressthe cell surface marker CD45RA.

The present invention provides pharmaceutical compositions. Suchcompositions comprise a therapeutically effective amount of Expanded CBStem Cells, and a pharmaceutically acceptable carrier or excipient. Sucha carrier can be but is not limited to saline, buffered saline,dextrose, water, glycerol, ethanol, and combinations thereof. Thecarrier and composition preferably are sterile. The formulation shouldsuit the mode of administration. The pharmaceutical composition isacceptable for therapeutic use in humans. The composition, if desired,can also contain pH buffering agents.

In a preferred embodiment, the composition is formulated in accordancewith routine procedures as a pharmaceutical composition adapted forintravenous administration to human beings. Typically, compositions forintravenous administration are solutions in sterile isotonic aqueousbuffer. Where necessary, the composition may also include a solubilizingagent and a local anesthetic such as lidocaine to ease pain at the siteof the injection.

The invention also provides a pharmaceutical pack or kit comprising oneor more containers filled with one or more of the Stem Cell or ExpandedCB Stem Cell populations produced by the methods of the invention and/orreagents to prepare said cells, or with reagents for the geneticmanipulation of the cells.

In a preferred embodiment, a kit of the invention comprises in one ormore containers one or more purified growth factors that promoteproliferation but not differentiation of a precursor cell and a purifiedNotch agonist, which growth factors and Notch agonist are togethereffective to expand Stem Cells exposed to them in culture. Optionally,cell culture medium is also provided.

Optionally associated with such container(s) can be a notice in the formprescribed by a governmental agency regulating the manufacture, use orsale of pharmaceuticals or biological products, which notice reflectsapproval by the agency of manufacture, use or sale for humanadministration.

6.9 Therapeutic Uses of the Expanded CB Stem Cells

The Expanded CB Stem Cells of the present invention can be used toprovide hematopoietic function to a patient in need thereof, preferablya human patient, without matching the HLA-type of the expanded humancord blood stem cell sample to the patient. The Expanded CB Stem Cellsthat are administered to a patient in need thereof can be derived fromthe umbilical cord blood and/or placental blood of a single human atbirth, or can be derived from the umbilical cord blood and/or placentalblood of more than 1 human at birth (pool of samples), as describedabove. In one embodiment, administration of Expanded CB Stem Cells ofthe invention is for the treatment of immunodeficiency. In a preferredembodiment, administration of Expanded CB Stem Cells of the invention isfor the treatment of pancytopenia or for the treatment of neutropenia.The immunodeficiency in the patient, for example, pancytopenia orneutropenia, can be the result of an intensive chemotherapy regimen,myeloablative regimen for hematopoietic cell transplantation (HCT), orexposure to acute ionizing radiation. Exemplary chemotherapeutics thatcan cause prolonged pancytopenia or prolonged neutropenia include, butare not limited to alkylating agents such as cisplatin, carboplatin, andoxaliplatin, mechlorethamine, cyclophosphamide, chlorambucil, andifosfamide. Other chemotherapeutic agents that can cause prolongedpancytopenia or prolonged neutropenia include azathioprine,mercaptopurine, vinca alkaloids, e.g., vincristine, vinblastine,vinorelbine, vindesine, and taxanes. In particular, a chemotherapyregimen that can cause prolonged pancytopenia or prolonged neutropeniais the administration of clofarabine and Ara-C.

In one embodiment, the patient is in an acquired or induced aplasticstate.

The immunodeficiency in the patient also can be caused by exposure toacute ionizing radiation following a nuclear attack, e.g., detonation ofa “dirty” bomb in a densely populated area, or by exposure to ionizingradiation due to radiation leakage at a nuclear power plant, or exposureto a source of ionizing radiation, raw uranium ore.

Transplantation of Expanded CB Stem Cells of the invention can be usedin the treatment or prevention of hematopoietic disorders and diseases.In one embodiment, the Expanded CB Stem Cells are used to treat orprevent a hematopoietic disorder or disease characterized by a failureor dysfunction of normal blood cell production and cell maturation. Inanother embodiment, the Expanded CB Stem Cells are used to treat orprevent a hematopoietic disorder or disease resulting from ahematopoietic malignancy. In yet another embodiment, the Expanded CBStem Cells are used to treat or prevent a hematopoietic disorder ordisease resulting from immunosuppression, particularly immunosuppressionin subjects with malignant, solid tumors. In yet another embodiment, theExpanded CB Stem Cells are used to treat or prevent an autoimmunedisease affecting the hematopoietic system. In yet another embodiment,the Expanded CB Stem Cells are used to treat or prevent a genetic orcongenital hematopoietic disorder or disease.

Examples of particular hematopoietic diseases and disorders which can betreated by the Expanded CB Stem Cells of the invention include but arenot limited to those listed in Table I, infra.

TABLE I DISEASES OR DISORDERS WHICH CAN BE TREATED BY ADMINISTERINGEXPANDED CB STEM CELLS OF THE INVENTION I. Diseases Resulting from aFailure or Dysfunction of Normal Blood Cell Production and Maturationhyperproliferative stem cell disorders aplastic anemia pancytopeniaagranulocytosis thrombocytopenia red cell aplasia Blackfan-Diamondsyndrome due to drugs, radiation, or infection Idiopathic II.Hematopoietic malignancies acute lymphoblastic (lymphocytic) leukemiachronic lymphocytic leukemia acute myelogenous leukemia chronicmyelogenous leukemia acute malignant myelosclerosis multiple myelomapolycythemia vera agnogenic myelometaplasia Waldenstrom'smacroglobulinemia Hodgkin's lymphoma non-Hodgkin's lymphoma III.Immunosuppression in patients with malignant, solid tumors malignantmelanoma carcinoma of the stomach ovarian carcinoma breast carcinomasmall cell lung carcinoma retinoblastoma testicular carcinomaglioblastoma rhabdomyosarcoma neuroblastoma Ewing's sarcoma lymphoma IVAutoimmune diseases rheumatoid arthritis diabetes type I chronichepatitis multiple sclerosis systemic lupus erythematosus V. Genetic(congenital) disorders anemias familial aplastic Fanconi's syndromeBloom's syndrome pure red cell aplasia (PRCA) dyskeratosis congenitalBlackfan-Diamond syndrome congenital dyserythropoietic syndromes I-IVChwachmann-Diamond syndrome dihydrofolate reductase deficienciesformamino transferase deficiency Lesch-Nyhan syndrome congenitalspherocytosis congenital elliptocytosis congenital stomatocytosiscongenital Rh null disease paroxysmal nocturnal hemoglobinuria G6PD(glucose-6-phosphate dehydrogenase) variants 1, 2, 3 pyruvate kinasedeficiency congenital erythropoietin sensitivity deficiency sickle celldisease and trait thalassemia alpha, beta, gamma met-hemoglobinemiacongenital disorders of immunity severe combined immunodeficiencydisease (SCID) bare lymphocyte syndrome ionophore-responsive combinedimmunodeficiency combined immunodeficiency with a capping abnormalitynucleoside phosphorylase deficiency granulocyte actin deficiencyinfantile agranulocytosis Gaucher's disease adenosine deaminasedeficiency Kostmann's syndrome reticular dysgenesis congenital leukocytedysfunction syndromes VI. Others osteopetrosis myelosclerosis acquiredhemolytic anemias acquired immunodeficiencies infectious disorderscausing primary or secondary immunodeficiencies bacterial infections(e.g., Brucellosis, Listerosis, tuberculosis, leprosy) parasiticinfections (e.g., malaria, Leishmaniasis) fungal infections disordersinvolving disproportions in lymphoid cell sets and impaired immunefunctions due to aging phagocyte disorders Kostmann's agranulocytosischronic granulomatous disease Chediak-Higachi syndrome neutrophil actindeficiency neutrophil membrane GP-180 deficiency metabolic storagediseases mucopolysaccharidoses mucolipidoses miscellaneous disordersinvolving immune mechanisms Wiskott-Aldrich Syndrome α1-antitrypsindeficiency

In one embodiment, the Expanded CB Stem Cells are administered to apatient with a hematopoietic deficiency. Hematopoietic deficiencieswhose treatment with the Expanded CB Stem Cells of the invention isencompassed by the methods of the invention include but are not limitedto decreased levels of either myeloid, erythroid, lymphoid, ormegakaryocyte cells of the hematopoietic system or combinations thereof,including those listed in Table I.

Among conditions susceptible to treatment with the Expanded CB StemCells of the present invention is leukopenia, a reduction in the numberof circulating leukocytes (white cells) in the peripheral blood.Leukopenia may be induced by exposure to certain viruses or toradiation. It is often a side effect of various forms of cancer therapy,e.g., exposure to chemotherapeutic drugs, radiation and of infection orhemorrhage.

Expanded CB Stem Cells also can be used in the treatment or preventionof neutropenia and, for example, in the treatment of such conditions asaplastic anemia, cyclic neutropenia, idiopathic neutropenia,Chediak-Higashi syndrome, systemic lupus erythematosus (SLE), leukemia,myelodysplastic syndrome, myelofibrosis, thrombocytopenia. Severethrombocytopenia may result from genetic defects such as Fanconi'sAnemia, Wiscott-Aldrich, or May-Hegglin syndromes and from chemotherapyand/or radiation therapy or cancer. Acquired thrombocytopenia may resultfrom auto- or allo-antibodies as in Immune Thrombocytopenia Purpura,Systemic Lupus Erythromatosis, hemolytic anemia, or fetal maternalincompatibility. In addition, splenomegaly, disseminated intravascularcoagulation, thrombotic thrombocytopenic purpura, infection orprosthetic heart valves may result in thrombocytopenia. Thrombocytopeniamay also result from marrow invasion by carcinoma, lymphoma, leukemia orfibrosis.

Many drugs may cause bone marrow suppression or hematopoieticdeficiencies. Examples of such drugs are AZT, DDI, alkylating agents andanti-metabolites used in chemotherapy, antibiotics such aschloramphenicol, penicillin, gancyclovir, daunomycin and sulfa drugs,phenothiazones, tranquilizers such as meprobamate, analgesics such asaminopyrine and dipyrone, anticonvulsants such as phenyloin orcarbamazepine, antithyroids such as propylthiouracil and methimazole anddiuretics. Transplantation of the Expanded CB Stem Cells can be used inpreventing or treating the bone marrow suppression or hematopoieticdeficiencies which often occur in subjects treated with these drugs.

Hematopoietic deficiencies may also occur as a result of viral,microbial or parasitic infections and as a result of treatment for renaldisease or renal failure, e.g., dialysis. Transplantation of Expanded CBStem Cell populations may be useful in treating such hematopoieticdeficiency.

Various immunodeficiencies, e.g., in T and/or B lymphocytes, or immunedisorders, e.g., rheumatoid arthritis, may also be beneficially affectedby treatment with the Expanded CB Stem Cells. Immunodeficiencies may bethe result of viral infections (including but not limited to HIVI,HIVII, HTLVI, HTLVII, HTLVIII), severe exposure to radiation, cancertherapy or the result of other medical treatment.

6.10 Banks of Frozen, Expanded Cord Blood Stem Cells

Since according to the present invention, matching of HLA-type is notnecessary for therapeutic use of the Expanded CB Stem Cells, it is nowpractical to store frozen Expanded CB Stem Cells since the presentinvention teaches that useful amounts can practically be stored. In theprior art, since it was expected that HLA matching to the recipientwould generally be necessary to find a useful sample of Expanded CB StemCells for therapeutic use, an unattainably large number of differentExpanded CB Stem Cell samples had to be stored to make it feasiblegenerally to find a match for a patient, the large numbers making itimpractical to store expanded samples, due to the even larger amount ofstorage space needed to store expanded units. In contrast, and inaccordance with the present invention, no HLA matching is required, andthus, the generation of a “bank” of CB Stem Cells which have beenexpanded and then cryopreserved, useful for the general human populationto use in stem cell transplantation, is feasible, since any Expanded CBStem Cell sample in the bank could feasibly be used with any recipientin a therapeutic method of the invention.

Once the Expanded CB Stem Cells are obtained and cryopreserved, thecryopreserved samples can be stored in a bank (a repository for thecollection of samples). The bank can consist of one or more physicallocations. Thus, the present invention is also directed to a collectionof frozen Expanded CB Stem Cell samples in a bank. The collection cancomprise at least 50, 100, 200, 250, 300, 400, 500, 600, 700, 750, 800,1,000, 2,000, 3,000, 5,000, 7,500, 10,000, 25,000, 50,000 or 100,000samples of Expanded CB Stem Cells, each sample derived from theumbilical cord blood and/or placental cord blood of a human at birth. Inanother embodiment, the bank comprises frozen mixtures of two or moredifferent Expanded CB Stem Cell samples, each different sample derivedfrom the umbilical cord blood and/or placental cord blood of a differenthuman at birth, e.g., pooled as described above. The Expanded CB StemCell samples are stored at a temperature no warmer than −20° C.,preferably at −80° C. In a preferred embodiment, samples can becryogenically stored in liquid nitrogen (−196° C.) or its vapor (−165°C.).

In certain embodiments, individual samples of Expanded CB Stem Cells canbe mixed prior to cryopreservation. In another embodiment, the mixturecontains Expanded CB Stem Cells of at least 2, at least 3, at least 4,at least 5 or at least 6 or more different HLA types.

In a preferred embodiment, all or most of the samples of Expanded CBStem Cells present in the bank have greater than 75 million viable CD34⁺cells, as determined prior to cryopreservation.

6.11 Apparatus, Computer and Computer Program Product Implementations

The selection of appropriate frozen Expanded CB Stem Cell populationsfor administration to a patient without regard to the HLA types of theExpanded CB Stem Cells or the patient can be implemented by use of acomputer program product that comprises a computer program mechanismembedded in a computer readable storage medium. Some embodiments of thepresent invention provide a computer system or a computer programproduct that encodes or has instructions for performing selecting andoutputting an identifier and optionally robotic retrieval of a frozenstored Expanded CB Stem Cell sample. The identifier distinguishes onefrozen, Expanded CB Stem Cell sample from other frozen, Expanded CB StemCell samples that are stored in a bank of frozen Expanded CB Stem Cellsamples as described above, and thus the identifier is unique to eachsample. Preferably, the collection of identifiers is stored in one ormore computer databases, wherein each identifier is preferablyassociated with information on the physical location of the Expanded CBStem Cell sample associated with the identifier, and/or with informationon one or more other characteristics of the sample, including but notlimited to, total hematopoietic stem cell or hematopoietic stem andprogenitor cell count (e.g., total CD34⁺ cell count) of the sample,total nucleated cell count of the sample, percentage hematopoietic stemcell or hematopoietic stem and progenitor cells (e.g., percentage ofCD34⁺ cells), volume of the sample, sex of the donor, date of freezingof the sample, HLA type of the sample, as described in Section 6.6.Thus, one or more databases store data on each frozen, Expanded CB StemCell sample. The database stores one or more of the followingcharacteristics of the stored, frozen, Expanded CB Stem Cell sample,including but not limited to, total CD34⁺ cell count of the sample,total nucleated cell count of the sample, volume of the sample, sex ofthe donor, race or ethnicity of the donor, date of freezing of thesample, HLA type of the sample.

Executable instructions for carrying out the selecting and outputting ofidentifiers, and/or robotic retrieval of the sample can be stored on aCD-ROM, DVD, magnetic disk storage product, or any other computerreadable data or program storage product. Such methods can also beembedded in permanent storage, such as ROM, one or more programmablechips, or one or more application specific integrated circuits (ASICs).Such permanent storage can be localized in a server, 802.11 accesspoint, 802.11 wireless bridge/station, repeater, router, mobile phone,or other electronic devices. Such methods encoded in the computerprogram product can also be distributed electronically, via the Internetor otherwise, by transmission of a computer data signal (in which thesoftware modules are embedded) either digitally or on a carrier wave.

Some embodiments of the present invention provide a computer programproduct that contains any or all of the program modules shown in FIG. 1.These program modules can be stored on a CD-ROM, DVD, magnetic diskstorage product, or any other computer readable data or program storageproduct. The program modules can also be embedded in permanent storage,such as ROM, one or more programmable chips, or one or more applicationspecific integrated circuits (ASICs). Such permanent storage can belocalized in a server, 802.11 access point, 802.11 wirelessbridge/station, repeater, router, mobile phone, or other electronicdevices. The software modules in the computer program product can alsobe distributed electronically, via the Internet or otherwise, bytransmission of a computer data signal (in which the software modulesare embedded) either digitally or on a carrier wave.

FIG. 1 illustrates a system 11 that is operated in accordance with oneembodiment of the present invention. System 11 comprises at least onecomputer 10. Computer 10 comprises standard components including acentral processing unit 22, memory 36, non-volatile storage 14 accessedvia controller 12 for storage of programs and data, user input/outputdevice 32, a network interface 20 for coupling computer 10 to othercomputers via a communication network (e.g., wide area network 34),power source 24, and one or more busses 30 that interconnect thesecomponents. User input/output device 32 comprises one or more userinput/output components such as a mouse, display 26, and keyboard 28.

Memory 36 comprises a number of modules and data structures that areused in accordance with the present invention. It will be appreciatedthat, at any one time during operation of the system, a portion of themodules and/or data structures stored in memory 36 can be stored inrandom access memory while another portion of the modules and/or datastructures can be stored in non-volatile storage 14. In a typicalembodiment, memory 36 comprises an operating system 40. Operating system40 comprises procedures for handling various basic system services andfor performing hardware dependent tasks. Memory 36 further comprises afile system 42 for file management. In some embodiments, file system 42is a component of operating system 40.

Memory 36 further discloses a number of modules including a selectingmodule 70 for selecting an identifier from a plurality of (preferably ofat least 50, 100, 200, 250, 500, 750, 1000, 1500, 2,000, 3,000, 5,000,7,500, 10,000, 25,000, 50,000 or 100,000) identifiers stored in acomputer database, each identifier identifying a frozen, stored expandedhuman cord blood stem cell sample derived from the umbilical cord bloodand/or placental blood of a different human individual at birth, whereinthe selecting does not take into account the respective HLA types of thestored frozen expanded human cord blood stem cell samples correspondingto the respective identifiers, an outputting or displaying module 72 foroutputting or displaying the identifier and optionally associatedinformation to a user, an internal or external component of a computer,a remote computer, or to storage on a computer readable medium, and anoptional retrieval module 74 for robotically retrieving the identifiedfrozen expanded cord blood stem cell sample. The selection module cancarry out computer-implemented selecting as described in Section 6.6above. It will be appreciated that one or more of these modules can berun on computer 10 or any other computer that is addressable by computer10. Thus, the present invention encompasses systems 11 that have morethan one computer, with each such computer optionally storing some orall of Expanded CB Stem Cell sample data 44 and performing any or all ofthe methods disclosed herein. In some embodiments, system 11 is acluster of computers.

In one embodiment of the invention, a computer-implemented method forselecting a frozen expanded human cord blood stem cell sample for use inproviding hematopoietic function to an immunodeficient human patient isprovided, which method comprises the following steps performed by asuitably programmed computer: (a) selecting an identifier from aplurality of at least 50, 100, 200, 250, 300, 400, 500, 600, 700, 750,800, 1,000, 2,000, 3,000, 5,000, 7,500, 10,000, 25,000, 50,000 or100,000 identifiers stored in a computer database, each identifieridentifying a frozen stored expanded human cord blood stem cell samplederived from the umbilical cord blood and/or placental blood of adifferent human individual at birth, wherein the selecting does not takeinto account the respective HLA types of the stored frozen expandedhuman cord blood stem cell samples corresponding to the respectiveidentifiers, wherein the selecting is for administration of the expandedhuman cord blood stem cell sample identified by said identifier to animmunodeficient human patient; and (b) outputting or displaying theselected identifier. In particular embodiments, the identifier isoutputted or displayed to a user, an internal or external component of acomputer, a remote computer, or to storage on a computer readablemedium. The outputting or displaying can also output or displayinformation on the physical location of the expanded human cord bloodstem cell sample identified by the identifier. In a specific embodiment,the method further comprises implementing robotic retrieval of theidentified frozen, expanded human cord blood stem cell sample. Theselecting can be as described in Section 6.6.

In another embodiment of the invention, a computer program product isprovided for use in conjunction with a computer system, which computerprogram product comprises a computer readable storage medium and acomputer program mechanism embedded therein, the computer programcomprising (a) executable instructions for selecting an identifier froma plurality of at least 50, 100, 200, 250, 300, 400, 500, 600, 700, 750,800, 1,000, 2,000, 3,000, 5,000, 7,500, 10,000, 25,000, 50,000 or100,000 identifiers stored in a computer database, each identifieridentifying a frozen stored expanded human cord blood stem cell samplederived from the umbilical cord blood and/or placental blood of adifferent human individual at birth, wherein the selecting does not takeinto account the respective HLA types of the stored frozen expandedhuman cord blood stem cell samples corresponding to the respectiveidentifiers, wherein the selecting is for administration of the expandedhuman cord blood stem cell sample identified by said identifier to animmunodeficient human patient; and (b) executable instructions foroutputting or displaying the selected identifier. In particularembodiments, the identifier is outputted or displayed to a user, aninternal or external component of a computer, a remote computer, or tostorage on a computer readable medium. In a specific embodiment, thecomputer program product further comprises executable instructions forimplementing robotic retrieval of the identified frozen, expanded humancord blood stem cell sample. The selecting can be as described inSection 6.6 above.

In yet another embodiment, the present invention provides an apparatuscomprising a processor; a memory, coupled to the processor, the memorystoring a module, the module comprising (a) executable instructions forselecting an identifier from a plurality of at least 50, 100, 200, 250,300, 400, 500, 600, 700, 750, 800, 1,000, 2,000, 3,000, 5,000, 7,500,10,000, 25,000, 50,000 or 100,000 identifiers stored in a computerdatabase, each identifier identifying a frozen stored expanded humancord blood stem cell sample derived from the umbilical cord blood and/orplacental blood of a different human individual at birth, wherein theselecting does not take into account the respective HLA types of thestored frozen expanded human cord blood stem cell samples correspondingto the respective identifiers, wherein the selecting is foradministration of the expanded human cord blood stem cell sampleidentified by said identifier to an immunodeficient human patient; and(b) executable instructions for outputting or displaying the selectedidentifier. In particular embodiments, the identifier is outputted ordisplayed to a user, an internal or external component of a computer, aremote computer, or to storage on a computer readable medium. In aspecific embodiment, the apparatus further comprises executableinstructions for implementing robotic retrieval of the identifiedfrozen, expanded human cord blood stem cell sample. The selecting can beas described in Section 6.6.

Alternative embodiments for implementing the methods and producing theStem Cell and Expanded CB Stem Cell populations of the present inventionwill be apparent to one of skill in the art and are intended to becomprehended within the accompanying claims. The experimental examplesin Sections 7-10, infra, are offered by way of illustration and not byway of limitation.

7. EXAMPLE Enrichment and Expansion of CD34⁺ Cells

This data presented herein supports the usefulness of CD34⁺ cord bloodstem cells which have been expanded ex vivo with an agonist of Notchfunction as an off-the-shelf, non-HLA matched product to provide rapidbut transient myeloid engraftment and to potentially facilitateautologous hematopoietic recovery in immunodeficient patients. In theprior art, it was not feasible to perform ex vivo expansion in advanceas the need for HLA-matching required an unattainable number ofpre-expanded units in order for an individual patient to find a suitablymatched unit. In contrast, where no, or limited, HLA-matching, isrequired for the expanded stem cell product, generation of a “bank” ofpre-expanded and then cryopreserved cells is possible, and the productswould be available for immediate use.

7.1 CD34⁺/CD38⁻ Versus CD34⁺

Growth characteristics and generation of SCID repopulating cells (SRC)starting from CD34⁺ or CD34⁺CD38⁻ human cord blood progenitor cellpopulations were compared. Enriched CD34⁺CD38⁻ cord blood progenitorscells were used as the starting cell population for Notch-mediatedexpansion as described in Delaney et al., 2005, Blood 106:1784-1789.Cells were cultured for 17-21 days in the presence of fibronectinfragments and immobilized engineered Notch ligand (Delta1^(ext-IgG)) orcontrol human IgG in serum free conditions supplemented with cytokines(SCF 300 ng/ml, Flt3L 300 ng/ml, TPO 100 ng/ml, IL-6 100 ng/ml, and IL-310 ng/ml, denoted as “5GF”). Delta1^(ext-IgG) consists of theextracellular domain of Delta1 fused to the Fc domain of human IgG1. Nosignificant difference was observed in absolute numbers of CD34⁺ cellsgenerated, with a CD34⁺ cell fold expansion of 138±64 and 163±64,(mean±sem, p=0.1612, data not shown) for the CD34⁺ versus the CD34⁺CD38⁻starting cell population, respectively. Assessment of in vivo NOD/SCIDrepopulating ability at 3, 6 and 10 weeks post infusion did, however,reveal enhanced human engraftment in the marrow of recipient mice when aCD34⁺ starting cell population was used as compared to a CD34⁺CD38⁻starting cell population (mean CD45% in CD34⁺ versus CD34⁺CD38⁻ startingcell populations cultured in the presence of Delta1^(ext-IgG): 3 weeks;6.7% versus 1.6%, p=0.02 and 10 weeks: 1.0% vs 0.2%, p=0.1). It wasfurther determined that the 5GF combination was superior to use ofcombinations utilizing fewer cytokines with respect to both in vitrogeneration of CD34⁺ cells and SRC frequency as determined by limitingdilution analysis (data not shown).

7.2 Culture of Cord Blood Progenitor Cells with Delta1^(ext-IgG) Resultsin Increased SCID Repopulating Cell (SRC) Frequency

Having identified the optimal conditions for Notch-mediated generationof UCB repopulating cells, 5 independent experiments were carried out totest this closed system for generation of stem/progenitor cells. HumanCD34⁺ cord blood cells were cultured for 17 days with Delta1^(ext-IgG)immobilized to the surface of the tissue culture vessel together withCH-296 fibronectin fragments in the presence of cytokines (IL-3 at 10ng/ml, IL-6 and TPO at 100 ng/ml, SCF and Flt3 ligand at 300 ng/ml) andlow density lipoproteins (LDL at 20 ng/ml) in serum free medium. Thenumber of repopulating cells generated was determined using quantitativelimit dilution assays in which groups of 8 to 15 mice received 1.5×10⁵,3×10⁴, or 6×10³ non-cultured cells or the cultured progeny of 3×10⁴,6×10³ or 1.2×10³ cells. Of note, mice that received non-cultured cellsalso received 2×10⁵ irradiated CD34⁻ cells as accessory supporting cellsto facilitate engraftment. Such accessory cells have not been requiredfor cultured cells as their function is provided by differentiatedmyeloid cells in the culture.

The frequency of repopulating cells in the starting cell population,determined using Poisson analysis with L-Calc™ software, demonstrated a15.8 fold increase in SRC frequency in Delta1^(ext-IgG)-cultured cellscompared to non-cultured cells at 3 weeks (p=0.0001) post infusion ofcells and a 6.3 fold increase in SRC frequency at 9 weeks (p=0.0001)(FIG. 2 a), thus indicating a significant increase in repopulatingability after culture with Delta1^(ext-IgG).

In addition, the fold expansion of the human CD34⁺ cells and the in vivolevel of human engraftment including lineage assessment (lymphoid versusmyeloid) of the human cells present was determined. In these 5experiments, there was a mean fold expansion of CD34⁺ cells of 230±53(mean±sem) for the Delta1^(ext-IgG) cultured cells versus 65±31(mean±sem) for the control cultured cells (p=0.03) (data not shown) anddemonstrated significantly higher engraftment of human CD45⁺ cells, aswell as CD33⁺ myeloid and CD19⁺ B cells from theDelta1^(ext-IgG)-cultured cells (FIG. 2 b). Although cells cultured withDelta1^(ext-IgG) led to increased overall hematopoietic reconstitutionat 9 versus 3 weeks, this was due primarily to an increase in engraftedlymphoid cells, presumably due to expansion of mature cells, whereasmyeloid engraftment decreased suggesting at least a portion ofengrafting cells were short term in nature.

7.3 Early Engrafting Potential of Delta1^(ext-IgG)-Cultured UCBProgenitors

In three independent experiments, in which the engraftment ofDelta1^(ext-IgG)-cultured human umbilical cord blood stem and progenitorcells produced as described in Section 7.2, supra, was compared toengraftment of non-Delta1^(ext-IgG)-cultured stem and progenitor cells,there was no measurable contribution to engraftment 10 days posttransplant in mice receiving non-cultured cord blood cells, whereas themice that received Delta1^(ext-IgG)-cultured cells all engrafted at alevel of >0.5% human engraftment consisting of >95% myeloid cells asmeasured by co-expression of the human antigens, CD33/CD45 (FIG. 3).Taken together, the above data suggests that culture of cord bloodprogenitors with Delta1^(ext-IgG) dramatically enhances the in vitrogeneration and frequency of NOD/SCID repopulating cells resulting inimprovement in the kinetics and level of human engraftment in a NOD/SCIDmouse model.

7.4 In Vivo Repopulating Ability is Retained Following Cryopreservationof the Expanded Cell Product

Using an immunodeficient mouse model, the ability of ex vivo expandedcryopreserved progenitor cells to engraft was evaluated. The cells wereexpanded according to the method set forth in Section 7.2, supra.Initial experiments compared in vivo repopulating ability of humanexpanded cells that were directly infused into immunodeficient mice uponharvest versus those that were harvested post expansion andcryopreserved for future use. There were no significant differencesobserved in the in vivo repopulating ability of cells that werecultured, cryopreserved (in standard media used for hematopoietic cellcryopreservation containing DMSO), and then thawed prior to transplantwhen compared to expanded progenitor cells that were harvested at theend of culture and freshly infused (FIG. 4 a). Additional experimentshave confirmed that repopulating ability of the expanded cell product isretained following cryopreservation. As shown in FIG. 4 b, all mice thatreceived human expanded cryopreserved cells engrafted (defined >0.5%human CD45 in the marrow) with an average overall human engraftment of8% at 2 weeks post infusion and 7% at 4 weeks post infusion. Lastly,various thawing methodologies were compared (thaw and wash, thaw anddilute with dextran/HSA and thaw and directly infuse) and have also notseen a significant difference in the three methods evaluated (FIG. 4 c).

7.5 Murine Hematopoietic Progenitor Cells Cultured with Delta1^(ext-IgG)Provide Short-Term Engraftment in H-2 Mismatched Recipients andFacilitates Autologous Recovery Following Radiation Exposure

The studies described below with a murine model show that expandednumbers of progenitor cells derived from murine hematopoieticprogenitors (LSK cells) are capable of providing short term engraftmentwhen transplanted in an H-2 mismatched recipient. LSK cells fromC57BL/6.J Ly5.1 (CD45.1) mice were cultured as previously described forfour weeks on Delta1^(ext-IgG) (Dallas et al., 2007, Blood109:3579-3587). For the congenic transplant, lethally irradiated C57BL/6(H-2b, CD45.1) mice received 10⁶ Delta1^(ext-IgG)-cultured Ly5.2 (H-2b,CD45.2) primary LSK cells along with 10⁵ C57BL/6 (H-2b, CD45.1)syngeneic whole bone marrow. For the allogeneic transplant, lethallyirradiated BALB.c (H-2d, CD45.1) recipients received 10⁶ Ly5.2 (H-2b,CD45.2) Deltaelta1^(ext-IgG)-cultured LSK cells along with 10⁵ BALB.c(H-2d, CD45.1) syngeneic whole bone marrow. Peripheral blood from micewere analyzed by FACS analysis at various times after transplantation toevaluate for donor chimerism (FIG. 5). The data show that the Deltacultured cells are able to provide short-term donor engraftment intransplant with major H-2 mismatch.

Furthermore, the data indicate that Delta1^(ext-IgG)-cultured cells haveenhanced hematopoietic engraftment early after irradiation compared toLSK bone marrow cells (which are depleted of T cells potentially able tocause graft-versus-host disease) in a competitive repopulation assay.This data demonstrates higher levels of early bone marrow repopulationfollowing infusion of cells cultured with Delta1^(ext-IgG), compared tonon-cultured precursors. The marrow of mice receiving allogeneic cellsfollowing culture with Delta1^(ext-IgG) contained a significantlygreater number of the allogeneic donor cells than mice that receivednon-cultured allogeneic donor LSK cells. Furthermore, assessment ofengraftment derived from syngeneic cells, provided to ensure survival ofthe recipient mice, demonstrated facilitation of engraftment of thesyngeneic cells when co-transplanted with Delta1^(ext-IgG)-culturedallogeneic cells. The number of cells derived from the host was higherin recipients of the Delta1^(ext-IgG)-cultured cells compared tonon-cultured allogeneic cells (FIG. 6). Thus, this data indicates thatengraftment by cultured cells can occur in mismatched settings, andmoreover the Delta1^(ext-IgG)-cultured cells can facilitate engraftmentof syngeneic cells, further suggesting their potential for facilitatingrecovery of autologous residual stem cells remaining after radiation.

In separate experiments, murine Ly5a Lin-Sca-1c-kit+ cells (H-2b,CD45.1) (“LSK”) cells obtained from the bone marrow of C57 black mice byflow cytometric sorting (10³) were expanded by culturing the cells withgrowth medium and immobilized Delta1^(ext-IgG) (expanded LSK cells).Control (unexpanded) LSK cells were cultured with IgG. The growth medium(Iscoves modified Dulbecco medium) was supplemented with 20% FBS and 4growth factors (4GF): murine stem cell factor, human Flt-3 ligand, andhuman IL-6, each at 100 ng/mL, and human IL-11 at 10 ng/mL (PeproTech,Rocky Hill, N.J.). Cell density was maintained at approximately 2.5×10⁵cells/cm² by transferring the cultures to larger vessels every 3 to 5days during the first 2 weeks (see Dallas et al., 2007, Blood109:3579-3587). After 14 days of culture, the cells were harvested andtransplanted into irradiated Balb-c (H-2d, CD45.2) mice. FIG. 7 is aschematic drawing of this experimental protocol. FIGS. 8 a-8 b depictthe level of engraftment of the expanded and non-expanded LSK cells ineither bone marrow (FIG. 8 a) or peripheral blood (FIG. 8 b) of lethallyirradiated Balb-c mice as a result of carrying out the protocol setforth in FIG. 7, measured as donor percent (percentage of donor cells inbone marrow or peripheral blood as determined by immunophenotyping andFACS analysis). The results confirmed that effective engraftment wasachieved when expanded stem and progenitor cells were infused in amismatched setting after a single dose of radiation. In a similarexperiment, 5×10⁶ cryopreserved LSK cells, expanded as described above,were infused into mice exposed to 7.5 Gy or 8 Gy of radiation. FIGS. 9a-9 b show that mice infused with the expanded LSK cells (indicated as“Delta”) had a greater survival rate as compared to a control groupinfused with saline. Similarly, the overall survival of mice lethallyirradiated at 8.5 Gy was increased after infusion of either 3×10⁶,5×10⁶, or 10×10⁶ elta1^(ext-IgG)-cultured (expanded) LSK cells ascompared to 1×10⁶ or 3×10⁶ IgG-cultured (non-expanded) LSK cells (FIG.10). In another experiment, following the protocol set forth in FIG. 7,donor engraftment of mismatched expanded LSK cells (DXI) was enhancedwith increasing dose of radiation as measured by the percentage of donorcells (donor percent) in bone marrow and peripheral blood, as determinedby immunophenotyping and FACS analysis (FIGS. 11 a-11 b).

7.6 Preliminary Results of a Phase I Clinical CBT Trial

Direct clinical translation of the above has resulted in an ongoingPhase I cord blood transplantation trial (FHCRC Protocol 2044) using exvivo expanded cord blood progenitor cells following myeloablativeconditioning. Results from the current Phase I trial have not onlydemonstrated safety of this protocol, but more importantly havedemonstrated rapid myeloid engraftment derived from ex vivo expandedhematopoietic progenitors and consequently, a significant reduction inmedian time to an absolute neutrophil count of 500/μl to just 14 days.This is a statistically significant (p=0.002) improvement in time toengraftment when compared to a cohort of patients (N=20) with the sametreatment regimen at our institution but with two non-manipulated cordblood units who engrafted at a median of 26 days (FIG. 12). The twocohorts did not differ significantly in age, weight, diagnosis orinfused cell doses as provided by the non-manipulated units. It has beensuggested that an ANC threshold of >100/μl is strongly associated with asurvival benefit post allogeneic stem cell transplant (Offner et al.,1996, Blood 88:4058). Among enrolled patients median time to achieve anANC >100/μl was 9 days versus 19 days in the conventional setting (asabove) (p=0.006, data not shown).

In the 11 patients analyzed to date, there has been no failure to exvivo expand the absolute numbers of CD34⁺ cells available for infusion.The average fold expansion of CD34⁺ cells was 163 (±43 SEM, range41-471) and 590 (±124 SEM, range 146-1496) for the total cell numbers,correlating with a significantly higher infused CD34 cell dose (CD34⁺cells/kg recipient body weight) derived from the expanded cord bloodgraft averaging 6×10⁶ CD34/kg (range 0.93 to 13×10⁶) versus 0.24×10⁶CD34/kg (range 0.06 to 0.54×10⁶) from the non-manipulated cord bloodgraft. It is important to note that the unit subjected to ex vivoexpansion is CD34-selected and therefore T cell depleted prior toculture initiation. Additional details of the final harvested product,including viability and additional immunophenotyping, can be found inTable II below. As demonstrated in Table II, no CD3⁺/CD4⁺ or CD3⁺/CD8⁺cells were identified. No mature T cells are generated during culture.Also, as discussed below, even in this setting where the expanded cellswere at least 4/6 HLA-matched to the recipient, there was nocontribution to CD3 engraftment from the expanded unit. CD4⁺/CD37CD8⁻cells were observed in culture and consistent with monocytes.

TABLE II Selected Immunophenotyping of Expanded Cell Product at HarvestPercent Cells/kg (range) (range) CD34 14.5 (6.2-26) 6.1 × 10⁶ (0.9-13.6)CD7  8.1 (5.9-12) 3.9 × 10⁶ (0.3-9.1) CD14 11.3 (1.8-23) 5.6 × 10⁶(0.1-14.6) CD15 20.5 (6-36) 9.0 × 10⁶ (1.1-23) CD34⁺/56⁺  2.9 (1.4-5.8)1.7 × 10⁶ (0.08-5.3) CD3⁻/CD16⁺/56⁺  5.4 (2.2-13.6) 2.7 × 10⁶ (0.1-12.4)CD20  0.1 (0-0.2) 3.6 × 10⁴ (0-14) CD3  0.2 (0-0.6) 4.8 × 10⁴ (0-13)CD4^(lo)/CD3^(neg)/CD8^(neg) 40.6 (16-67) 1.7 × 10⁷ (0.2-6.1) CD8  0.1(0-0.5) 3.4 × 10⁴ (0-17)

Contribution to donor engraftment as derived from the expanded ornon-manipulated grafts was determined weekly in the first monthbeginning at day 7 post-transplant on peripheral blood sorted cellfractions. In eight of the nine engrafted patients there were sufficientnumbers of peripheral blood sorted myeloid cells for evaluation and ineach of these patients revealed a predominance of donor cell engraftmentderived from the expanded cell graft in both the CD33 and CD14 cellfractions. Contribution to early myeloid recovery at day 7 was derivedalmost entirely from the expanded cell graft, but generally did notpersist beyond day 14 to 21 post-transplant. Despite this, time toengraftment was decreased significantly, indicating of a potentialfacilitating effect exerted by the ex vivo expanded cells on thenon-manipulated unit. In all but one patient, as expected, thenon-manipulated donor graft has emerged as the source of sustained donorengraftment.

Longer-term in vivo persistence of the expanded cell graft was observedin two patients. In one patient, analysis at day 240 post transplantrevealed a portion (10-15%) of the donor CD14, CD56 and CD19 cells werederived from the expanded graft but was no longer present by one year.In the second patient at day 180 post transplant, contribution toengraftment from the expanded cell population at day 180 post transplantin CD33, CD14, CD56 and CD19 cells ranged from 25 to 66% of total donorengraftment. However, the expanded graft did not contribute to CD3⁺ cellengraftment.

8. EXAMPLE Clinical Enrichment and Expansion

The following section describes the production and storage of expandedhuman cord blood stem cell samples, as depicted as a flow chart in FIG.13.

The umbilical cord blood/placental blood unit(s) were collected from asingle human at birth. The collected blood was then mixed with ananti-coagulant to prevent clotting. The blood was stored underquarantine at 4° C. in a monitored refrigerator. The received unit(s)were assessed, and which unit(s) will be processed for expansion wasdetermined. The following information was collected on the units: datereceived, age in hours of the unit, gestational age of the donor inweeks, sex of the donor, and volume of the unit. Further, totalnucleated cell count and total CD34⁺ cell count of each unit wasdetermined and percent CD34⁺ cells was calculated. If the unit had lessthan 3.5 million CD34⁺ cells, the unit was discarded. When a unit wasselected for expansion, it was removed from quarantine and assigned aunique Lot Number identifier, which it retains throughout themanufacturing process.

Prior to planned initiation of expansion cultures, tissue culturevessels were first coated overnight at 4° C. or a minimum of 2 hours at37° C. with Delta1^(ext-IgG) at 2.5 μg/ml and RetroNectin® (arecombinant human fibronectin fragment) (Clontech Laboratories, Inc.,Madison, Wis.) at 5 μg/ml in phosphate buffered saline (PBS). The flaskswere then washed with PBS and then blocked with PBS-2% Human SerumAlbumin (HSA). The fresh cord blood unit was processed to select forCD34⁺ cells using the CliniMACS® Plus Cell Separation System. Prior toCD34 selection, an aliquot of the fresh cord blood unit was checked fortotal cell count and CD34 content. Both CD34⁺ and CD34⁻ cell fractionswere recovered after processing. After enrichment, the percentage ofCD34⁺ cells in the sample increased by 88- to 223-fold relative to thepercentage of CD34⁺ cells in the sample prior to enrichment. DNA wasextracted from a sample of the CD34⁻ cell fraction for initial HLAtyping. The enriched CD34⁺ cell fraction was resuspended in finalculture media, which consists of STEMSPANT™ Serum Free Expansion Medium(StemCell Technologies, Vancouver, British Columbia) supplemented withrhlL-3 (10 ng/ml), rhIL-6 (50 ng/ml), rhTPO (50 ng/ml), rhFlt-3L (50ng/ml), rhSCF (50 ng/ml).

The CD34⁺ enriched cells were added to the specifically labeled andprepared tissue culture vessels at a concentration of ≦1.8×10⁴ totalnucleated cells/cm2 of vessel surface area, and then placed intoindividually monitored and alarmed incubators dedicated solely to thatlot of product. After 2-4 days of culture, 50% of the original volume offresh culture media (as above) was added to the vessels. The cellculture vessels were removed from the incubator periodically (every 1-3days), and examined by inverted microscope for cell growth and signs ofcontamination. On day 5-8, the vessel was gently agitated to mix thecells, and a 1 ml sample was removed for in process testing. The sampleof cells was counted and phenotyped for expression of CD34, CD7, CD14,CD15 and CD56. Throughout the culture period, cells were transferred toadditional flasks as needed when cell density increases to ≧8×10⁵cells/ml. On the day prior to harvesting the cells for cryopreservation,fresh media was added.

On day 14-16, the expanded cell population was harvested forcryopreservation. The vessels were agitated and the entire contentstransferred to sterile 500 ml centrifuge tubes. The harvested cells werecentrifuged and then washed one time by centrifugation in PBS andresuspended in a cryoprotectant solution containing HSA, Normosol-R(Hospira, ake Forrest, Ill.) and Dimethylsulfoxide (DMSO). Samples forcompletion of release testing were taken. The Expanded CB Stem cellpopulation product was frozen in a controlled-rate freezer andtransferred to storage in a vapor-phase liquid nitrogen (LN2) freezer.

At the end of the culture period, the resulting cell population washeterogeneous, consisting of CD34⁺ progenitor cells and more maturemyeloid and lymphoid precursors, as evidenced by flow cytometricanalysis for the presence of CD34, CD7, CD14, CD 15 and CD56 antigens.Typical flow cytometry characterization of the expanded cells at the endof the expansion period is presented in Table III below.

TABLE III Expanded Cell Phenotype (N = 9, * N = 5) Mean Percent (range)CD34 12.8 (4.9-25)  CD7 9.7 (4.3-21) CD14 7.7 (3.5-22) CD15 42 (23-66)CD34⁺/56⁺  1.8 (0.7-3.1) CD3⁻/CD16⁺/56⁺ 3.5 (0-9.5)  CD20* 0.4 (0-1.2) CD3⁺4⁺*  0.7 (0.04-1.4)  CD3⁺8⁺* 0 TNC Fold Expansion  1586 (617-3337)CD34 Fold Expansion  204 (100-387)

There was a significant increase of CD34⁺ and total cell numbers duringthe culture period, ranging from 100 to 387 fold expansion of CD34⁺cells and 617 to 3337 fold expansion of total cell numbers (N=9individual cord blood units, processed per the final clinical expansionprocedures as described above). There was essentially a complete lack ofT cells as measured by immunophenotyping. Functionally, these cells arecapable of multi-lineage human hematopoietic engraftment in a NOD/SCIDmouse model as described above.

Data from ten full-scale ex vivo expansions are presented in Table IVbelow. The average fold expansion for total cell numbers was 1723±230(mean±sem) and for CD34⁺ cells was 179±30 (mean±sem).

TABLE IV Pre- and Post-expansion absolute cell numbers and foldexpansion TNC (total number cells) CD34 Starting Ending Fold StartingEnding Fold Number banked (cryopreserved) Cells Run Number NumberExpansion Number Number Expansion TNC CD34# # Bags TNC/Bag CD34/Bag 1 1.9 × 10⁶ 2.01 × 10⁹ 1068 1.66 × 10⁶ 2.13 × 10⁸ 129 n/a n/a n/a n/a n/a2 1.76 × 10⁶ 1.20 × 10⁹ 690 1.41 × 10⁶ 3.04 × 10⁸ 216 n/a n/a n/a n/an/a 3 2.60 × 10⁶ 5.47 × 10⁹ 2104 2.29 × 10⁶ 2.69 × 10⁸ 117 4.20 × 10⁹2.06 × 10⁸ 2 2.10 × 10⁹ 1.03 × 10⁸ 4 2.40 × 10⁶ 4.67 × 10⁹ 1944 2.04 ×10⁶ 6.07 × 10⁸ 298 2.90 × 10⁹ 3.77 × 10⁸ 1 2.90 × 10⁹ 3.77 × 10⁸ 5 2.17× 10⁶ 3.22 × 10⁹ 1484 1.76 × 10⁶ 2.71 × 10⁸ 154 2.12 × 10⁹ 1.78 × 10⁸ 12.12 × 10⁹ 1.78 × 10⁸ 6 1.90 × 10⁶ 2.59 × 10⁹ 1364 1.70 × 10⁶ 1.70 × 10⁸100 2.00 × 10⁹ 1.32 × 10⁸ 1 2.00 × 10⁹ 1.32 × 10⁸ 7 4.80 × 10⁶  1.60 ×10¹⁰ 337 4.32 × 10⁶ 1.69 × 10⁹ 387  1.29 × 10¹⁰ 1.35 × 10⁹ 4 3.23 × 10⁹3.38 × 10⁸ 8 4.86 × 10⁶ 9.94 × 10⁹ 2045 4.23 × 10⁶ 7.28 × 10⁸ 172  1.02× 10¹⁰ 7.47 × 10⁸ 3 3.40 × 10⁹ 2.49 × 10⁸ 9 1.70 × 10⁶ 2.55 × 10⁹ 14991.39 × 10⁶ 1.46 × 10⁸ 105 2.25 × 10⁹ 1.29 × 10⁸ 1 2.25 × 10⁹ 1.29 × 10⁸10 2.06 × 10⁶ 3.48 × 10⁹ 1692 1.77 × 10⁶ 1.92 × 10⁸ 108 2.75 × 10⁹ 1.51× 10⁸ 1 2.75 × 10⁹ 1.51 × 10⁸ average 2.62 × 10⁶ 5.11 × 10⁹ 1723 2.26 ×10⁶ 4.59 × 10⁸ 179 4.92 × 10⁹ 4.09 × 10⁸ 2.59 × 10⁹ 2.07 × 10⁸ n/a: notavailable

Table V sets forth the starting, ending and fold expansion numbers fortotal nucleated cells and CD34⁺ cells post-expansion for 19 full scaleex vivo expansions.

TABLE V CD34 CD34 Purity TNC Unit ID Fold Starting Ending Fold Product #Starting # Ending # Expansion % % Starting # Ending # Expansion S0012.29 × 10⁶ 2.69 × 10⁸ 117 88 4.9 2.60 × 10⁶ 5.47 × 10⁹ 2104 S002 2.04 ×10⁶ 6.07 × 10⁸ 298 85 13 2.40 × 10⁶ 4.67 × 10⁹ 1944 S003 1.76 × 10⁶ 2.71× 10⁸ 154 81 8.4 2.17 × 10⁶ 3.22 × 10⁹ 1484 S004 1.70 × 10⁶ 1.70 × 10⁸100 91 6.6 1.90 × 10⁶ 2.59 × 10⁹ 1364 S005 4.32 × 10⁶ 1.69 × 10⁹ 387 9010.4 4.80 × 10⁶  1.60 × 10¹⁰ 3337 S006 4.23 × 10⁶ 7.28 × 10⁸ 172 87 7.34.86 × 10⁶ 9.94 × 10⁹ 2045 S007 1.39 × 10⁶ 1.46 × 10⁸ 105 82 5.7 1.70 ×10⁶ 2.55 × 10⁹ 1499 S008 1.77 × 10⁶ 1.92 × 10⁸ 108 86 5.5 2.06 × 10⁶3.48 × 10⁹ 1692 S009 2.70 × 10⁶ 4.74 × 10⁸ 176 88 8.8 3.07 × 10⁶ 5.42 ×10⁹ 1765 S010 2.02 × 10⁶ 7.92 × 10⁸ 392 75 11.6 2.69 × 10⁶ 6.84 × 10⁹2543 S011 1.64 × 10⁶ 4.25 × 10⁸ 259 82 15.2 2.00 × 10⁶ 2.79 × 10⁹ 1395S012 1.64 × 10⁶ 4.25 × 10⁸ 259 82 15.2 2.82 × 10⁶ 2.12 × 10⁹ 752 S0131.97 × 10⁶ 2.25 × 10⁸ 114 70 10.6 2.96 × 10⁶ 6.25 × 10⁹ 2111 S014 2.28 ×10⁶ 6.49 × 10⁸ 285 77 10.4 2.60 × 10⁶ 2.15 × 10⁹ 827 S015 1.74 × 10⁶1.42 × 10⁸ 82 67 6.63 2.50 × 10⁶ 2.97 × 10⁹ 1187 S016 1.88 × 10⁶ 2.80 ×10⁸ 149 75 9.4 4.46 × 10⁶ 7.65 × 10⁹ 1715 S017 3.75 × 10⁶ 1.04 × 10⁸ 27684 13.6 6.90 × 10⁶ 4.07 × 10⁹ 590 S018 6.28 × 10⁶ 2.91 × 10⁸ 46 91 7.142.34 × 10⁶ 2.18 × 10⁹ 932 S019 1.78 × 10⁶ 2.29 × 10⁸ 129    76% 10.522.16 × 10⁶ 2.00 × 10⁹ 926

These 19 expanded human cord blood stem cells were cryopreserved in oneor more bags. Table VI sets forth total nucleated cell (TNC) and CD34⁺cell counts for each of the expanded human cord blood stem cell sampleand cell viability prior to cryopreservation, and TNC and CD34⁺ cellcounts in each frozen bag.

TABLE VI Unit ID Banked Cells Final Viability Product # TNC CD34 # #Bags TNC/Bag CD34#/Bag Trypan Blue S001 4.20 × 10⁹ 2.06 × 10⁸ 2 2.10 ×10⁹ 1.03 × 10⁸ 67% S002 2.90 × 10⁹ 3.77 × 10⁸ 1 2.90 × 10⁹ 3.77 × 10⁸62% S003 2.12 × 10⁹ 1.78 × 10⁸ 1 2.12 × 10⁹ 1.78 × 10⁸ 69% S004 2.00 ×10⁹ 1.32 × 10⁸ 1 2.00 × 10⁹ 1.32 × 10⁸ 55% S005  1.29 × 10¹⁰ 1.35 × 10⁹4 3.23 × 10⁹ 3.38 × 10⁸ 67% S006  1.02 × 10¹⁰ 7.47 × 10⁸ 3 3.40 × 10⁹2.49 × 10⁸ 57% S007 2.25 × 10⁹ 1.29 × 10⁸ 1 2.25 × 10⁹ 1.29 × 10⁸ 70%S008 2.75 × 10⁹ 1.51 × 10⁸ 1 2.75 × 10⁹ 1.51 × 10⁸ 79% S009 6.30 × 10⁹5.51 × 10⁸ 2 3.15 × 10⁹ 2.76 × 10⁸ 59% S010 4.93 × 10⁹ 5.70 × 10⁸ 2 2.47× 10⁹ 2.85 × 10⁸ 66% S011 1.82 × 10⁹ 2.77 × 10⁸ 1 1.82 × 10⁹ 2.77 × 10⁸57% S012 1.70 × 10⁹ 1.81 × 10⁸ 1 1.70 × 10⁹ 1.81 × 10⁸ 59% S013 5.14 ×10⁹ 5.34 × 10⁸ 2 2.57 × 10⁹ 2.67 × 10⁸ 68% S014 1.50 × 10⁹ 9.91 × 10⁷ 11.50 × 10⁹ 9.91 × 10⁷ 68% S015 1.94 × 10⁹ 1.83 × 10⁸ 1 1.94 × 10⁹ 1.83 ×10⁸ 62% S016 4.08 × 10⁹ 5.53 × 10⁸ 2 2.04 × 10⁹ 2.76 × 10⁸ 54% S017 3.90× 10⁹ 2.78 × 10⁸ 1 3.90 × 10⁹ 2.78 × 10⁸ 65% S018 1.23 × 10⁹ 1.29 × 10⁸1 1.23 × 10⁹ 1.29 × 10⁸ 68% S019 2.19 × 10⁹ 2.23 × 10⁸ 1 2.19 × 10⁹ 2.23× 10⁸

Further, an additional 12 samples of enriched CD34⁺ cells were expandedwith Delta1^(ext-IgG), and showed an average 141-fold expansion (SEM 17)of CD34⁺ cells, prior to cryopresevation.

9. EXAMPLE Treatment of Patients with AML

9.1: Design

The below discussion describes the design of a clinical trial aimed atproviding rapid restoration of hematopoietic function to patientssuffering from acute myelogenous leukemia (AML) who have been treatedwith intensive induction chemotherapy by administering expanded humancord blood stem cells. This study will enroll in three cohorts at 10-15patients per cohort, each with separate inclusion criteria based ondisease status. Cohort A will enroll first for a total of 10 patients.If safety criteria are met, enrollment will occur in cohort B for atotal of 15 patients; if safety criteria are again met, enrollment willoccur in cohort C for a total of 15 patients.

Cohort A: Diagnosis of acute myeloid leukemia by WHO criteria, eitherrelapsed or refractory. Acute promyelocytic leukemia [Acutepromyelocytic leukemia with t(15;17)(q22;q12) and variants] will beeligible only after failure of a regimen containing arsenic trioxide.Patients in this cohort must have had an initial remission duration of<1 year and can not have received any prior salvage chemotherapy.

Cohort B: Untreated AML patients with cytogenetic or molecularabnormalities associated with poor prognosis.

Cohort C: Untreated AML patients with intermediate prognosis.

In addition to disease criteria established above, all patients mustmeet inclusion criteria listed below:

-   -   1. The first three patients enrolled in each cohort must be less        than 60 years old. Thereafter, patients aged ≧18 and ≦70 are        eligible.    -   2. The first three patients enrolled in each cohort must have an        ECOG performance status of 0-1. Thereafter, ECOG performance        status of 0-2 is required.    -   3. The patients must have adequate renal and hepatic functions        as indicated by the following laboratory values:        -   a. Serum creatinine ≦1.0 mg/dL; if serum creatinine >1.0            mg/dl, then the estimated glomerular filtration rate (GFR)            must be >60 mL/min/1.73 m2 as calculated by the Modification            of Diet in Renal Disease equation where predicted GFR            (ml/min/1.73 m2)=186×(Serum Creatinine)−1.154×(age in            years)−0.023×(0.742 if patient is female)×(1.212 if patient            is black).        -   b. Serum total or direct bilirubin ≦1.5×upper limit of            normal (ULN), aspartate transaminase (AST)/alanine            transaminase (ALT)≦2.5×ULN, alkaline phosphatase ≦2.5×ULN    -   4. Capable of understanding the investigational nature,        potential risks and benefits of the study, and able to provide        valid informed consent.    -   5. Female patients of childbearing potential must have a        negative serum pregnancy test within 2 weeks prior to        enrollment.    -   6. Male and female patients must be willing to use an effective        contraceptive method during the study and for a minimum of 6        months after study treatment.    -   7. Panel reactive antibody (PRA) negative or with specific        antibodies characterized and known to not be donor-directed        against cord blood antigens.

The following individuals are excluded from this trial:

-   -   1. Allogeneic transplant recipients.    -   2. Current concomitant chemotherapy, radiation therapy, or        immunotherapy other than as specified in the protocol.    -   3. Have any other severe concurrent disease, or have a history        of serious organ dysfunction or disease involving the heart,        kidney, liver (including symptomatic hepatitis, veno-occlusive        disease), or other organ system dysfunction.    -   4. Patients with a systemic fungal, bacterial, viral, or other        infection not controlled (defined as exhibiting ongoing        signs/symptoms related to the infection and without improvement,        despite appropriate antibiotics or other treatment).    -   5. Pregnant or lactating patients.    -   6. Any significant concurrent disease, illness, or psychiatric        disorder that would compromise patient safety or compliance,        interfere with consent, study participation, follow up, or        interpretation of study results.

The expanded cord blood stem cells to be used for this trial will beselected from a bank of previously expanded cord blood progenitors thathave been cryopreserved for future clinical use. Each individualprogenitor cell product is derived from a single cord blood unit (donor)that is CD34 selected (and therefore T cell depleted), ex vivo expandedin the presence of Notch ligand and then cryopreserved as describedabove. The fresh cord blood units are obtained through a collaborationwith the Cord Blood (CB) Program at the Puget Sound BloodCenter/Northwest Tissue Center (PSBC/NTC). Selection of the expandedcord blood stem cells will be based on the following:

A. Panel Reactive Antibody (PRA) to be performed on all enrolledpatients, and product selected based on the specificity of donordirected antibodies when present. PRA negative patients may receive anyproduct that fits cell dose restrictions. HLA matching will not beconsidered outside of PRA+ patients.

-   -   1. For patients eligible for a second dose of expanded cell        product: PRAs will be repeated prior to selection of cord blood        progenitor cell products.

B. Cell Doses:

-   -   1. Infused TNC/kg cell dose will not exceed 1×10⁸ TNC/kg        recipient body weight.    -   2. No upper limit will be placed on the CD34⁺ cells/kg infused.    -   3. All expanded products are evaluated by immunophenotyping for        the presence of CD3⁺ cells prior to freezing. While there has        been no convincing evidence of a CD3⁺ cell population, if a        product has evidence of a T cell (CD3⁺) population, this product        will not be used unless the dose of CD3⁺ cells is <5×10⁵ CD3⁺        cells/kg (recipient weight).

C. Repeat Infusions of Expanded Progenitors: Patients with severeinfusional toxicities are not eligible for repeat infusions.

FIG. 14 depicts the plan for treating enrolled patients suffering fromAML.

Patients will receive one cycle of induction chemotherapy followed byinfusion of expanded cord blood progenitors, with the possibility of asecond cycle with infusion of expanded cell product beginning on day 21to 28 post chemotherapy, provided the following conditions are met:

-   -   1. The patient does not have residual leukemia, defined as <5%        marrow blasts by morphology.    -   2. The patient has not experienced any extramedullary grade 3-4        toxicities.    -   3. The neutrophil count has recovered to 500/μl (on or off        G-CSF).    -   4. The patient has no uncontrolled infections.    -   5. The patient has not had a history of severe infusional        toxicities with the first expanded product infusion.

Plan for Consolidation Cycles: Only patients who achieve a remission(defined as <5% blasts by morphology) after reinduction (withoutexpanded cells) or cycle 2 (with expanded cells) as per FIG. 14 will beeligible to receive additional consolidation therapy. Eligible patientswill receive a maximum of two cycles of consolidation therapy. Whetheror not a patient receives consolidation therapy will depend on whetherthe patient will be undergoing additional therapy such as a stem celltransplant. Consolidation will be offered without the use of expandedcord blood progenitor cells.

D. Induction Therapy (See also FIG. 14):

-   -   1. All patients will receive an initial induction cycle followed        by infusion of expanded cord blood progenitors (“Cycle 1” in        diagram, FIG. 14. Patients will receive a second infusion of        expanded cord blood progenitors with induction cycle 2 only if        eligible, as outlined in “Eligibility for repeat expanded cell        infusion with induction cycle 2” in FIG. 14. All other patients        will undergo reinduction therapy without infusion of expanded        cord blood progenitors, as per FIG. 14.    -   2. The dosing of clofarabine, Ara-C and G-CSF is the same for        induction cycles 1 and 2, regardless of whether the patient is        eligible for a second infusion of expanded progenitor cells.    -   3. G-CSF: 5 μg/kg subcutaneously (SQ), rounded up to nearest        vial size, beginning 24 hours prior to chemotherapy and        continued daily through day 5. Infusion of the expanded cell        product will occur on day 6 and G-CSF will be held that day.        G-CSF will be resumed on day 7 and continued daily until        ANC >2000 for two consecutive days.    -   4. Clofarabine: A dose of 25 mg/m2 will be administered as a 1        hour intravenous infusion once daily for 5 days.    -   5. Ara-C: A dose of 2 gm/m2 will be administered as a 2-hour        intravenous infusion once daily for 5 days, starting 4 hours        after the start of the clofarabine infusion.    -   6. Infusion of expanded, cryopreserved cord blood stem cells of        the invention:        -   a. Dosage and selection of expanded product: Infused total            nuclear cell count(TNC)/kg cell dose will not exceed 1×10⁸            TNC/kg recipient body weight. CD34 cell dose: No upper limit            will be placed on the CD34 cells/kg infused. All expanded            products are evaluated by immunophenotyping for the presence            of CD3⁺ cells prior to freezing. While there has been no            convincing evidence of a CD3⁺ cell population, if a product            has evidence of a T cell (CD3⁺) population, this product            will not be used unless the dose of CD3⁺ cells is <5×10⁵ CD3            cells/kg (recipient weight).

The infusion rate of the expanded cord blood stem cells of the inventionis infuse at a rate of 3-5 ml/min for the first 4 minutes. If tolerated,the rate is increased to “wide open”. No medications or fluids should begiven piggyback through the catheter that is being used for the expandedcell infusion.

TABLE VII Induction Therapy Cycle 1 and 2 “Reinduction” Day (withexpanded cells) (without expanded cells) 0 G-CSF 5 μg/kg SQ G-CSF 5μg/kg SQ 1-5 Clofarabine 25 mg/m² IV over Clofarabine 25 mg/m² IV over 1hour 1 hour Ara-C 2 gm/m² IV over 2 hours Ara-C 2 gm/m² IV over 2 hoursG-CSF 5 μg/kg SQ G-CSF 5 μg/kg SQ 6 Hold GCSF Continue GCSF until ANCInfusion of expanded cord blood >2000 for two consecutive daysprogenitors 7 Resume GCSF and continue until ANC >2000 for twoconsecutive days

E. Consolidation Therapy

-   -   1. Patients in remission (defined as <5% marrow blasts by        morphology) will be eligible to receive up to two cycles of        consolidation, depending on whether the patient will be going on        to receive additional therapy such as a stem cell transplant.        Patients with refractory disease after cycle 2 with expanded        cell infusion or reinduction without expanded cell infusion will        be removed from the study.    -   2. G-CSF: 5 μg/kg subcutaneously (SQ), rounded up to nearest        vial size, beginning 24 hours prior to chemotherapy and        continued daily until ANC >2000 for two consecutive days.    -   3. Clofarabine: A dose of 20 mg/m2 will be administered as a 1        hour intravenous infusion once daily for 5 days.    -   4. Ara-C: 1 gm/m2 as a two hour intravenous infusion once daily        for five days, starting four hours after the start of the        clofarabine infusion. Patients in remission (defined as <5%        marrow blasts by morphology) will be eligible to receive up to        two cycles of consolidation, depending on whether the patient        will be going on to receive additional therapy such as a stem        cell transplant. Patients with refractory disease after cycle 2        with expanded cell infusion or reinduction without expanded cell        infusion will be removed from the study.

TABLE VIII Consolidation Therapy: Day 0 G-CSF 5 μg/kg SQ Day 1-5Clofarabine 20 mg/m² IV over 1 hour Ara-C 1 gm/m² IV over 2 hours G-CSF5 μg/kg SQ Day 6 Continue G-CSF until ANC >2000 for two consecutive days

Evaluation Guidelines:

A. Pre-Treatment Evaluation

-   -   1. Complete physical examination.    -   2. Medical history: Detailed documentation of disease and        treatment history with outcomes.    -   3. ECOG performance status    -   4. 12 lead EKG    -   5. Hematology: CBC with differential and platelet count and        peripheral blood smear.    -   6. Serum chemistries: Electrolytes (sodium, potassium, chloride,        and bicarbonate), blood urea nitrogen (BUN), creatinine,        glucose, and liver function tests (aspartate aminotransferase        (AST) and/or alanine aminotransferase (ALT), alkaline        phosphatase (ALP), total bilirubin, lactate dehydrogenase (LDH).    -   7. Panel Reactive Antibody (PRA).    -   8. Adverse event assessment from time of first dose of G-CSF.    -   9. Initial standard of care diagnostic bone marrow reports,        including hematopathology, cytogenetics/FISH, and flow        cytometry.    -   10. To subsequently determine post transplant chimerism,        heparinized peripheral blood from the patient will be obtained        and chimerism analysis by DNA analysis will be performed.

B. Evaluation to be Completed the Morning of Expanded ProgenitorInfusion:

-   -   1. Physical exam and review of systems done by provider    -   2. Weight by nursing    -   3. CBC [CBD] (includes HCT, HGB, WBC, RBC, indices, platelets,        DIFF/SMEAR EVAL)    -   4. [SRFM] and [SHFL] (HSCT Renal function panel with magnesium        and HSCT Hepatic function panel with LD; SRFM includes NA, K,        CL, CO2, GLU, BUN, CRE, CA, P, ALB, MG and SHFL includes ALT,        AST, ALK, BILIT/D, TP, ALB, LD)    -   5. Complete urinalysis

C. Evaluation During Infusion of Ex Vivo Expanded Cord Blood Progenitors

-   -   1. RN must be in attendance during infusion.    -   2. MD or PA must be available on the inpatient unit.    -   3. If any changes in cardiac status, notify physician and obtain        ECG.    -   4. Obtain and record vital signs including temperature, BP, HR,        Respirations, and O2 saturation at the following time points:

TABLE IX Pre-infusion 1 hour after the start of infusion 15 minutesafter the start of 2 hours after the start of infusion infusion 30minutes after the start of 4 hours after the start of infusion infusion45 minutes after the start of 24 hours after the start of infusioninfusion

-   -   5. Dipstick for HGB/protein every voided urine for 24 hours        after infusion of expanded cells. Record HGB and Protein.

D. Evaluation 24 Hours Post Infusion of Ex Vivo Expanded Cord BloodProgenitors

-   -   1. CBC [CBD] (includes HCT, HGB, WBC, RBC, indices, platelets,        DIFF/SMEAR EVAL)    -   2. [SRFM] and [SHFL] (HSCT Renal function panel with magnesium        and HSCT Hepatic function panel with LD; SRFM includes NA, K,        CL, CO2, GLU, BUN, CRE, CA, P, ALB, MG and SHFL includes ALT,        AST, ALK, BILIT/D, TP, ALB, LD    -   3. Complete Urinalysis

E. Post-Treatment Evaluation

-   -   1. Engraftment studies: Contribution to hematopoietic recovery        from the expanded cell product will be assessed from sorted        peripheral blood (cell sorted for CD3⁺, CD33⁺, CD14⁺, and CD56⁺        cell fractions) on day 7, 14, 21, 28 and 56 following the        infusion of expanded cells (or days 13, 20, 27, 34 and 62 of the        chemotherapy cycle). If the patient is 100% host at the day 14        time point, all subsequent analyses will not be performed.        However, should there be persistent evidence of engraftment        derived from the expanded cell infusion at day 56, donor-host        chimerism studies will be performed every 2 to 4 weeks as        necessary to follow donor-host kinetics of engraftment. The        percentages of donor-host chimerism will be evaluated by        polymerase chain reaction (PCR)-based amplification of        variable-number tandem repeat (VNTR) sequences unique to donors        and hosts and quantified by phosphoimaging analyses.    -   2. Alloimmunization: Repeat PRA to evaluate for the development        of anti-HLA antibodies will be performed upon count recovery or        prior to the next cycle of chemotherapy.    -   3. Hematology: CBC with differential and platelet count and        peripheral blood smear daily while in hospital and/or until        hematopoietic recovery, then at each outpatient clinic visit        during the induction, re-induction, and consolidation cycles.    -   4. Serum chemistries: Electrolytes (sodium, potassium, chloride,        and bicarbonate), BUN, creatinine, glucose, and liver function        tests (AST, ALT, ALP, total bilirubin, LDH) twice weekly while        in hospital, then weekly during the induction, re-induction, and        consolidation cycles.    -   5. Bone marrow evaluations: Post induction cycles or        reinduction: Marrow evaluations will be performed for        hematopathology, cytogenetics/FISH, flow cytometry and whole        marrow chimerism evaluations on day 8 and 15 (if necessary)        following the infusion of expanded cells (or days 14 and 21 (if        necessary) of the chemotherapy cycle). Additional marrows will        be done as clinically indicated. If there is no count recovery        by day 42 post chemotherapy, a bone marrow evaluation will be        performed for hematopathology, cytogenetics/FISH, flow cytometry        and whole marrow chimerism to rule out aplasia induced by a        graft-versus-host phenomenon from the expanded cell population        versus aplasia due to persistent disease or chemotherapy induced        aplasia. Post consolidation cycles (if received): Marrow        evaluations will be performed for hematopathology,        cytogenetics/FISH, and flow cytometry evaluations on day 21 and        upon hematopoietic recovery (if necessary).    -   6. Host and Donor Immunologic Interaction Studies        -   a. Prior to the start of chemotherapy (and after consent            obtained): 40 ml of peripheral blood will be collected in            green top tubes to generate EBV transformed LCL lines from            the patient for research studies evaluating donor/host            immunologic reactions.        -   b. Post infusion of expanded cells on up to five occasions,            30 to 40 ml of peripheral blood may be collected in green            top tubes to assay for immune mediated responses occurring            between the host and donors. Investigator discretion on the            timing of samples is provided to allow investigators to            obtain samples once individual hematopoietic recovery has            occurred and to avoid obtaining samples if patients have            been placed on steroids for treatment of a GVHD (steroids            interfere with the studies).        -   c. Samples should be drawn on Monday through Friday only.    -   7. Adverse Events: Adverse events will be evaluated and        recorded.    -   8. GVHD: All patients will be monitored for development of        potential transfusion related GVHD. If signs or symptoms of        acute GVHD occur, patients will be assessed. Treatment of GVHD        will be per institutional guidelines, but only if biopsy proven        GVHD is present.    -   9. Follow-up through 6 months:    -   a. Complete blood count, renal function, and liver function        tests obtained for clinical reasons for a period of 6 months, as        needed to define toxicity or duration of response.    -   b. Disease free and overall survival data will be assessed by        contacting the referring MD or the patient every three to six        months for the first two years, then annually for 3 years.

F. Supportive Care Guidelines

-   -   1. Blood Products: All blood products are to be irradiated and        leukocyte-reduced. Also, CMV-negative patients will receive        blood products as outlined by institutional standard practice        guidelines. Transfusions will be administered for symptomatic        anemia, or below standard threshold levels appropriate to the        clinical setting.    -   2. Infection Prophylaxis: Prophylactic oral acyclovir and        levofloxacin will be used during the period of neutropenia. To        the extent possible, use of nephrotoxic (e.g., vancomycin,        amphotericin B, etc.) and hepatotoxic (e.g., voriconazole,        cyclosporine, etc) agents is to be avoided during clofarabine        administration for all treatment cycles.    -   3. Treatment of Fever and Neutropenia: Standard diagnostic        testing will be performed as per institutional guidelines, and        empiric antibiotic coverage will be utilized. Specific        antibiotics will be used for positive cultures.    -   4. Colony Stimulating Factors: G-CSF will be utilized as per        protocol during induction and consolidation chemotherapy as        outlined above. Erythropoietic stimulating agents will not be        utilized during induction or consolidation.    -   5. Concomitant Therapy: No concomitant cytotoxic therapy or        investigational therapy is allowed during the study with the        exception of intrathecal therapy for leukemic meningitis.        Intrathecal therapy must not be given during or within 24 hours        of any 5 day Clofarabine/Cytarabine treatment period.

G. Duration of Therapy: Patients will receive one to four cycles ofstudy treatment. Expanded cord blood progenitors will be used withinduction cycle #1 and cycle #2 unless:

-   -   1. There is a history of severe infusional toxicity associated        with the expanded cell product, in which case the patient will        not be eligible to receive additional doses of the expanded cell        product.    -   2. There is evidence of disease progression.    -   3. General or specific changes in the patient's condition render        the patient unacceptable for further treatment per the        investigator's judgment.    -   4. The patient chooses to withdraw from the study.    -   5. The patient becomes pregnant or fails to use adequate birth        control if able to conceive.    -   6. The patient is not able to comply with the protocol        requirement.

9.2: Implementation

Frequent infections are a common complication of induction chemotherapyand salvage regimens used in the treatment of AML, and, in fact, are aleading cause of treatment failure. Use of clofarabine and high doseara-c, in combination with granulocyte colony stimulating factor (G-CSF)has been studied in a phase I/II trial in the treatment of AML (Beckeret al., 2008, Blood 112 ASH Annual Meeting Abstracts) (such achemotherapy cycle is referred to herein as “GCLAC”). Clofarabine haspotent anti-leukemic activity, and clofarabine and high dose ara-c, incombination with G-CSF appears to be at least as effective as the morecommonly used combination of idarubicin and ara-C. However, clofarabineis also profoundly immunosuppressive and, in conjunction with ara-C, ishighly myelosuppressive, with periods of prolonged neutropeniapost-GCLAC of greater than three weeks. The combined immune- andmyelosuppressive effects of clofarabine and the delayed hematopoieticrecovery results in frequent infections and prevents dose intensivetherapy. In a cohort of patients treated at our center, >50% of patientsexperienced infectious complications post GCLAC, and approximately 13%of patients experienced grade 4 infections (Becker et al., 2008, Blood112 ASH Annual Meeting Abstracts). Importantly, infusion of expandedhuman cord blood stem and progenitor cells can help overcome both ofthese challenges. Additionally, the immunosuppression caused by theclofarabine-based regimen increases the likelihood that the expandedhuman cord blood stem cell sample may temporarily engraft and provideclinical benefit.

To date, nine adult patients with relapsed (n=7) or primary refractory(n=2) AML have been enrolled according to the criteria set out inSection 9.1, supra. The age range was 40 to 55 years. Patients receivedtheir first cycle of chemotherapy: clofarabine 25 mg/m²/day for 5 days,ara-C₂ gm/m²/day for 5 days, G-CSF 5 mcg/kg/day for 6 days (“GCLAC”),followed approximately 24 hours after completion of GCLAC by infusion ofan expanded human cord blood stem cell sample without regard to matchingthe HLA-type of the expanded human cord blood stem cell sample to theHLA-type of the patient. The expanded human cord blood stem cell samplewas produced according to the method set forth in Example 8, supra. Ifresponse to GCLAC was demonstrated by achievement of morphologicremission (based on bone marrow aspirate), patients were eligible toreceive a second cycle of GCLAC and a second expanded human cord bloodstem cell sample.

A total of twelve expanded human cord blood stem cell samples wereinfused into the nine patients. Of the nine patients treated, fourpatients were refractory to GCLAC therapy, and therefore werenon-evaluable for neutrophil recovery. Three of the five patients whoachieved remission received a second cycle of GCLAC and a secondexpanded human cord blood stem cell sample. Two out of the five patientswho achieved remission after the first cycle of GCLAC and expanded cordblood stem cell sample, were given a hematopoietic stem cell transplantof a type determined by the treating physician. For these remaining 5patients (2 male, 3 female), the average time to achieve an absoluteneutrophil count (ANC) >500 per μl was 19 days (see FIG. 15), comparingfavorably to 21 days in a historical cohort of patients receiving GCLAConly without expanded cells. Importantly, in the nine patients therehave been no safety issues with the infusion of the expanded human cordblood stem cell samples, or serious adverse events attributed to theexpanded human cord blood stem cell samples to date.

Only 2 of the 9 enrolled patients have experienced clinicallysignificant infections (e.g., bacteremia, fungal infections, pneumonia)compared to 17 out of 28 patients in the comparison cohort. Finally,three out of three patients who received a second cycle of GCLAC with asecond expanded human cord blood stem cell sample were found to havetransient donor contribution (as measured by peripheral blood cellsorted DNA chimerism studies) to myeloid recovery one week afterinfusion of the cells, ranging from 85 to 100% donor in the CD33/CD14cell lineages. In these three patients, the cells were also able to hometo the marrow as evidenced by transient myeloid engraftment of donororigin in the marrows of recipients (day 7 after infusion of the cells)ranging from 3 to 15% (FIG. 16).

10. EXAMPLE Treatment of Patients with Hodgkin'S Lymphoma, Non-Hodgkin'SLymphoma and Multiple Myeloma

The below discussion describes the design of a clinical trial aimed atproviding rapid restoration of hematopoietic function to patientssuffering from Hodgkin's lymphoma, non-Hodgkin's lymphoma and multiplemyeloma who have been treated with intensive chemotherapy and/orradiation therapy in preparation for autologous transplant byadministering expanded human cord blood stem cells. This study willenroll patients will the following characteristics:

Patients with Hodgkin's or non-Hodgkin's lymphoma and multiple myelomaare eligible. Histologically confirmed Hodgkin's or non-Hodgkin'slymphoma who have failed at least 1 prior therapy. Histologicallyconfirmed, symptomatic multiple myeloma who have received at least 1line of conventional chemotherapy. Failure to collect an optimum numberof PBSC after at least 1 attempt at mobilization. For purposes of thistrial this shall be defined as <3×10⁶ CD34⁺ cells/kg, however, the first3 patients enrolled will have 1 to 2×106 CD34⁺ cells/kg. Patients mayhave more than 1 attempt at mobilization as long as the total dose is<3×106 CD34⁺ cells/kg. Patients must have at least 1×106 CD34⁺ cells/kgPBSC product available to be eligible for this trial.

The patients will be between the ages of 18 and 70 and will have 0-2ECOG performance status results. Further, the patients will haveadequate renal and hepatic functions as indicated by the followinglaboratory values: Serum creatinine ≦2.0 mg/dL; if serum creatinine >2.0mg/dl, then the estimated glomerular filtration rate (GFR) must be >60mL/min/1.73 m2 as calculated by the Modification of Diet in RenalDisease equation where predicted GFR (ml/min/1.73 m2)=186×(SerumCreatinine)−1.154×(age in years)−0.023×(0.742 if patient isfemale)×(1.212 if patient is black). Serum total or direct bilirubin≦1.5× upper limit of normal (ULN), aspartate transaminase (AST)/alaninetransaminase (ALT) ≦2.5×ULN, alkaline phosphatase ≦2.5×ULN. The patientswill be capable of understanding the investigational nature, potentialrisks and benefits of the study, and able to provide valid informedconsent. Female patients of childbearing potential must have a negativeserum pregnancy test within 2 weeks prior to enrollment. Male and femalepatients must be willing to use an effective contraceptive method duringthe study and for a minimum of 6 months after study treatment. Panelreactive antibody (PRA) negative or with specific antibodiescharacterized for product selection will be performed (to avoiddonor-directed antibodies against the potential cord blood product). Alleligible patients will have a preliminary donor search conducted priorto the initiation of therapy to identify potential donors (related orunrelated and including suitable cord blood units) in the event of graftfailure.

The following types of patients are excluded: Allogeneic transplantrecipients, current concomitant chemotherapy, radiation therapy, orimmunotherapy other than as specified in the protocol, use of otherinvestigational agents within 30 days or any anticancer therapy within 2weeks before study entry. Other exclusion factors are any other severeconcurrent disease, or have a history of serious organ dysfunction ordisease involving the heart, kidney, liver (including symptomatichepatitis, veno-occlusive disease), or other organ system dysfunction,history of HIV infection, patients with a systemic fungal, bacterial,viral, or other infection not controlled (defined as exhibiting ongoingsigns/symptoms related to the infection and without improvement, despiteappropriate antibiotics or other treatment), pregnant or lactatingpatients, patients having any significant concurrent disease, illness,or psychiatric disorder that would compromise patient safety orcompliance, interfere with consent, study participation, follow up, orinterpretation of study results, having central nervous systeminvolvement with malignancy, and patients having no potential donoravailable (based on preliminary search) for allogeneic transplant in theevent of graft failure.

The expanded cord blood progenitors to be used for this trial will beselected from a bank of previously expanded cord blood progenitors thathave been cryopreserved for future clinical use. Each individualprogenitor cell product is derived from a single cord blood unit (donor)that is CD34 selected (and therefore T cell depleted), ex vivo expandedin the presence of Notch ligand (as described above in Section 8) andthen cryopreserved. The fresh cord blood units are obtained through acollaboration with the Cord Blood (CB) Program at the Puget Sound BloodCenter/Northwest Tissue Center (PSBC/NTC).

Selection of the expanded progenitors will be based on the following:

A Panel Reactive Antibody (PRA) to be performed on all enrolledpatients, and product selected based on the specificity of donordirected antibodies when present. PRA negative patients may receive anyproduct that fits cell dose restrictions. HLA matching will not beconsidered outside of PRA+ patients.

B. Cell Doses:

-   -   1. TNC/kg pre-cryopreservation cell dose will not exceed 1.2×10⁹        TNC/kg recipient body weight, to account for an anticipated        approximate 20% cell loss upon thaw with the goal of maintaining        cell doses at ≦1×10⁹ TNC/kg.    -   2. CD34 cell dose: No upper limit will be placed on the CD34        cells/kg infused.    -   3. All expanded products are evaluated by immunophenotyping for        the presence of CD3⁺ cells prior to freezing. While there has        been no convincing evidence of a CD3⁺ cell population, if a        product has evidence of a T cell (CD3⁺) population, this product        will not be used unless the dose of CD3⁺ cells is <5×10⁵ CD3⁺        cells/kg (recipient weight).

The patient will be referred for treatment of lymphoma or multiplemyeloma. The patient will be completely evaluated. The protocol will bediscussed thoroughly with the patient and family, including requirementfor data collection and release of medical records, and all knownsignificant risks to the patient will be described. The procedure andalternative forms of therapy will be presented as objectively aspossible and the risks and hazards of the procedure explained to thepatient. Informed consent will be obtained using forms approved by theInstitutional Review Board of the Fred Hutchinson Cancer ResearchCenter. A summary of the conference should be dictated for the medicalrecord detailing what was covered.

The patients will be treated according to the following plan:

A. Peripheral Blood Stem Cell Collection: Peripheral blood stem cells(PBSC) will be collected by serial leukaphereses by any knowmobilization method). At least 1.0×10⁶ CD34⁺ cells/kg must be availablefor transplant.

B. High dose conditioning regimens:

-   -   Multiple myeloma patients    -   Standard conditioning using melphalan 200 mg/m2 will be utilized        for all patients.

TABLE X Day Treatment −5 −4 −3 −2 −1 0 +1 Allopurinol (300 mg) X X X XBactrim (1 DS tab BID) X X X X Melphalan 200 mg/m² X Infusion:autologous PBSC + X expanded cord blood G-CSF 5 mcg/kg/d until ANC > X2000 for two consecutive days

Lymphoma Patients

TBI-based regimen for patients who have not received prior dose limitingTBI (>20 Gy to any critical normal organ (e.g. lung, liver, spinalcord).

TABLE XI Day Treatment −11 −10 −9 −8 −7 −6 −5 −4 −3 −2 −1 0 +1 +2Palifermin 60 X X X X X X mcg/kg/day TBI 1.5 Gy BID X X X X (total dose12 Gy) Etoposide 60 mg/kg IV X Rest X Cyclophosphamide X 100 mg/kg IVRest X Infusion: X autologous PBSC + expanded cord blood G-CSF 5mcg/kg/d until X X ANC > 2000 for two consecutive days

Cyclophosphamide Dosage: Cyclophosphamide will be administered at a doseof 100 mg/kg/day IV on day 2 of conditioning. Preparation,administration and monitoring will be according to standard methods.Dosing in patients >100% of IBW will be per standard practice. MESNAwill be given for bladder prophylaxis according to standard practice.Continuous bladder irrigation is an alternative for bladder prophylaxisat the attending physician's discretion. Hydration and monitoring fortoxicities will be according to standard practice.

Total Body Irradiation: Total body irradiation (TBI), 1.5 Gy BID×4 days(for a total dose of 12 Gy) is delivered via a linear accelerator at adose rate of 8 Gy/min.

IV Hydration and Antiemetic Therapy: IV hydration should be given at 2liters/m2/24 hrs. Scheduled doses of antiemetics per standard practice.

BEAM conditioning regimen: Patients ineligible for a TBI based regimenwill receive high dose therapy with a BEAM conditioning regimen.

TABLE XII Day Treatment −7 −6 −5 −4 −3 −2 −1 0 +1 BCNU 300 mg/m2 X IV ×1 d Etoposide 100 X X X X mg/m2 IV BID × 4 d Ara-C 100 mg/ X X X X m2 IVBID × 4 d Melphalan 140 X mg/m2 × 1 d Rest X Infusion: Autologous XPBSC + expanded cord blood G-CSF 5 mcg/kg/d X until ANC > 2000 for twoconsecutive days

BCNU (Carmustine):

Dosage: Carmustine 300 mg/m2 IV×1 will be infused over 3 hours on day −7of conditioning. Carmustine should not be infused with solutions ortubing containing or previously containing bicarbonate solution.

Chemistry: Carmustine, a nitrosourea derivative, is generally consideredto be an alkylating agent. The drug is available as a white lyophilizedpowder at 4° C. It is slightly soluble in water, freely soluble inalcohol, and highly soluble in lipids.

Administration: Carmustine is available as a sterile powder as 100 mgvials. The drug is reconstituted by dissolving the contents of the 100mg vial in 3 ml of sterile dehydrated (absolute) alcohol, followed bythe addition of 27 ml of sterile water for injection. The resultantsolution contains 3.3 ml of carmustine per ml of 10% alcohol. Thissolution may be further diluted with 0.9% sodium chloride or 5% dextroseinjection to a final concentration of 0.2 mg/ml in glass containers.Only glass containers are recommended to be used for administration ofthis drug. Carmustine is rapidly degraded in aqueous solutions at a pHgreater than 6.

After IV administration, carmustine is rapidly cleared from the plasmawith no intact drug detectable after 15 minutes. Carmustine is rapidlymetabolized, although the mechanism is not fully elucidated. Excretionof the metabolites occurs mainly through the urine and some metabolitesare known to be active.

Maintenance hydration: Normal saline plus 20 mEq KCL is to be started at2 liters/m2/day pre-Carmustine and continued until 24 hours after thelast dose of Melphalan.

Pharmacokinetics: Because of their high lipid solubility, carmustineand/or its metabolites readily cross the blood-brain barrier.Substantial CSF concentrations occur almost immediately afteradministration of carmustine, and CSF concentrations ofradiolabeled-BCNU have been variously reported to range from 15-70% ofconcurrent plasma concentrations. Carmustine metabolites are distributedinto milk, but in concentrations less than those in maternal plasma.

Etoposide (VP-16, Vepesid):

Dosage: Etoposide 100 mg/m2 IV BID will be administered in 500-1000 ccnormal saline over 2 hours on days −6, −5, −4, and −3 of conditioningfor a total dose of 800 mg/m2.

Chemistry and mechanism of action: Etoposide is a semi-syntheticpodophyllotoxin. The epipodophyllotoxins exert phase-specific spindlepoison activity with metaphase arrest and, in contrast to the vincaalkaloids, have an additional activity of inhibiting cells from enteringmitosis. Suppression of tritiated thymidine, uridine, and leucineincorporation in human cells in tissue culture suggests effects againstDNA, RNA, and protein synthesis.

Storage and stability: Unopened vials of VP-16 are stable for 24 monthsat room temperature. Vials diluted as recommended to a concentration of0.2 or 0.4 mg/mL are stable for 96 and 24 hours, respectively, at roomtemperature (25° C.) under normal room fluorescent light in both glassand plastic containers. Undiluted VP-16 in plastic syringes has beenreported to be stable for up to 5 days.

Availability, reconstitution and administration: Etoposide iscommercially available in 100 mg/5 ml, 150 mg/7.5 ml, 500 mg/25 ml or1000 mg/50 ml sterile multiple dose vials. VP-16 should be diluted priorto use with either 5% Dextrose Injection, USP, or 0.9% Sodium ChlorideInjection, USP, to give a final concentration of 0.2 or 0.4 mg/ml.Precipitation may occur at solutions above 0.4 mg/ml concentration. Itis recommended that VP-16 solution be administered IV over 2 hours.However, a longer duration of administration may be used when infusinglarge volumes of fluid. VP-16 should not be infused rapidly. To avoidlarge volumes, VP-16 can be given undiluted, with special equipment andprecautions. If VP-16 is administered undiluted, a 4-way stopcock andtubing made with “chemo resistant” (not containing acrylic or ABScomponents) plastic must be used. Undiluted VP-16 cannot be infusedwithout concurrent IV solution infusing through the Hickman catheter.Infusion of undiluted VP-16 alone will cause Hickman catheter occlusion.

Supportive Care: Appropriate anti-emetics and sedatives should be givenbefore the infusion begins. Before and 2 hours into the infusion, thepatient is to receive 25 mg of diphenhydramine, and 100 mg ofhydrocortisone to prevent allergic reactions. Normal saline plus 20 mEqKCL is to be continued at 2 liters/m2/day. If necessary, diuretics maybe given. Since in rare cases metabolic acidosis has been observed afterhigh dose VP-16, additional NaHCO3 may be added to hydration, though notinfused while VP-16 is infusing.

Cytarabine(Ara-C):

Dosage: Cytarabine 100 mg/m2 IV BID will be infused over 3 hours on days−6, −5, −4 and −3 of conditioning.

Chemistry: Cytarabine is a synthetic pyrimidine nucleoside andpyrimidine antagonist anti-metabolite.

Availability and administration: Cytarabine is available in areconstituted form in solutions containing 20, 50 and 100 mg ofcytarabine per ml. These solutions have been reconstituted from asterile powder with bacteriostatic water containing 0.945% benzylalcohol for injection. The manufacturers state that the reconstitutedsolutions with water for injection may be diluted with 0.9% sodiumchloride or 5% dextrose. The diluted solutions containing 0.5 mg ofcytarabine per mL are stable for at least 8 days at room temperature.

Pharmacokinetics: Cytarabine is not effective when administered orally.

Continuous IV infusions produce relatively constant plasmaconcentrations of the drug in 8-24 hours. Cytarabine is rapidly andwidely distributed into tissues and fluids, including liver, plasma, andperipheral granulocytes and crosses the blood-brain barrier to a limitedextent. The drug apparently crosses the placenta. It is not known ifcytarabine is distributed in milk. After rapid IV injection, plasma drugconcentrations appear to decline in a biphasic manner with a half-lifeof about 10 minutes in the initial phase and about 1-3 hours in theterminal phase. Cytarabine is rapidly and extensively metabolized mainlyin the liver but also in the kidneys, gastrointestinal mucosa,granulocytes, and to a lesser extent in other tissues by the enzymecytidine deaminase, producing the inactive metabolite1-B-d-arabinofuranosyluracil (ara-U). Cytarabine and ara-U are excretedin urine. After rapid IV, IM, SQ, or IT injection or continuous IVinfusion of cytarabine, about 70-80% of the dose is excreted in theurine within 24 hours.

Melphalan:

Dosage: Melphalan will be administered at a dose of 140 mg/m2 IV×1infused over 30 minutes on day −2 of conditioning.

Chemistry: Melphalan (L-phenylalanine mustard) is a typical alkylatingagent that can be given intravenously or orally.

Administration: Melphalan is available in 50 mg vials and whenreconstituted with 10 ml sterile water results in a concentration of 5mg/ml. The reconstituted melphalan is diluted in 250 cc normal saline toa concentration not greater than 0.5 mg/ml. Melphalan is administeredover 15 minutes, not to exceed 60 minutes.

Pharmacokinetics: Plasma melphalan levels are highly variable after oraldosing, both with respect to the time of the first appearance ofmelphalan in plasma (range: 0 to 336 minutes) and to the peak plasmaconcentration (range: 0.166 to 3.741 mg/mL) achieved. These results maybe due to incomplete intestinal absorption, a variable “first pass”hepatic metabolism, or to rapid hydrolysis.

C. Cell Infusion:

-   -   1. Autologous PBSC will be thawed and infused on the morning of        day 0.    -   2. Expanded cell infusion: Expanded cells will be thawed and        infused as per standard guidelines and infused approximately 4        hours after infusion of the autologous stem cell graft.

D. Supportive Care:

-   G-CSF: 5 mcg/kg subcutaneously (SQ), rounded up to nearest vial    size, beginning the day after autologous stem cell infusion and    expanded cell product infusion. G-CSF will be continued daily until    ANC >2000 for two consecutive days.

Evaluation Guidelines

A. Pre-Transplant Evaluation

-   -   1. History, physical exam, Karnofsky score.    -   2. CBC, serum sodium, potassium, CO2, BUN, creatinine, uric        acid, LDH, calcium, bilirubin, alkaline phosphatase, AST, ALT,        hepatitis screen, ABO/RH typing, blood crossmatch, CMV, VZV,        HSV, HIV, and toxoplasmosis serology.    -   3. CT/PET (lymphoma).    -   4. MM of skeleton, and osseous survey needed for staging        (myeloma).    -   5. Bone marrow aspirations and biopsies; samples for pathology,        flow cytometry and cytogenetics including FISH.    -   6. Serum protein electrophoresis and immunofixation (myeloma).    -   7. Quantitative serum immunoglobulin levels, beta 2        microglobulin.    -   8. 24 hour urine collection to determine creatinine clearance        and total protein excretion, urine protein electrophoresis,        quantitative Bence Jones excretion and immunofixation (myeloma).    -   9. PFTS, MUGA.    -   10. Clinical immune reconstitution studies.

B. Evaluation During Conditioning:

-   -   1. Daily CBC until ANC >500/ul and platelet count >20,000/ul        following the nadir.    -   2. Electrolyte panel (sodium, potassium, chloride, CO2, calcium,        magnesium, phosphorus, albumin, BUN creatinine) 3× per week at a        minimum.    -   3. Liver function tests (ALT, AST, ALK phos, bilirubin, and LDH)        2× per week at a minimum.

C. Evaluation to be Completed the Morning of Autologous PBSC andExpanded Progenitor Infusion:

-   -   1. Physical exam and review of systems done by provider    -   2. Weight by nursing    -   3. CBC [CBD] (includes HCT, HGB, WBC, RBC, indices, platelets,        DIFF/SMEAR EVAL)    -   4. [SRFM] and [SHFL] (HSCT Renal function panel with magnesium        and HSCT Hepatic function panel with LD; SRFM includes NA, K,        CL, CO2, GLU, BUN, CRE, CA, P, ALB, MG and SHFL includes ALT,        AST, ALK, BILIT/D, TP, ALB, LD)    -   5. Complete urinalysis

D. Evaluation During Infusion of Ex Vivo Expanded Cord Blood Progenitors

-   -   1. RN must be in attendance during infusion.    -   2. MD or PA must be available on the inpatient unit.    -   3. If any changes in cardiac status, notify physician and obtain        ECG.    -   4. Obtain and record vital signs including temperature, BP, HR,        Respirations, and O2 saturation at the following time points:

TABLE XIII Pre-infusion 1 hour after the start of infusion 15 minutesafter the start of 2 hours after the start of infusion infusion 30minutes after the start of 4 hours after the start of infusion infusion45 minutes after the start of 24 hours after the start of infusioninfusion

-   -   5. Dipstick for HGB/protein every voided urine for 24 hours        after infusion of expanded cells. Record HGB and Protein.

E. Evaluation 24 Hours Following the Infusion of Expanded Cord BloodProgenitors:

-   -   1. CBC [CBD] (includes HCT, HGB, WBC, RBC, indices, platelets,        DIFF/SMEAR EVAL)    -   2. [SRFM] and [SHFL] (HSCT Renal function panel with magnesium        and HSCT Hepatic function panel with LD; SRFM includes NA, K,        CL, CO2, GLU, BUN, CRE, CA, P, ALB, MG and SHFL includes ALT,        AST, ALK, BILIT/D, TP, ALB, LD.    -   3. Complete Urinalysis

F. Evaluation from Day 0 to Day 60:

-   -   1. Daily CBC until ANC >500/ul and platelet count >20,000/μl        following the nadir. Thereafter CBC 3× per week until day +28        and 2× per week until day +60.    -   2. Electrolyte panel (sodium, potassium, chloride, CO2, calcium,        magnesium, phosphorus, albumin, BUN creatinine) 3× per week        until day 60.    -   3. Liver function tests (ALT, AST, ALK phos, bilirubin, and LDH)        2× per week until day 28 then weekly until day 60.    -   4. Engraftment studies: Contribution to hematopoietic recovery        from the expanded cell product will be assessed from sorted        peripheral blood (cell sorted for CD3⁺, CD33⁺, CD14⁺, and CD56⁺        cell fractions) on day 7, 14, 21, 28 and 60 following the        infusion. If at any time point the patient is 100% host, all        subsequent analyses will not be performed. If there is evidence        of engraftment from expanded cell product which persists at day        60, chimerism studies will be continued at 2-4 week intervals        until the patient is 100% host. The percentages of donor-host        chimerism will be evaluated by polymerase chain reaction        (PCR)-based amplification of variable-number tandem repeat        (VNTR) sequences unique to donors and hosts and quantified by        phosphoimaging analyses.    -   5. Alloimmunization: Repeat PRA to evaluate for the development        of anti-HLA antibodies will be performed upon count recovery.    -   6. GVHD: All patients will be monitored for development of        potential transfusion related GVHD. If signs or symptoms of        acute GVHD occur, patients will be assessed. Treatment of GVHD        will be per institutional guidelines, but only if biopsy proven        GVHD is present.    -   7. Bone Marrow Evaluations: Marrow evaluations will be performed        for hematopathology, cytogenetics/FISH, flow cytometry and whole        marrow chimerism evaluations on day 14 and 21 (if necessary). In        the event of graft failure, a marrow evaluation will be        performed to rule out aplasia due to graft versus host effect.        Additional marrows will be done as clinically indicated.    -   8. Adverse event monitoring until day 60 evaluation.    -   9. Clinical immune reconstitution studies.

G. Day 60 Re-Staging Evaluation

-   -   1. History, physical exam, Karnofsky score.    -   2. CBC, serum sodium, potassium, CO2, BUN, creatinine, uric        acid, LDH, calcium, bilirubin, alkaline phosphatase, AST, ALT,        hepatitis screen.    -   3. CT/PET imaging (lymphoma).    -   4. Osseous survey use skeletal survey for re-staging, and MRI of        skeleton (myeloma).    -   5. Bone marrow aspiration and biopsy; samples for pathology,        flow cytometry and cytogenetics including FISH. If there is        persistence of the expanded cord blood cells (as demonstrated on        peripheral blood chimerism analysis), this marrow will be sent        for whole marrow chimerism as well.    -   6. Quantitative serum immunoglobulin levels.    -   7. Serum protein electrophoresis and immunofixation (myeloma).    -   8. 24 hour urine collection to determine creatinine clearance        and total protein excretion, urine protein electrophoresis,        quantitative Bence Jones excretion and immunofixation (myeloma).    -   9. Serum B2 microglobulin.    -   10. Repeat PRA to evaluate for the development of anti-HLA        antibodies.    -   11. Adverse event monitoring    -   12. Clinical immune reconstitution studies

H. Immune Reconstitution:

Clinical Studies (to be performed as possible):

-   -   1. Quantitative immunoglobulin levels (IgG, IgA, IgM) will be        assessed at Day 28, 60, 100, 6 months, 1 year and 2 years.    -   2. Total T lymphocytes and subset enumeration (Lymphocytes        panel) will be assessed pre-transplant and at Day 28, 60, 100, 6        months, 1 year and 2 years.

I. Follow-Up

-   -   1. Complete blood count, renal function, and liver function        tests obtained for clinical reasons for a period of 6 months, as        needed to define toxicity or duration of response.    -   2. Disease free and overall survival data will be assessed by        contacting the referring MD or the patient every three to six        months for the first two years, then annually for 3 years.

J. Supportive Care Guidelines

-   -   1. Blood Products: All blood products are to be irradiated and        leukocyte-reduced. Also, CMV-negative patients will receive        CMV-safe blood products. Transfusions will be administered for        symptomatic anemia, or below standard threshold levels        appropriate to the clinical setting.    -   2. Infection Prophylaxis: Prophylactic oral levofloxacin will be        used during the period of neutropenia. Acyclovir and bactrim        prophylaxis will be used according to standard practice        guidelines.    -   3. Treatment of Fever and Neutropenia; Standard diagnostic        testing will be performed as per institutional guidelines, and        empiric antibiotic coverage will be utilized. Specific        antibiotics will be used for positive cultures.    -   4. Colony Stimulating Factors: G-CSF will be utilized as        outlined above. Erythropoietic stimulating agents will not be        utilized.    -   5. Concomitant Therapy: No concomitant cytotoxic therapy or        investigational therapy is allowed during the study with the        exception of prophylactic intrathecal therapy per standard        practice guidelines.

11. EXAMPLE Treatment of AML Patients with Expanded Human Cord BloodStem Cells and Cord Blood Transplant

This protocol involves the administration of one or more umbilical cordblood/placental blood units (“Grafts” or “cord blood transplants”) incombination with an expanded cord blood stem cell sample of theinvention for the treatment of acute myelogenous leukemia (AML) in humanpatients. The cord blood transplants were cord and/or placental wholeblood, except that red blood cells were removed.

To date, six patients with leukemia at high risk of relapse have beenenrolled and received treatment per the treatment protocol set forth inFIG. 17, which is a myeloablative, total body irradiation (TBI)-basedcord blood transplant (CBT) protocol for patients with hematologicmalignancy (“CSAJMIMF” refers to cyclosporin and micophenylatemofetil, aconventional immune-suppressive treatment to prevent graft vs. hostdisease (GVHD)). The conditioning and post-transplant immune suppressionregimens in this study are identical to the ex vivo expansion trialdescribed in Example 9, supra, and are considered standard of care formyeloablative cord blood transplant. The patients received twopreviously cryopreserved cord blood transplants (depleted of red bloodcells) with a minimum of 1.5×10⁷ total nucleated cells (“TNC”)/kg(depending on algorithm of cell dose and HLA typing) and one expandedcord blood stem cell sample produced as described in Example 8, supra.

To date, all patients treated received a double cord blood transplant(cord blood transplants from the cord and/or placental blood of twodifferent individuals) followed by infusion of a previouslycryopreserved and thawed, expanded human cord blood stem cell samplewithout regard to HLA matching, on day 0. No toxicities were observed atthe time of infusion and no serious adverse events have been attributedto the expanded human cord blood stem cell sample to date. The firstpatient was infused on Sep. 22, 2010, and the sixth patient is now 2months post transplant. The infused TNC and CD34⁺ cell doses arepresented in the table below.

TABLE XIV Demographics, Infused Cell Doses and Engraftment, Patients 1-6Infused Infused Infused Infused 1^(st) Day 1^(st) Day Date TNC* TNC**CD34* CD34** ANC ANC Platelet Pt # Age Wt (kg) Diagnosis (×10⁷/kg)(×10⁷/kg) (×10⁶/kg) (×10⁶/kg) >100 >500 >20 k 1 35   67.1 AML 8.9 2.70.31 4.1  8 26 35 2  5   27.4 ALL 7.3 10.0  0.37 9.8 13 15 26 3 24  76.4 ALL 4.0 6.9 0.12 9.2  9 19 37 4 21   74   ALL 4.8 4.7 0.16 4.9 1621 35 5 13   57   ALL 4.2 7.2 0.15 8.8  7 26 45 6 33   72   AML 5.2 6.80.16 11.1   9 19 33 Mean 21.2 61.2 — 5.7 6.5 0.21 8   10 21 35 *Total ofboth unmanipulated units. **Based on pre-freeze total of off-the-shelfexpanded unit.

The kinetics of hematopoietic recovery and the relative contribution ofthe expanded cells and cord blood graft cells to engraftment weredetermined beginning on day 7 post transplant. All patients treated todate have engrafted. It has been previously demonstrated that an ANC≧100 is a critical threshold to reduce the risk of death prior to day100 post hematopoietic cell transplant (Offner et al., 1996, Blood88:4058). Furthermore, in our own single center analysis of severeneutropenia following cord blood transplant, both ANC <100 and time toengraftment as a time-dependent covariate, correlates significantly withboth day 200 transplant related mortality (“TRM”) and overall survival.In this analysis of 88 patients undergoing cord blood transplant, at anygiven time point, an ANC <100 is associated with a 4.77-fold increase inthe risk of overall mortality compared to an ANC >100 (1.74-13.11,p=0.002) and an 8.95-fold increase in risk of day 200 TRM (2.59-30.89,p=0.00095). This is similar to findings when modeling the time toengraftment (ANC >500), such that engraftment at a specific time pointis associated with a 0.23-fold risk of death as compared to lack ofengraftment at this time (0.08-0.62, p=0.004), and a 0.11-fold risk ofday 200 TRM (0.03-0.38, p=0.0005). Therefore, the time to achieve an ANC≧100 and the time to achieve ANC ≧500 were evaluated in patients whounderwent a myeloablative double cord blood transplant withadministration of a previously cryopreserved expanded human cord bloodstem cell sample without regard to HLA matching(off-the-shelf+unmanipulated), compared (i) to a concurrent cohort ofpatients who received a conventional myeloablative double cord bloodtransplant (conventional dCBT), and (ii) to a cohort of patients whoreceived a myeloablative double cord blood transplant withadministration of a partially HLA matched expanded human cord blood stemcell sample that was not cryopreserved (expanded+unmanipulated), asdescribed in Delaney et al., 2010 Nature Med. 16:232-236.

While the patient numbers were small, an advantage for earlier myeloidrecovery is suggested in the patients treated to date with thecryopreserved expanded human cord blood stem cell sample without regardto HLA matching (off-the shelf+unmanipulated), and in the patientstreated with the partially HLA matched expanded human cord blood stemcell sample (expanded+unmanipulated) compared to the conventional doublecord blood transplant (conventional dCBT) (see FIG. 18 and FIG. 19). Inone of the six patients administered the expanded human cord blood stemcell sample without regard to HLA matching, in vivo persistence of theexpanded cord blood stem cells continues to persist when last checked atday 56. Retrospectively, this patient was found to be fortuitouslymatched at 3/6 HLA antigens to the off-the-shelf product.

Early myeloid recovery at day 7 was derived almost entirely from thepreviously cryopreserved expanded human cord blood stem cell sample thatwas administered to all 6 patients without regard to HLA matching, butgenerally such recovery did not persist beyond day 14 post-transplant(see FIG. 20). This result is in accord with results seen when infusinga freshly harvested (not cryopreserved) and partially HLA matchedexpanded human cord blood stem cell sample, as described in Delaney etal., 2010 Nature Med. 16; 232-236.

It is envisioned that future patients will receive one, two or more cordblood transplants in addition to the expanded human cord blood stem cellsample.

The present invention is not to be limited in scope by the specificembodiments described herein. Indeed, various modifications of theinvention in addition to those described herein will become apparent tothose skilled in the art from the foregoing description and accompanyingfigures. Such modifications are intended to fall within the scope of theappended claims.

Various publications, including patents, patent applicationpublications, and scientific literature, are cited herein, thedisclosures of which are incorporated by reference in their entiretiesfor all purposes.

1. A method for providing hematopoietic function to a human patient inneed thereof, comprising administering an expanded human cord blood stemcell sample to the patient, wherein said administering is done withoutmatching the HLA-type of the expanded human cord blood stem cell sampleto the HLA-type of the patient, wherein the expanded human cord bloodstem cell sample has been subjected to an expansion technique that hasbeen shown to result in an at least 50-fold increase in hematopoieticstem cells or hematopoietic stem and progenitor cells in an aliquot of ahuman cord blood stem cell sample subjected to the expansion technique,relative to an aliquot of the human cord blood cell stem cell sampleprior to being subjected to the expansion technique.
 2. The method ofclaim 1, wherein the hematopoietic stem cells or hematopoietic stem andprogenitor cells are CD34⁺.
 3. A method for providing hematopoieticfunction to a human patient in need thereof, comprising: a. selecting anexpanded human cord blood stem cell sample for administration to thepatient, wherein said selecting does not take into account the HLA-typeof the sample or the HLA-type of the patient; and b. administering theselected sample, or an aliquot thereof, to the patient.
 4. The method ofclaim 3, wherein the selecting is from among at least 50 frozen expandedhuman cord blood stem cell samples.
 5. The method of claim 1, whereinthe expanded human cord blood stem cell sample is derived from theumbilical cord blood and/or placental blood of a single human at birth.6. The method of claim 1, wherein the expanded human cord blood stemcell sample is a pool of two or more different expanded human cord bloodstem cell samples, each different sample in the pool derived from theumbilical cord blood and/or placental blood of a different human atbirth.
 7. The method of claim 6, wherein all the samples in the pool arederived from the umbilical cord blood and/or placental blood of humansof the same race.
 8. The method of claim 6, where all the samples in thepool are derived from the umbilical cord blood and/or placental blood ofhumans of the same ethnicity.
 9. The method of claim 1, wherein theexpanded human cord blood stem cell sample contains at least 75 millionviable CD34⁺ cells.
 10. The method of claim 1, wherein the methodfurther comprises producing said expanded human cord blood stem cellsample by a method comprising expanding ex vivo isolated human cordblood stem cells or stem and progenitor cells obtained from theumbilical cord blood and/or placental blood of a human at birth.
 11. Themethod of claim 3, wherein the expanded human cord blood stem cellsample has been subjected to an expansion technique that has been shownto result in an at least 50-fold increase hematopoietic stem cells orhematopoietic stem and progenitor cells in a human cord blood stem cellsample subjected to the expansion technique, relative to the human cordblood cell stem cell sample prior to being subjected to the expansiontechnique.
 12. The method of claim 11, wherein the hematopoietic stemcells or hematopoietic stem and progenitor cells are CD34⁺.
 13. Themethod of claim 10, wherein the expanding step comprises contacting thehuman cord blood stem cells or stem and progenitor cells with an agonistof Notch function.
 14. The method of claim 1, wherein the expanded humancord blood stem cell sample has been subjected to an expansion techniquethat has been shown to increase the number of SCID repopulating cells ina human cord blood stem cell sample subject to the expansion technique,relative to the human cord blood stem cell sample prior to being subjectto the expansion technique.
 15. The method of claim 11, wherein theexpansion technique has been shown to result in an at least 50-foldincrease in CD34⁺ cells in an aliquot of a human cord blood stem cellsample subjected to the expansion technique, relative an aliquot of thehuman cord blood cell stem cell sample prior to being subjected to theexpansion technique.
 16. The method of claim 1 wherein the expandedhuman cord blood stem cell sample is frozen prior to said administeringstep, and wherein the method further comprises a step of thawing saidsample prior to said administering.
 17. A method for providinghematopoietic function to a human patient in need thereof, comprising:(a) enriching for hematopoietic stem cells or hematopoietic stem andprogenitor cells from the umbilical cord blood and/or placental blood ofone or more humans at birth to produce a population enriched inhematopoietic stem cells or hematopoietic stem and progenitor cells; (b)expanding ex vivo the population enriched in hematopoietic stem cells orhematopoietic stem and progenitor cells to produce an expanded stem cellsample; and (c) administering the expanded stem cell sample, or analiquot thereof, to a human patient in need of hematopoietic function,wherein said administering is done without matching the HLA type of theexpanded cell sample to the HLA type of the patient.
 18. The method ofclaim 17, wherein the method further comprises the steps of freezing andthawing the expanded stem cell sample after step (b) and before step(c).
 19. The method of claim 1, wherein the patient has pancytopenia orneutropenia.
 20. The method of claim 19, wherein the pancytopenia orneutropenia is caused by an intensive chemotherapy regimen, amyeloablative regimen for hematopoietic cell transplantation, orexposure to acute ionizing radiation.
 21. A method of producing a bankof frozen, expanded human cord blood stem cells comprising the followingsteps in the order stated: (a) expanding, ex vivo, human cord blood stemcells present in a population enriched for hematopoietic stem cells orhematopoietic stem and progenitor cells obtained from the umbilical cordblood and/or placental blood of one or more humans at birth to producean expanded human cord blood stem cell sample; (b) freezing the expandedhuman cord blood stem cell sample to produce a frozen expanded humancord blood stem cell sample; (c) storing the frozen expanded human cordblood stem cell sample; and (d) repeating steps (a)-(c) at least 50times to produce a bank of at least 50 stored, frozen expanded humancord blood stem cell samples.
 22. The method of claim 21, wherein thehematopoietic stem cells or hematopoietic stem and progenitor cells arederived from the umbilical cord blood and/or placental blood of a singlehuman at birth.
 23. The method of claim 21, wherein the method furthercomprises a step of assigning each frozen expanded human cord blood stemcell sample an identifier that distinguishes the frozen expanded humancord blood stem cell sample from the other frozen expanded stem cellsamples.
 24. The method of claim 23, wherein the method furthercomprises a step of storing the identifier in one or more computerdatabases, wherein said stored identifier is associated with informationon the physical location where the frozen expanded human cord blood stemcell sample corresponding to the identifier is stored in said bank. 25.A blood bank comprising at least 50 units of frozen expanded human cordblood stem cell samples.
 26. A computer-implemented method for selectinga frozen expanded human cord blood stem cell sample for use in providinghematopoietic function to a human patient in need thereof, comprisingthe following steps performed by a suitably programmed computer: (a)selecting an identifier from a plurality of at least 50 identifiersstored in a computer database, each identifier identifying a frozenstored expanded human cord blood stem cell sample derived from theumbilical cord blood and/or placental blood of one or more differenthumans at birth, wherein the selecting does not take into account therespective HLA types of the stored frozen expanded human cord blood stemcell samples corresponding to the respective identifiers, wherein theselecting is to identify a frozen stored expanded human cord blood stemcell sample for administration of the expanded human cord blood stemcell sample, or an aliquot thereof, identified by said identifier to ahuman patient in need thereof; and (b) outputting or displaying theselected identifier.
 27. The method of claim 26, wherein the frozenexpanded human cord blood stem cell sample is derived from the umbilicalcord blood and/or placental blood of a single human at birth.
 28. Thecomputer-implemented method of claim 26, wherein the outputting ordisplaying step further outputs or displays information on the physicallocation of the expanded human cord blood stem cell sample identified bythe identifier.
 29. The computer-implemented method of claim 26, whereinthe method further comprises implementing robotic retrieval of theidentified frozen, expanded, human cord blood stem cell sample.
 30. Acomputer program product for use in conjunction with a computer system,the computer program product comprising a computer readable storagemedium and a computer program mechanism embedded therein, the computerprogram mechanism comprising: (a) executable instructions for selectingan identifier from a plurality of at least 50 identifiers stored in acomputer database, each identifier identifying a frozen stored expandedhuman cord blood stem cell sample derived from the umbilical cord bloodand/or placental blood of one or more humans at birth, wherein theselecting does not take into account the respective HLA types of thestored frozen expanded human cord blood stem cell samples correspondingto the respective identifiers, wherein the selecting is to identify afrozen stored expanded human cord blood stem cell sample foradministration of the expanded human cord blood stem cell sample, or analiquot thereof, identified by said identifier to a human patient inneed thereof; and (b) executable instructions for outputting ordisplaying the selected identifier.
 31. An apparatus comprising: aprocessor; a memory, coupled to the processor, the memory storing amodule, the module comprising: (a) executable instructions for selectingan identifier from a plurality of at least 50 identifiers stored in acomputer database, each identifier identifying a frozen stored expandedhuman cord blood stem cell sample derived from the umbilical cord bloodand/or placental blood of one or more humans at birth, wherein theselecting does not take into account the respective HLA types of thestored frozen expanded human cord blood stem cell samples correspondingto the respective identifiers, wherein the selecting is to identify afrozen stored expanded human cord blood stem cell sample foradministration of the expanded human cord blood stem cell sample, or analiquot thereof, identified by said identifier to a human patient inneed thereof; and (b) executable instructions for outputting ordisplaying the selected identifier.
 32. The method of claim 3, whereinthe selecting comprises rejecting expanded human cord blood stem cellsamples that do not contain at least 75 million CD34⁺ cells.
 33. Themethod of claim 3, wherein the selecting further comprises rejectingexpanded human cord blood stem cell samples that contain more than500,000 CD3⁺ cells per kilogram patient weight.
 34. Thecomputer-implemented method of claim 26, wherein the selecting comprisesrejecting identifiers that identify samples that do not contain at least75 million CD34⁺ cells.
 35. The computer-implemented method of claim 26,wherein the selecting further comprises rejecting identifiers thatidentify samples that contain more than 500,000 CD3⁺ cells per kilogrampatient weight.
 36. The computer program product of claim 30, whereinthe executable instructions for selecting comprise instructions forrejecting identifiers that identify samples that do not contain at least75 million CD34⁺ cells.
 37. The computer program product of claim 30,wherein the executable instructions for selecting further compriseinstructions for rejecting identifiers that identify samples thatcontain more than 500,000 CD3⁺ cells per kilogram patient weight. 38.The apparatus of claim 31, wherein the executable instructions forselecting comprise instructions for rejecting identifiers that identifysamples that do not contain at least 75 million CD34⁺ cells.
 39. Theapparatus of claim 31, wherein the executable instructions for selectingfurther comprise instructions for rejecting identifiers that identifysamples that contain more than 500,000 CD3⁺ cells per kilogram patientweight.
 40. The method of claim 1, which further comprises administeringto the human patient one or more samples of thawed, previouslycryopreserved red blood cell-depleted, whole human umbilical cordblood/placental blood samples.